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“QUEM PLANTA TAMAREIRAS, NÃO COLHE TÂMARAS!”  
 
Um jovem aproximou-se de um idoso  
que plantava tamareiras no deserto e interpelou-o:  
Por que é que o senhor perde tanto tempo a plantar o que não irá colher?  
O senhor virou a cabeça e calmamente respondeu: “Se todos pensassem  
como você, ninguém no mundo jamais colheria tâmaras. Se hoje sei o  
sabor da tâmara é porque um dia alguém plantou uma tamareira.  
O relevante não é quem beneficiará dos frutos, o importante  
é o trabalho realizado. Não é perda de tempo, é sim 
uma grande oportunidade de deixarmos um 
legado para ser explorado.  
 
Provérbio Árabe  
adaptado de Vandi Dogado  
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THESIS OVERVIEW 
The present dissertation is organized in six chapters. An initial chapter with a general 
introduction (CHAPTER I), four chapters describing the original research work undertaken 
for this thesis, most published or submitted for publication in peer-reviewed scientific journals 
(CHAPTER II-V) and a final discussion of the main conclusions (CHAPTER VI).  
CHAPTER I includes an introductory description of the covered issues, being divided in 
two subchapters addressing 1) the need of new antileishmanial agents and 2) the utility of the 
algae from the Cystoseira genus as source of bioactive compounds.  
The chemical diversity of the genus Cystoseira as source of bioactive compounds has 
been elucidated by several authors. To better understand the chemical potentialities of this 
genus, CHAPTER II provides a comprehensive review of the compounds isolated from 
different Cystoseira species carried out under the aims of this thesis.  
The potential of these algae as source of molecules useful against Leishmania parasites 
was explored under the scope of two additional publications. CHAPTERS III and IV describe 
the evaluation of the antileishmanial activity and cytotoxicity of several macroalgae species 
collected in coastal areas of Portugal and Spain, and the isolation and identification of 
compounds with antileishmanial properties in selected Cystoseira species, respectively. 
In addition, and justified by the controversial taxonomic classification of the genus 
Cystoseira and by the importance of the accurate identification of the biomass used for 
phytochemical purposes, CHAPTER V describes the genetic assignment carried out for this 
genus. The results described in this chapter show the value of the molecular and chemical 
tools for the establishment of phylogenetic relationships between species and also for sample 
identification. The phylogeny of this genus is analysed and discussed. 
Furthermore, in order to gain a general perspective on the utility of the Cystoseira genus 
as source of bioactive compounds against Leishmania parasites, the final CHAPTER VI 
includes an integrated discussion of the main conclusions retrieved from literature. Some 
perspectives for future research are also discussed.   
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ABSTRACT 
This thesis aimed to identify Cystoseira macroalgae compounds displaying 
antileishmanial activity. Concerning the need to ensure the identification of the samples used 
for the drug screening, a second aim was determined to evaluate the usefulness of 
mitochondrial markers for identification of Cystoseira. A comprehensive review showed that 
marine algae, and in particular Cystoseira, are important sources of bioactive compounds, 
which can be used as antiparasitic agents (Chapter I and II). This work revealed that these 
algae contains compounds with antileishmanial activity. Forty five extracts from 15 species 
was submitted to bio-guided fractionation and its activity against L. infantum promastigotes and 
their cytotoxicity evaluated. Among the studied algae, Cystoseira extracts (C. baccata, 
C. barbata, C. nodicaulis and C. tamariscifolia) displayed the most interesting activities 
against this parasite (Chapter III). C. baccata hexane extract was further investigated, to the 
isolation of two active meroterpenoids: the (3R)- and (3S)-tetraprenyltoluquinone with an 
unknown structure, and the (3R)- and (3S)-tetraprenyltoluquinol previously isolated and active 
against Leishmania intracellular amastigote forms. Promastigote ultrastructural alterations, 
DNA fragmentation and mitochondrial potential variations suggest that the mechanism of 
action of these compounds interfere with the mitochondrial metabolism (Chapters IV). 
Moreover, the investigation of the chemical composition of the Cystoseira crude extracts 
showed that these algae contain fatty acids, triacylglycerols, carotenoids, steroids and 
meroterpenoids (Chapter III). This characterization complement published data, suggesting 
that these compounds might also be involved in the antileishmanial activity here unravelled 
(Chapter II). Concerning the identification of Cystoseira, samples from twenty-two 
Cystoseira species were analysed generating 135 new sequences of three mitochondrial 
regions (COI, 23S and mt-spacer). This work demonstrated that these three markers are 
suitable to distinguish these species. The results allowed for the correct identification of 
Cystoseira samples used for drug screening, encouraging the study of taxonomy and 
evolutionary elucidation of these brown algae using genetic tools (Chapter V).  
 
Keywords: Leishmania; algae; Cystoseira; meroterpenoids; tetraprenyltoluquinol; 
tetraprenyltoluquinone mitochondrial markers, phylogeny  
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RESUMO 
Este trabalho teve como objectivo a identificação de compostos de algas do género 
Cystoseira com actividade antileishmania. Perante a necessidade de assegurar a identificação 
das amostras utilizadas na pesquisa dos compostos activos, o segundo objectivo foi  avaliar a 
utilidade de marcadores mitocondriais para a identificação de espécies de Cystoseira. A 
revisão alargada da bibliografia, mostrou que as algas marinhas, em particular as Cystoseira, 
são importantes fontes de produtos bioactivos com potencialidades antiparasitárias (Capítulos 
I e II). Os resultados revelaram que estas algas contêm compostos com actividade 
antileishmania. Quarenta e cinco extractos de 15 espécies de algas, submetidos a 
fraccionamento bioguiado, foram avaliados quanto à sua actividade contra promastigotas de 
L. infantum e a sua citotoxicidade. Os extractos das espécies de Cystoseira (C. baccata, 
C. barbata, C. nodicaulis and C. tamariscifolia) foram os que revelaram actividades 
antiparasitárias mais interessantes (Capítulo III). O extracto de hexano de C. baccata foi 
estudado, conduzindo ao isolamento de dois meroterpenóides activos: (3R)- and (3S)-
tetrapreniltoluquinona com uma estrutura desconhecida, e (3R)- and (3S)-tetrapreniltoluquinol 
descrito anteriormente e activo contra formas amastigotas intracellulares de Leishmania. A 
observação de alterações ultraestruturais  fragmentação do DNA e variações do potencial 
mitocondrial dos promastigotas sugerem que o  mecanismo de acção destes compostos 
interfere com o metabolismo mitocondrial (Chapters IV). Para além destes resultados, a 
análise da composição dos extractos estudados, revelou que estas algas contém acidos gordos, 
triacilgliceróis, carotenoides, esteroides e meroterpenoides (Chapter III). Esta caracterização 
vem complementar a informação publicada, sugerindo que estes compostos podem também 
estar envolvidos na actividade antileishmania explorada neste trabalho (Capítulo II).  
No que diz respeito à identificação das Cystoseira, foram analisadas amostras de vinte e 
duas espécies de Cystoseira, que geram 135 novas sequências nucleotídicas de três regiões 
mitocondriais (COI, 23S e mt-spacer). Este estudo demonstra que estes marcadores os são, de 
modo geral, eficientes a distinguir estas espécies. Os resultados permitiram a correcta 
identificação das amostras utilizadas na pesquisa dos compostos bioactivos, vindo encorajar o 
estudo da taxonomia e elucidação da historia evolutiva destas algas castanhas com recurso a 
ferramentas genéticas biologia molecular.   
 
Palavras-chave: Leishmania; Cystoseira; algas; meroterpenoides; tetraprenyltoluquinol; 
tetrapreniltoluquinona; marcadores mitocondriais, filogenia  
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1.1. THE NEED FOR NEW ANTILEISHMANIAL AGENTS 
1.1.1. LEISHMANIASES  
Leishmaniasis is a complex of zoonotic vector-borne diseases resulting from infection 
of human and animal vertebrate hosts by different species of euglenozoan kinetoplastid 
parasites of the genus Leishmania Ross, 1903, which are transmitted by several species of 
phlebotomine sand flies in the Old World, and in the New World (WHO, 2010; Ready, 2013). 
Even though the signs of cutaneous leishmaniasis (CL) were already mentioned in 
ancient Assyrian texts dated from 2500 BC, the discovery of the etiological agent responsible 
for these ailments only occurred around the 18
th
 century. Depictions of skin lesions and facial 
deformities that are typical of cutaneous and mucocutaneous leishmaniasis are represented in 
pre-Incan pottery from Ecuador and Peru. In this region, Inca texts from the 15
th
 and 16
th
 
century and also reports from Spanish conquistadors described ulcers and skin lesions on 
agricultural workers in the Andes. This is usually refered to as “white leprosy” and “Andean 
sickness” (Marstellera et al., 2011; Mans et al., 2016). 
With the advent of the microscopy, the parasite responsible for the cutaneous disease in 
the Old World was observed and described for the first time by D. Cunningham in 1885 and 
P. F. Borovsky in 1898. However, as they were worked in India and Russia their studies 
(reviewed by Cox, 2002) remained virtually unknown until 1903, when J. H. Wright revealed 
a similar discovery in a tropical ulcer observed in an Armenian child (Wright, 1903). 
Independently, and almost simultaneously, W. Leishman and C. Donovan discovered the 
causative agent of the visceral disease in spleens of patients with “Dum Dum fever” / ”Kala-
azar” in 1900. This disease was originally confused with an acute form of malaria. In 1921, G. 
Vianna found that Leishmania from South America - the causative agent of cutaneous and 
disfiguring mucocutaneous forms of the disease, differed from those detected in India and 
Africa, suggesting they were different species. At this time, Etienne and Edouard Sergent 
demonstrated that Phlebotomus sand flies were responsible for the transmission of the 
Leishmania parasites in the Old World, and Lutzomyia sand flies were identified as 
Leishmania vectors in the New World in 1922 (reviewed by Cox, 2002 and Killick-Kendrick, 
2010, 2013). Definitive proof that the bite of the phlebotomine sand fly was necessary for the 
transmission of the pathogen was achieved only two decades later (Adler et al., 1941). 
With a large infection spectrum, ranging from the subclinical (not apparent) to localized 
(skin lesion), and disseminated (mucocutaneous and visceral), leishmaniases are a major 
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health problem worldwide (Alvar et al., 2012). Beyond its impact on human health, this 
parasite is also a serious veterinary problem in more than 70 countries due to canine 
leishmaniasis (Franco et al., 2011). 
1.1.1.1. Epidemiology 
A recent update of the World Health Organization (WHO) database on diseases caused 
by Leishmania identified 98 countries that reported endemic leishmaniases. It is estimated 
that about 2 million cases occur each year worldwide (Alvar et al., 2012). These data cover 
the different illnesses caused by these parasites, ranging from cutaneous forms (localized, 
mucocutaneous, and diffuse) to the potentially fatal visceral form. Being among the ten 
neglected tropical diseases (NTDs) which exert their largest burden on developing countries, 
these diseases are strongly associated with poverty (WHO 2010, 2015a). With mandatory 
report in only 34% of the endemic countries, it is estimated that 12 million people are infected 
by Leishmania parasites. However, the exact worldwide burden of the disease has not been 
determined (WHO, 2015a). Affecting particularly the world’s poorest populations and 
causing chronic disability and poverty in low- and middle-income countries (Hotez and 
Pecoul, 2010), it was determined that these disorders have a worldwide impact of 2.35 million 
disability-adjusted life years (DALYs), 2.3% of which in the Americas (WHO, 2015b). The 
very low income of the affected population influences the prognosis of these diseases, since 
their treatment can cost more than 50% of the annual household earnings. This scenario has 
contributed to the increase of the level of poverty of families with at least one infected 
individual (Boelaert et al., 2009; Meheus et al., 2010). 
In the past two decades, the expansion of the distribution area of this complex of 
diseases and an exponentially growing incidence of about 1.3 million/year new human cases 
has been observed. About 1 million of CL cases were mostly found in Afghanistan, Algeria, 
Brazil, Colombia, Iran, Pakistan, Peru, Saudi Arabia, Syria and Tunisia. The mucocutaneous 
form occurred mostly in Bolivia, Brazil and Peru, whereas 0.3 million cases of visceral 
leishmaniasis (VL) were mainly found in Bangladesh, Brazil, Ethiopia, India, Nepal, South 
Sudan and Sudan. Overall, 350 million people were at risk to become infected (Alvar et al., 
2012; WHO, 2015a). Because of these numbers, CL has been ranked as an emerging and 
uncontrolled disease of category 1 (de Vries et al., 2015); simultaneously, and despite its 
lower prevalence, it is estimated that severe VL alone is responsible for 20,000-50,000 deaths 
per year (WHO, 2010; Alvar et al., 2012; WHO, 2015c).  
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The dispersion of leishmaniases depends on several different risk factors. Housing 
conditions, urbanization and other socioeconomic conditions influence the nutritional status 
and the overall health of the affected populations. In particular, health conditions involving 
immunosuppression can be an important risk factor. Other contributing factors are the 
increase in general traveling and migration to escape armed conflicts and the deleterious 
effects of climatic and environmental changes (Aagaard-Hansen et al., 2010; Argaw et al., 
2013; Savoia, 2015). All these factors should be considered with more attention in terms of 
the One Health approach in order to reduce the prevalence and impact of these neglected 
vector-born diseases (Mansueto et al., 2014). Early diagnosis, treatment, vector control, 
disease surveillance, and education of the populations are key factors for prevention and 
control of infection (Savoia, 2015). It is also important to invest on the improvement of living 
conditions and control of reservoir populations.  
In Europe, Asia, North Africa and South America, the infection caused by L. infantum 
constitutes an important zoonosis, with dogs being the main reservoir for human infection. 
Dogs are also the major host of L. infantum parasites and the disease is a serious public health 
and veterinary problem in the Mediterranean basin, being endemic in 22 countries (Albania, 
Algeria, Bosnia-Herzegovina, Croatia, Cyprus, Egypt, France, Greece, Israel, Italy, Libia, 
Malta, Monaco, Montenegro, Morocco, Portugal, Slovenia, Spain, Syria, Tunisia, Turkey; 
WHO, 2010). L. infantum is the causative agent of both CL and VL forms of human 
leishmaniasis in the Mediterranean basin (Campino et al., 2006). However, VL is the most 
frequent clinical form with about 900 human cases reported each year (Alvar et al., 2012). It 
has also been suggested that more than 2.5 million dogs are infected in Southwestern Europe 
(Moreno and Alvar, 2002).  
The spread of leishmaniasis in Mediterranean region and up to Northern Europe is 
mentioned by different authors (Arce et al., 2013; Bart et al., 2013; Cortes et al., 2011; 
Gkolfinopoulou et al., 2013; Gramiccia et al., 2013; Harizanov et al., 2013; Lachaud et al., 
2013; Šiško-Kraljević et al., 2013; Varani et al., 2013).  The increase in the infection risk in 
this region is related with alterations in the epidemiological patterns due to several factors: 
climate change, which has resulted in increased exposure to the sand fly; migration from rural 
to urban and peri-urban areas; increased influx of migrants, travellers and dogs coming from 
endemic areas; and increased numbers of stray dogs (Campino et al., 2006; Dujardin et al., 
2008; Ready, 2010; Miró et al., 2012; Mansueto et al., 2014; Savoia, 2015).  
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In the Mediterranean region, human infections ocurred mainly in children until the 
1960-70s. However, the human immunodeficiency virus (HIV) brought new challenges, in 
particular during the 1980-90s, when Leishmania/HIV coinfection emerged, increasing the 
number of visceral cases, mostly in France, Italy, Portugal, and Spain (Monge-Maillo et al., 
2014). At the end of 1996, the introduction in Europe of the Highly Active AntiRetroviral 
Therapy (HAART) led to a significant reduction in the number of cases of VL in 
immunocompromised patients of these countries - from 1440 cases (1990-1998) to 299 cases 
(2001-2006; Alvar et al., 2008). This study showed that Spain and Portugal were the countries 
with higher coinfection rates, with 130 and 98 coinfected patients, respectively, diagnosed in 
the latter period. Taking into account that human leishmaniasis are underreported in Portugal 
(Serrada, 2010), Campino and Maia (2010) reported 107 VL/HIV coinfected patients 
diagnosed between 2000-2009, showing that the incidence described by Alvar et al. (2008) 
remained stable in that period. 
In Spain, between 1982 and 1995, a total of 1,574 accumulated human cases were 
reported (Gil-Prieto et al., 2011). In this period, leishmaniasis was declared as a disease 
notifiable to local health authorities. Between 1997 and 2011, 3,442 hospitalizations with 
leishmaniasis (82.6% VL and 3.4% CL) as first diagnosis were reported, 36.5% of which 
corresponding to HIV-positive patients (Herrador et al., 2015).  
A WHO report (www.who.int/leishmaniasis/resources/SPAIN.pdf) states that the economic 
impact of leishmaniasis in the period of 1982-1995 represented more than 13 million euros. 
Various seroepidemiological canine leishmaniasis (CanL) surveys have been performed from 
North to South regions of Spain, reporting a prevalence between 1.1% and 35.6%, with the 
northern and eastern regions showing the highest values (Morillas et al., 1996; Amusátegui et al., 
2004; Gálvez et al., 2010; Martín-Sánchez et al., 2009; Miró et al., 2012).  
Between 2009-2012, the largest CL and VL outbreaks of leishmaniasis in Europe were 
reported in the Spainish Autonomous Region of Madrid, emphasizing the importance of the 
sylvatic cycle in the transmission of leishmaniasis in the peri-urban areas and reinforcing the 
importance of environmental measures to control this disease (Aguado et al., 2013; Arce et 
al., 2013; Gomez-Barroso et al., 2015).  
In Portugal, VL is the most frequent clinical form, but a few CL cases have also been 
reported (Campino et al., 2006). With 20-30 visceral human cases reported yearly in 
immunocompetent patients (80% of them in children) is thus considered a hypoendemic 
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country (Campino and Maia, 2010), where three endemic foci have been identified (Alto 
Douro, Lisbon and Algarve Regions). Although sporadic cases occur all over the country, the 
higher number of human cases was reported in Lisbon Metropolitan area in 2001, especially 
in HIV patients, with an incidence of 0.2 cases per 100,000 inhabitants per year (Campino and 
Maia, 2010). In Portugal CanL has increased over the last two decades. Recent canine 
epidemiological surveys revealed a 6.31% global prevalence of anti-Leishmania antibodies in 
the general canine population (Cortes et al., 2012), value that reached nearly 20% in some 
localities (Cardoso et al. 2004; Sousa et al. 2011; Cortes et al., 2012). This is in agreement 
with a predictive study published on Western Europe that calculated a risk of CanL 
seroprevalence of 5-20 % in the Portuguese territory (Franco et al., 2011).  
1.1.1.2. Clinical forms 
Humans can be infected by more than 20 Leishmania species (WHO, 2010; 
Schönian et al., 2010). In the last 20 years, it has also been described the existence of 
natural hybrids resulting from the genetic recombination between different strains and 
species both in the New World (Belli et al., 1994; Dujardin, 1995; Delgado et al., 1997; 
Bañuls et al., 1999) and the Old World (Kelly et al., 1991; Hide and Bañuls, 2007; Ravel 
et al., 2006; Hamad et al., 2011).  
Infectious species/strains are responsible for several disseminated and localized disease 
forms, ranging from the VL to the different skin disorders: cutaneous leishmaniases (CL; 
Table 1.1.). The occurrence of the clinical manifestations is clearly related with the virulence, 
tropism and pathogenicity of the Leishmania species involved (Bañuls et al., 2007). However, 
immune competence of the mammalian host strongly determines the outcome of the disease 
(WHO, 2010; Magill, 2015; Santos-Mateus et al., 2016). 
The VL can be resultant from anthroponotic or zoonotic transmission. In the Old World, 
etiological agents of VL or Kala-azar are mainly species of the L. donovani-L. infantum 
complex. Being a systemic disease, chronic in the inhabitants of endemic areas where 
children are especially affected, this clinical form may be acute in travellers originated from 
Leishmania-free areas. VL can occur as an endemic (WHO, 2010), sporadic (Adhikari et al., 
2010) or epidemic (Arce et al., 2013) disease, displaying different clinical manifestations and 
responses to therapy in each situation. Infections could be asymptomatic and may resolve 
spontaneously. However, because of the parasite tropism to the internal organs, some human 
hosts eventually develop clinical VL, in particular malnourished and immunosuppressed 
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individuals, such as HIV-positive patients. The parasite affects the liver, spleen, bone marrow 
and lymph nodes, typically inducing weight loss, anorexia, anemia, irregular fever, abdominal 
distension with spleno- and hepatomegaly and lymphadenopathy. Other symptoms, such as 
coughing, chronic diarrhea, darkening of the skin, chronic kidney disease, can also occur. The 
risk of thrombocytopenia and leukopenia increase the susceptibility to other infections. This 
disease is thus considered to be the most severe form of leishmaniasis. As a result of 
secondary infections and other complications, this disease is potentially fatal if not treated 
(Ezquerra, 2001; Assimina et al., 2008; CFSPH, 2009). 
In East Africa and in the Indian subcontinent, where L. donovani is endemic, Post-kala-
azar dermal leishmaniasis (PKDL) can eventually appear as sequelae of VL after a period of 
apparent healing (up to 50% in Sudan and 5-15% in Bangladesh; WHO, 2013a). 
CL is the most common form of human leishmaniasis, varying between and within 
regions, according with the transmission cycle of the parasite, and genetic and immunological 
characteristics of the infected patients (Alvar et al., 2012). Involving only the skin, CL covers 
a number of clinical variants ranging from a single ulcer of spontaneous healing - i.e., 
localized cutaneous leishmaniasis (LCL) - to the presence of multiple mixed type (non-
ulcerative) skin lesions with chronic evolution spread throughout the body – i.e., disseminated 
CL in anergic patients (DCL; WHO, 2010; Masmoudi et al., 2013). Depending on the 
infective species, papules and ulcers can occur, smooth nodules, plaques or hyperkeratotic flat 
wart-like lesions, sometimes together with regional lymphadenopathy. Skin lesions are 
usually painless; however, complications can occur if it becomes secondarily infected. 
Healing can be spontaneous or take more than a year, also depending on the Leishmania 
species and the immunological status of the patient, and some lesions can lead to social 
stigma (Ramdas et al., 2016) if they produce disfiguring scars (CFSPH, 2009). In the Old 
World, LCL also known as oriental sore, is caused by species of the subgenus Leishmania (L.) 
(Table 1.1; WHO, 2010; CDC, 2016). 
Some zymodemes from the L. donovani complex reveal cutaneous tropism in the 
Mediterranean region (Campino and Abranches, 2002; Campino et al., 2005; Rhajaoui et al., 
2012). Species from the L. enriettii complex apparently occur in Africa as well (Kwakye-Nuakoa 
et al., 2015). In the New World, CL causative agents belong to species of the subgenera 
Leishmania (V.) and Leishmania (L.) (Table 1.1.; CFSPH, 2009; Castro et al., 2016). Although 
occurring worldwide, DCL is rare and has higher incidence in the New World; in the Old World, 
it appears essentially associated with HIV-positive patients. Being difficult to treat, this form  
INTRODUCTION 
9 
 
Table 1.1. Vectors, pathology, geographic distribution, reservoirs and type of transmission cycle per 
Leishmania species (Adapted from CFSPH, 2009; Ready et al., 2013; Bates et al., 2015). 
(Vectors) 
      Leishmania species 
Geographic distribution Reservoirs Transmission /  
Clinical form 
(Plebotomus spp.)    
 L.(L.) donovani Bangladesh, Buthan, China, India; 
Ethiopia, Kenya, Nepal, Sudan, 
Uganda, Yemen 
Man, Rodents, 
Canids 
Anthroponotic / VL 
 L.(L.) infantum Balkans, China, Mediterranean 
Europe, Middle East. North Africa, 
Southwest Asia  
Canids Zoonotic; Peridomestic / 
CL, VL 
 L.(L.) aethiopica Ethiopia, Kenya, Uganda Hyraxes Zoonotic; Silvatic / CL 
 L.(L.) major Arabic peninsula, Central Asia, 
Iran and neighbors, Kenya, Middle 
East, North Africa, Northwest 
India; Pakistan, Sub-Saharan 
Africa, Yemen, Sudan 
Rodents Zoonotic; Rural / CL 
 L.(L.) tropica  Afghanistan, India, Iran, Pakistan, 
Middle East, North Africa, Sub-
Saharan Africa  
Man, Canids,  
Hyraxes 
Anthroponotic; Zoonotic 
/ CL 
(Lutzomyia spp.)    
 L.(L.) infantum 
(Syn. L. chagasi) 
Central and South America Canids Zoonotic; Peridomestic / 
VL, CL 
 L.(L.) amazonensis South America Rodents, Marsupials Zoonotic; Silvatic / CL 
 L.(V.) braziliensis South America Rodents, Marsupials, 
Canids 
Zoonotic; Peridomestic, 
Silvatic / CL 
 L.(V.) guyanensis South America Edentates, Rodents, 
Marsupials 
Zoonotic; Silvatic / CL 
 L.(V.) lainsoni Bolivia, Brazil, French Guiana, 
Peru, Suriname 
Rodents Zoonotic; Silvatic / CL 
 L.(V.) naiffi Brazil; French Guiana; Panama Edentates; Armadillo Zoonotic; Silvatic / CL 
 L.(L.) mexicana Central and South America; 
Southern United States 
Rodents, Marsupials, 
Canids 
Zoonotic; Silvatic / CL 
 L.(V.) panamensis Belize, El Salvador, Northern 
Venezuela West of Andes  
Marsupials, Rodents, 
Canids, Edentates 
Zoonotic; Silvatic / CL 
 L.(V.) peruviana Peru Man, Rodents, 
Marsupials, Canids  
Zoonotic; Peridomestic, 
Silvatic / CL 
 L.(V.) shawi Brazil Primates, Edentates  Zoonotic; Silvatic / CL 
 L. (V.) columbiensis Columbia, Panama, Venezuela Edentates Zoonotic; Silvatic / CL 
 L. (V.) venezuelensis Northern Venezuela - Zoonotic; Silvatic / CL 
L. (L.) - Subgenus Leishmania (Leishmania); L. (V.) - Subgenus Leishmania (Viannia); VL - Visceral 
leishmaniasis; CL - Cutaneous leishmaniasis. 
 
causes damage to internal tissues, changing the physical aspect of the patients and seriously 
influencing their psychological condition (Turetz et al., 2002; Purohit et al., 2012). 
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Mucocutaneous (MCL) or espundia, mostly caused by L. braziliensis, occurs mainly in 
Latin America, usually after a healed episode of CL. Starting with erythema and ulcerations at 
the nostrils with frequent bleeding, this infection induces a destructive inflammation of the 
upper respiratory tract. Affecting the mucosal membranes, it may perforate the nasal septum, 
causing severe disfigurement of the face, pharynx or larynx and even other mucosal tissues 
such as the genitalia (Goto and Lindoso, 2010; CFSPH, 2009; McGwire and Satoskar, 2014).  
1.1.1.3. Leishmania parasite biology, reservoir host and vectors  
Among the 35 species belonging to the genus Leishmania, ca. 20 of them are 
pathogenic to humans (Fraga et al., 2013). These parasites are classified in the order 
Kinetoplastidae, family Trypanosomatidae. They have been divided into two subgenera, 
Leishmania (Leishmania) and Leishmania (Viannia) (Table 1.1.), based on specificities 
related with their development in the sand fly midgut (Lainson et al. 1977 cited by Bates, 
2007). This division has been confirmed by different authors using various isoenzymatic and 
molecular approaches (Bañuls et al., 1999; Campino et al., 2006; Fraga et al., 2010, 2013). 
Different isolates/strains are usually identified by their zymodemes or schizodemes profiles 
and classified by international codes (WHO, 2010). Leishmania nomenclature is being revised 
using highly discriminatory methodologies, such as multilocus sequencing and microsatellite 
typing (Schönian et al., 2010). 
Spread all over the world, vectors of the pathogenic Leishmania species are insects 
belonging to the order Diptera, family Psychodidae and subfamily Phlebotominae (ECDPC, 
2013). Within this subfamily, two genera and around 70 species have been implicated in the 
transmission of these pathogens and recognized as of medical importance, namely 
Phlebotomus and Lutzomyia in the Old and New World, respectively (Killick-Kendrick, 1999; 
Ready, 2013). In this system, these kinetoplastid parasites are maintained by multiple 
domestic and wild hosts from seven different mammal orders (Roque and Jansen, 2014; 
Table 1.1.). Within the mammal host reservoirs, two carnivore species are highlighted due to 
their close association with humans, namely dogs and cats. Although they can be infected 
with other Leishmania species, dogs are considered to be the most important domestic/ 
peridomestic reservoir hosts of L. infantum in Europe and South America, (Cortes et al., 2012; 
Dantas-Torres, 2012). The relevance of cats in the epidemiology of this parasite is currently 
being unraveled (Maia et al., 2011; Pennisi, 2013) and evaluated in several countries of the 
Mediterranean Basin and also in Brazil, where this zoonosis is endemic (Poli et al., 2002; 
Savani et al., 2004; Solano-Gallego et al., 2007; Maia et al., 2010, 2015).  
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Leishmania has a digenetic and heteroxenic life cycle involving two hosts (vertebrate 
and invertebrate) and two developmental stages (amastigote and promastigote). The sucess of 
the parasite transmission to a vertebrate host is dependent on the vector-parasite-host 
interaction, including the capacity of the vector to infect and adapt to the ecological niche of 
the vertebrate host (Ezquerra, 2001; Bates et al., 2015), and also the parasite species and 
dispersion strategies (ex: tropism). These factors influence the transmissibility competence 
(capacity to infect vectors) of a specific vertebrate species and consequently its role as a 
reservoir host (Roque and Jansen, 2014). 
Biologically, the phlebotomine sand flies are silent, have crepuscular or nocturnal 
activity and females are predominantly exophagic (outdoor feeding) and exophilic (resting 
outdoors) (Killick-Kendrick, 1999), and undergo complete metamorphosis (egg, 4 larval 
stages and pupa; Figure 1.1.). The larvae are terrestrial, the ovoposition being held in sandy 
dark places with high relative humidity, constant temperature and rich in organic matter to 
ensure larvae feeding (Ezquerra, 2001). The form of the Leishmania that infects vertebrate 
hosts are the promastigotes, which live as extracellular parasites in the alimentary tract of the 
female insect vector. It has a fusiform shape with around 10-20 μm length and 1.5-3.0 μm 
width (Figure 1.2A). These forms are motile due to one flagellum that emerges from the front 
part of the cell body, allowing it to move in the insect gut and during the process of infection 
of the vertebrate host. Amastigotes, however, are obligate intracellular parasites of the 
mononuclear phagocytic system of mammalian hosts with tropism to macrophages. This form 
has a rounded shape (2.5-6.8 μm of length) and contains the same organelles as the 
promastigote form, although in a different arrangement. It has a vestigial, immobile flagellum 
(axoneme; Figure 1.2.B). As a kinetoplastid organism belonging to the phylum Euglenozoa, 
Leishmania cells have an ultrastructural organization of a eukaryote, which includes a cell 
membrane, nucleus, a single mitochondrion containing a network of mitochondrial DNA 
 
Figure 1.1. Sand fly biological stages. Eggs (A); First stage larvae (B); adult female at rest (C); 
Female with the abdomem engorged by the blood meal (D). Author’s photographs. 
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Figure 1.2. Leishmania biology - Structural organization of the promastigote (A) and amastigote (B) 
cells. Adapted from Teixeira et al. (2013). 
(kinetoplast), cytoskeleton and endoplasmatic reticulum (Bates, 2007; Wheeler et al., 2011; 
Rodrigues et al., 2014a). 
Description of this biological cycle has been deeply performed by many authors 
(revised by Dostálová and Volf, 2012) (Figure 1.3.).  The infection of the sand fly by 
Leishmania starts when a female insect bites an infected reservoir, ingesting a pool of blood 
infected with amastigotes (Killick-Kendrick, 1999).  
In the vector and to successfully achieve the transmission to the vertebrate, Leishmania 
has to overcome several obstacles to its development. Once in the midgut, blood meal and 
parasites are involved by the peritrophic matrix, starting its development, which is induced by 
the temperature drop and the pH increase (Bates and Rogers, 2004). Moreover, parasites have 
to face the action of midgut proteases and the oxidative stress caused by the heme digestion of 
the blood meal and sand fly immune reactions (Bates, 2007; Dostálová and Volf, 2012). The 
peritrophic matrix chemical composition (protein, glycoprotein, chitin) is specific to each 
sand fly species, influencing the selectivity for the Leishmania species that it can host 
(Walters et al., 1993). 
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Figure 1.3. Leishmania life cycle. (1) The sand fly female bites an infected mammal and during the blood 
meal collects macrophages infected with amastigote forms of the parasite; (2) amastigotes transform into 
procyclic promastigotes that multiply in the midgut, becoming infective metacyclic promastigotes; (3) in 
another blood meal, the insect releases metacyclic promastigotes into other mammalian hosts; (4) 
metacyclic promastigotes infect macrophages, transforming into amastigotes that multiply in the 
parasitophorous vacuole; (5) the intense amastigote multiplication induces lysis of the macrophage; (6) 
amastigote being fagocitised by a macrophage (Adapted from Teixeira et al., 2013). 
In addition to the morphological variations between the form infecting the vertebrate 
and the invertebrate hosts and to overcome all the barriers inside the hosts, Leishmania 
parasites undergo several behavioral and biochemical changes to sustain its life cycle. These 
changes differ between the various species and are key to its tropism and success as 
pathogens. During the intravectorial development, the parasite undergoes a sequence of 
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promastigote stages: procyclic, nectomonad, leptomonad, haptomonad and metacyclic. These 
stages differ in morphology, cell division capacity, motility, ability to bind to the tissues and 
infectivity (Bates, 2007; Dostálová and Volf, 2012). For example, the vertebrate host is 
infected by parasites in the metacyclic stage.  
 Once inoculated in the mammalian host, promastigotes present in the serum activate 
the host complement system, attracting macrophages to the inoculation site, being rapidly  
phagocytized. Once inside the cell, the promastigotes attach to the parasitophorous vacuole 
membrane and transform into amastigotes. Macrophages, neutrophils and B and T 
lymphocytes work together to lyse the parasites, inducing the release of cytokines and 
chemokines, complement-mediated lysis, production of nitric oxide and of other 
leishmanicidal factors (Silva et al., 1989; Sørensen et al., 1989; Guy and Belosevic, 1993; 
Brittingham et al., 1995; reviewed by de Almeida et al., 2003). Simultaneusly, parasites use 
complement factors to enable its recognition and promote fast internalization. 
Inside the macrophage, lysosomes loaded with hydrolases merge with the phagosomes 
carrying parasites, generating acid phagolysosomes where reactive oxygen species (ROS) and 
nitric oxide (NO) are released together with lysosomal proteases in an acid environment 
(Bogdan et al., 1990) apparently adverse to the parasite. However, and despite this aggressive 
attack, amastigote intensively multiply by binary fission, inducing the burst of the phagocytic 
cell and releasing large amounts of new amastigotes, that are rapidly internalized by other 
macrophages (Kima, 2007). 
Transformation into amastigotes is part of the parasite strategic mechanisms of adaptation 
to the extracellular environment and of resistance to the host immune system, ensuring its survival 
and succeful dispersion. To escape from the host immune response, Leishmania uses mechanisms 
involving surface membrane antigens, namelly the metalloproteinase of 63 kDa - (gp63) and the 
specific lipophosphoglycan layer (LPG; Brittingham et al., 1995; Sacks et al., 2000). Gp63 has 
suppressive activity of cytokines (e.g. IL-10) and regulates T-cell activation, allowing the 
oposonization of the infectious forms and its rapid phagocytosis (Guy and Belosevic, 1993), while 
LPG inactivates the hydrolytic enzymes, promoting the synthesis of ROS scavengers and 
inhibiting the NO generation through the down-regulation of NADPH oxidase and iNOS 
(inducible nitric oxide synthase) expression. As a result, parasite degradation is inhibited (Bogdan 
and Röllinghoff, 1998; Shio and Olivier, 2010; Gupta et al., 2013). 
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1.1.2. DRUGS AGAINST LEISHMANIA PARASITES 
As already mentioned, in the absence of a vaccine, treatment and control of 
leishmaniasis relies on the use of chemotherapeutic agents. The advent of parasites resistance 
to the in-use molecules, together with a limited therapeutic index and significant toxicities, 
became a major concern. This has entailed new challenges to the use of existing drugs and 
prompted the search for more effective antiparasitic drugs able to withstand these resistances 
(Croft et al., 2006). 
The use of natural products (NPs), currently recognized as tradicional medicine, has 
been reported since antiquity. Mesopotamian, Egyptian, Chinese and Indian registries reveal 
that plant-based products were used for the treatment of different diseases, including parasitic 
infections (Borchardt, 2002; Moo-Puc et al., 2008; Petrovska, 2012; Clausen and Demaitre, 
2015). Over time, traditional knowledge has continued to play a crucial role in health care of 
many populations around the world (Sheng-Ji, 2001; Gurib-Fakim, 2006; Lifongo et al., 2014; 
Hosseinzadeh et al., 2015). Concerning its medical importance, the use of products of natural 
origin is recognized as a complementary strategy for the fight against NTDs, such as 
leishmaniasis, being included in the WHO traditional medicine strategy for the next decade 
2014-2023 (WHO, 2001, 2003, 2013b).  
Terrestrial plants have been used in traditional medicine as natural sources of 
antiprotozoal compounds (Wright and Phillipson, 1990), and contemporary science has 
acknowledged the importance of the NPs bioactivities, including a wide range of drugs are 
plant NPs or are derived from them. An example of the former is the antileishmanial 
amphotericin B, whereas the anti-malarials artesunate and mefloquine are based on natural 
scafolds (Watts et al., 2010).  
Known since the ancient times, quinine and artemisinin, isolated from Cinchona spp. 
(reviewed in Achan et al., 2011) and Artemisia annua (reviewed in Faurant, 2011), 
respectively, are known as the most successful antiparasitic molecules from plant origin, 
remaining effective against one of the causative agents of malaria, the alveolate Plasmodium 
falciparum (Sullivan, 2013). Despite these successful cases, to the best of the author’s 
knowledge, no plant source has traditionally been used for treatment of leishmaniasis. This 
could probably be related with the fact that, till the end of the 19
th
 century, the symptoms 
associated with leishmaniasis were not matched with a given pathogen. 
In recent years, growing interest in NP-based drug discovery has been observed. Many 
papers describe several studies assaying extracts and biochemicals against Leishmania 
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parasites (Newman and Cragg, 2012; Schmidt et al., 2012a,b; Cragg and Newman, 2013; 
Brito et al., 2013; Adebayo et al., 2013; Oryan, 2015). 
As with land plants, the wide biodiversity of marine organisms and chemical diversity 
of their secondary metabolites have stimulated the search for novel natural molecules of 
marine origin for an array of biomedical purposes (Watts et al., 2010; Mayer et al., 2013; 
Blunt et al., 2016). The need for new products that could be used alone or in combination 
therapy with conventional drugs is explored below. 
1.1.2.1. Conventional drugs  
Available drugs of first and second choice include pentavalent antimonials, 
amphotericine B deoxycholate and its liposomal formulation, pentamidine, miltefosine and 
paramomycin (Croft and Olliaro, 2011; Table 1.2. and Figure 1.4.). 
Table 1.2. Drugs in use for treatment of human leishmaniasis (Alvar et al., 2006; Croft et al., 2006; 
Gradoni et al., 2008; Croft and Olliaro, 2011; Singh et al., 2016).  
Drug Properties Administration  
and toxicity 
Mode of action 
Pentavalent antimonials 
Sodium 
stibogluconate 
Organo-metal 
complexes in 
polymeric forms.  
Intravenous or 
intramuscular; 
GI, cutaneous (rash); 
myalgia, arthralgia, renal 
and cardiac toxicity.  
Not completely understood.  
Act as prodrug, inhibits trypanothione 
reductase, and increase the ROS. 
Inhibits macromolecular biosynthesis 
in amastigotes. 
Meglumine 
antimoniate  
 
Amphotericin B 
AmB 
deoxycholate 
Polyene antibiotic, 
fermentation 
product of 
Streptomyces 
nodus. 
Intravenous; 
Infusion-related (fever, chills, 
bone pain, rarely cardiac 
arrest), delayed hypokalaemia 
and impaired renal function. 
Form complexes with sterols mainly 
ergosterols of parasite membrane 
leading to increase permeability 
inducing cell death. 
Liposomal AmB Unilamellar 
liposome. 
Intravenous; 
Rare and minor (fever, rigor, 
backache). 
Targeted delivery of drug to infected 
macrophages and kill the parasites 
as AmB 
Miltefosine 
 
Hexadecylphospho
choline, alkyl 
phospholipid 
Oral; 
GI (vomiting, diarrhoea, 
elevated liver enzymes), rash, 
nephrotoxicity, teratogenicity. 
Modulate cell surface receptors and 
inositol metabolism of parasites, and 
cell death is mediated by apoptosis; 
Inhibits COI. 
Pentamidine 
 
Diamidine, as 
isethionate salt 
Intramuscular; 
Diabetes, rare in VL: shock, 
myocarditis, death. 
Inhibits mitochondrial 
topoisomerase II and the 
transcription process 
Paromomycin Aminoglycoside, 
fermentation 
product of 
Streptomyces 
rimosus. 
Intramuscular for VL and 
topical for CL; 
Generally safe in VL, pain 
at injection site, cholear and 
renal toxicity.  
Binds to 30S ribosomal subunit 
interfering with protein biosynthesis, 
inhibits RNA synthesis, decreases the 
membrane potential of parasite and 
inhibits respiration 
GI - gastrointestinal; ROS - reactive oxygen species; COI - cytochrome C oxidase; AmB - amphotericine B;  
CL, cutaneous leishmaniasis; VL, visceral leishmaniasis; PKDL, post kala-azar dermal leishmaniasis. 
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Pentavalent antimonial family (Sb
v
) includes sodium stibogluconate (Pentostam
®
) and 
meglumine antimoniate (Glucantime
®
; Table 1.2.  and Figure 1.4). Even though the response 
to these compounds varies from place to place, these drugs have been recommended by WHO 
as first-line treatment against CL and VL in most regions of the world, with the exception of 
Europe and the Indian Bihar State (Croft et al., 2006; Singh et al., 2012; Gradoni et al., 2008; 
WHO, 2016). The identification of parasite resistance to these drugs in the 1980’s (Sundar, 
2001; Chakravarty and Sundar, 2010) prevented their use in some hyper-endemic regions of 
India and Nepal, where around 70% of the patients appear refractory to the treatment (Singh 
et al., 2016). However, in the Mediterranean region, antimony resistance is not considered to 
be an issue (Gradoni et al., 2008). History of the parasite resistance to antimonials shows that 
problems are mainly associated with non-completion of the treatment and use of inadequate 
dosages. Still in 1980’s, sodium stibogluconate was freely available in India, which has led to 
widespread misuse by medical practitioners, who often did not have proper qualification to 
prescribe it effectively. To minimize toxicity, initial small doses were recommended, leading 
to an increasing and irreversible tolerance of the parasite to the drug (Chakravarty and Sundar, 
2010). Furthermore, as leishmaniasis has an exceptionally anthroponotic transmission cycle in 
the Indian subcontinent and in East Africa, faster selection and increment of the prevalence of 
the drug-resistant parasites in the infected population is promoted (Chakravarty and Sundar, 
2010). Along with gastrointestinal, cutaneous, myalgia, arthralgia and renal symptoms, 
cardiac problems are the major side effects (Alvar et al., 2006). Not being completely 
understood, the processes involved in Sb
v
 resistance have been the subject of intensive 
research (reviewed in Ashutosh et al., 2007), being suggested that the mechanisms of action 
of these drugs implicate both parasite and the infected macrophage (Sundar and Chakravarty, 
2015a; Table 1.2.).  
To overcome the problems associated with resistance to antimonials, pentamidine 
(Table 1.2.  and Figure 1.4) was used as a second-line drug to the treatment of refractory VL 
patients. However, its use has been drastically reduced due to declining efficacy (Croft et al., 
2006). High cardiac and gastrointestinal toxicity, development of hypotension and diabetes 
mellitus and cure rates lower than that of amphotericine B have virtually restricted the use of 
this drug to combination therapies and secondary prophylaxis in HIV-VL co-infection (Das et 
al., 2001a, Rybniker et al., 2010).  
After being firstly recommended for the treatment of patients refractory to antimonials 
in India (Thakur et al., 1993), amphotericin B deoxycholate (AmB; Table 1.2.  and Figure 
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1.4), commercialized as Fungizone
®
 and other names, depending on the country, is currently 
being used as first-line drug for VL treatment in endemic areas, as well as for CL and other 
complex forms of CL (WHO, 2016). AmB has high toxicity (high fever with rigor and chills, 
bone pain, thrombophlebitis, renal dysfunction, severe hypokalaemia, myocarditis and even 
cardiac arrest). As a result, the therapeutic programs need prolonged hospitalization for 
parentral administration and monitoring of the clinical parameters (Alvar et al., 2006; Sundar 
et al., 2008; Singh et al., 2016). Like fungi, the Leishmania cell membrane contains 
ergostane-based sterols. This property justifies the high selectivity of AmB towards this 
parasite (Chattopadhyay and Jafurulla, 2011). Being an antifungal agent, AmB acts on the 
ergosterol of the parasite cell membrane, changing its permeability and allowing the loss of 
intracellular components (Ramos et al., 1996). Although this seems to be the main mechanism 
of action of this drug, other mechanisms may also contribute to its activity (Chattopadhyay 
and Jafurulla, 2011).  
AmB deoxycholate is a low-cost treatment; however, in the 1980s its toxicity boosted 
the development of less toxic and higher efficacy liposomal formulations: liposomal 
amphotericin B (AmBisome
®
), amphotericin B colloidal dispersion (Amphocil
®
) and 
 
Figure 1.4. Chemical structures of the drugs with antileishmanial activity recommended for the 
treatment of leishmaniasis (https://pubchem.ncbi.nlm.nih.gov). 
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amphotericin B lipid complex (Albacete
®
; Sundar et al., 2004; Table 1.2.  and Figure 1.4). 
AmBisome
®
 is the standard treatment recommended by WHO for VL in several European 
countries and USA (Copeland and Aronson, 2015; WHO, 2016). Efforts are being made by 
WHO with the pharmaceutic companies to reduce the high costs of these drugs. However, this 
treatment is expensive, since it requires intravenous administration of several doses and 
follow-up of the patient to control the side effects. Stability of the product due temperature 
changes is also a problematic issue (Croft and Olliaro, 2011).  
The alkyl phospholipid miltefosine (Table 1.2.  and Figure 1.4), initially introduced as an 
antineoplasic agent, was later approved as the first oral drug to treat VL (Berman, 2005) and CL. 
Having a high efficacy, and low costs, this drug is commercialized for human use as Impavido® 
(Freitas-Junior et al., 2012). Despite its effectiveness, therapies require a long period of 
administration with some limited mild and temporary side effects (gastrointestinal dysfunctions, 
rash, nephrotoxicity) (Alvar et al., 2006) which contributes for the abandonment and non-
compliance of the treatment by the patients (Rijal et al., 2013). Moreover, this compound has a 
long half-life in the body, which has also promoted the emergence of parasite resistance (Dorlo et 
al., 2012). Teratogenicity also compromises its use in women during reproductive age (Maes et 
al., 2013). Because of all these issues and to avoid the aforementioned risks, its use in therapeutic 
combinations is preferred (Murray et al., 2005). The strategies, effectiveness and costs of its use 
are being evaluated in various endemic regions (Dorlo et al., 2012; Singh et al., 2016). The 
mechanism of action of miltefosine involves the modulation of the cell surface receptors and 
inositol metabolism of parasites, and the inhibition of cytochrome c oxidase leading to parasite 
death through an apoptosis-like process due to the mitochondria membrane depolarization (Paris 
et al., 2004; Luque-Ortega and Rivas, 2007). Induction of changes in the lipid saturation, also 
interfere with ergosterol content, increasing the rigidity of the parasite plasma membrane (Saint-
Pierre-Chazalet et al., 2009). 
The antileishmanial activity of the aminoglycoside antibiotics (paramomycin or 
aminosidine, monomycin; Table 1.2.  and Figure 1.4) was known since the 1960’s. However, 
only in the 1990’s its properties were highlighted after several clinical trials conducted in 
Kenya, Sudan and India, have shown its high efficacy and good tolerance against VL when 
used in mono- or in combination therapy with sodium stibogluconate (Singh et al., 2016). 
Being generally safe at therapeutic VL dosages, its parentral administration induces some side 
effects such as oto- and renal toxicity (Maes et al., 2013). Although it is known that 
aminoglycosides inhibit RNA synthesis, affect protein synthesis, decrease mitochondrial 
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membrane potential and inhibit cellular respiration of the parasite, further studies are required 
to fully elucidate their mechanisms of action (Chawla et al., 2011).  
Several studies on VL suggest that multidrug therapies are safe and effective (Thakur et 
al., 1992; Das et al., 2001a; Sundar et al., 2008, 2011a,b).  This strategy is recommended in 
order to increase the efficacy of the used drug, to delay the emergence of parasite resistance, 
to reduce the time of treatment and decrease costs (Singh et al., 2016).  
Regarding CanL, and taking into account that none of the available drugs allow 
parasitological cure, several drugs are available (e.g. allopurinol, meglumine antimoniate, 
miltefosine, aminosidine, levamisole, domperidone). However, no standard treatment has 
been recommended for this disease. Allopurinol, alone or in combination with Sbv or 
miltefosine, is the main drug used for the control of CanL in Spain, Portugal and Italy 
(Solano-Gallego et al., 2011; Maia and Campino, 2013; Manna et al., 2015). Miltefosine 
showed to be therapeutically efficient and well tolerated in dogs infected with L. infantum 
(Woerly et al., 2009 cited by Andrade et al., 2011). However, long-term follow-up of dogs 
with leishmaniasis revealed that dogs treated with a combination therapy of meglumine 
antimoniate/allopurinol show higher stability of the laboratorial parameters than those treated 
with miltefosine/allopurinol. Therefore, it is possible that maintenance therapy with 
allopurinol might be crucial for stabilizing canine leishmaniasis (Manna et al., 2015). 
Allopurinol is a purine analog not used for human leishmaniasis, having low costs and good 
safety. It is recommended as first-line drug for the treatment of CanL (WHO, 2010). Its 
activity on Leishmania parasites is related with the inhibition of the enzyme hypoxanthine-
guanine phosphoribosyl transferase of the purine pathway. L. infantum resistance against this 
drug was only described this year in dogs with CanL relapse (Yasur-Landau et al., 2016).  
In the attempt at finding compounds able to overcome the toxicity, long-term and 
parentral therapies, efficacy and resistance issues concerning currently drugs used, the search 
for compounds with antileishmanial activity has been intense. Just from January 2010 to June 
2013, 38 patents of compounds with antileishmanial activity, belonging to 37 different 
chemical classes, were registered, not including vaccines and peptides (reviewed by Rama et 
al., 2015). Event though a large body of research and patents have been published, most of 
these works do not elucidate mechanism of action of the proposed drugs, making difficult the 
comparative assessment of their effectiveness (reviewed in Jose et al., 2004, Monzote 2008, 
2011 and Rama et al., 2015).  
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Despite the large number and chemical diversity of the registered patents and 
investigation work, it has been difficult to discover novel potential candidates for preclinical 
development, because molecules against Leishmania showing better results than those 
described above are seldom found. For example, sitamaquine, an oral 8-aminoquinoline, has 
been evaluated with high expectations for several years. Although it reached phase-II clinical 
trials (Sundar et al., 2011c), its development was abandoned in 2010 (Maes et al., 2013). In 
addition, the efficacy of antifungic azoles (ketoconazole, fluconazole, and itraconazole), 
shown to be active against Leishmania parasites trough the inhibition of sterol biosynthesis, is 
not high enough to support its use in monotherapy. However, these drugs remain potential 
candidates to be used in combination therapy (de Macedo-Silva et al., 2013, Maes et al., 
2013). 
Despite the significant advances made in the treatment of VL in the past decade, the 
impact of the scientific progress achieved in the field of leishmaniasis on clinical treatment 
was almost null (Singh et al., 2016). These justifies the importance and the need to reinforce 
the effort on the research and development of new antileishmanial therapeutics with 
appropriate screening procedures and use of recommended models in order to find a cheaper, 
less toxic, but more effective anti-Leishmania drug (Croft and Olliaro, 2011). 
In view of the current therapeutic panorama, WHO has recently presented the scaffold 
priorities for leishmaniasis: improve rapid diagnostic tests, develop easy treatments for CL, 
vaccines and new therapeutics (WHO, 2015c), including the complementary use of products 
of natural origin (WHO, 2013b). In this context, the identification of novel or already known 
molecules, which allow the development of better therapeutic approaches for this disease, is a 
priority.  
1.1.2.2. Marine natural products as scaffolds for new drugs 
Natural products (NPs) are chemical compounds synthesized by an organism or a group 
of organisms that have the capacity to produce an effect on another biological target. They 
can also possess nutraceutical or toxicological properties that can be used in therapeutic 
procedures. NPs are usually secondary metabolites, i.e. molecules that are not essential to 
growth and are produced by the source organism to defend itself from environmental threats, 
including predators (Colegate and Molyneux, 2008). The same compounds can also be used 
to attract mates or to out-compete competitors for limited resources (Jaspars et al., 2016). 
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Exposed to several abiotic (such as pH, pressure, temperature, osmolarity) and biotic 
stresses, marine organisms produce a wide variety of specific secondary metabolites that enable 
them to respond to challenges posed by the marine environment. Covering around 70% of the 
Earth’s surface, the marine ecosystem contains an immeasurable biodiversity (Mora et al., 2011), 
which has been recognized as a rich source of bioactive metabolites (Haefner, 2003; Cragg and 
Newman, 2013). Many of these chemicals have uncommon functional groups (such as isonitrile, 
dichloroimine, isocyanate, and halogenated functional groups) different from the ones commonly 
found in higher plants (Hu et al., 2012; Watts et al., 2010; Rocha-Martin et al., 2014).  
The interest in the chemical wealth of marine organisms as a potential source of 
antiprotozoal agents has increased over the last decade (Fattorusso and Taglialatela-Scafati, 2009; 
Mayer et al., 2011; Tempone et al., 2011). Since the isolation of the first biologically active 
molecules in the late 1950’s (Bergmann and Feeneyz, 1951), more than 28,000 compounds from 
marine organisms have been identified (Blunt et al., 2015). These compounds have been 
comprehensively compiled since 1984 in a series of periodic reviews organized by Faulkner 
(1977, 1984 untill 1990), Blunt et al. (2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2012, 
2013, 2014, 2015, 2016), Mayer, 1998) and Mayer et al. (2000, 2002, 2004, 2005, 2007, 2009, 
2011, 2013). Isolated from sponges (65.4%), fungi (15.0%), cyanobacteria (8.3%), algae (3.0%), 
actinomycetes (3.0%), corals (3.0%) and ascidians (2.3%; Watts et al., 2010), these compounds 
encompass a wide variety of chemical diversity such as alkaloids, peptides, polyketides, terpenes 
and other unidentified and uncharacterized structures that have demonstrated several 
pharmacological activities (antitumor, anti-inflammatory, anticoagulant, cardiovascular, nervous 
system, antibacterial, antifungal, antiviral, antiprotozoal). However, despite the promising results 
of many of the screening studies on marine species and from the thousands of compounds isolated 
from them, few compounds with antiprotozoal activity have been identified.   
Several natural isolated structures have been used as models for the chemical synthesis of 
novel drugs. Currently, many synthetic compounds are based on natural scaffolds, demonstrating 
the importance of the discovery of compounds with different chemical skeletons, which can be 
used in the design of new and target-specific bioactive molecules. For this reason, the secondary 
metabolites produced by marine organisms have great value in drug discovery. 
The evaluation and approval of drugs for medicinal use is simultaneously performed by 
the United States Food and Drug Administration (FDA; http://www.fda.gov/) and the 
European Medicines Agency (EMA; http://www.ema.europa.eu). At the moment, 22 marine‐
derived products are either approved or are at different phases of the clinical pipeline and a 
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larger number are under preclinical evaluation. Among these marine-derived products, only 
four have antiprotozoal purposes, two of which were isolated from macroalgae (Figure 1.5. 
and Figure 1.6.) and all of them are still at the beginning of the approval process (i.e. 
preclinical phase; Table 1.3.). 
Table 1.3. Marine pharmacological pipeline: compounds, source marine organism and target 
disease. Adapted from Malve, 2016 and http://marinepharmacology.midwestern.edu. 
Marine 
organism 
Compound Target disease 
Chemical class  Name and  clinical status 
Algae   
 Glycolipid Floridosides
1
 Inflammation 
 Shikimate Chrysophaentin A
1
 Bacterial infections 
 Terpene Bomophycolides
1
 Malaria 
 Terpene 4-acetoxydolastane
1
 Leishmania 
Bacteria   
 Alkaloid Pulicatin A
1
 Nervous system 
 ‐lactone‐γ lactam Marizomib (salinosporamide A)
2
 Cancer 
 Peptide Arenamides A and B
1
 Inflammation 
  Grassystatins A-C
1
 Immunity 
  Soblidotin (TZT 1027)
4
 Cancer 
  Tasidotin, synthadotin (ILX‐651)3 Cancer 
 Polyketide Pseudoalteromonas sp. metabolites
1
 Bacterial infections 
 Shikimate Phenethylamine
1
 Bacterial infections 
Bryozoa   
 Alkaloid Peziza vesiculosa 
1β‐carboline1 Fungal infections 
 Polyketide Bryostatin 
2
 Cancer 
Fish   
 Guanidinium alkaloid Tetrodotoxin
4
 Chronic pain 
 Omega‐3 fatty acid Omega‐3‐acid ethyl esters5 Hypertriglyceridemia 
Fungi   
 Diketopiperazine Plinabulin (NPI‐2358)3 Cancer 
Mollusks / Cyanobateria   
 Antibody drug conjugate 
(MMAE) 
Brentuximab vedotin (SGN‐35)5 Cancer, lymphoma 
 Glembatumumab vedotin
3
 Breast cancer, melanoma 
  Pinatuzumab vedotin (DCDT‐2980S) 
and (DCDS‐4501A)2 
Non‐Hodgkin lymphoma, 
chronic lymphocytic leukemia 
  HuMax ® ‐TF‐ADC2 Cancer for ovary,  cervix, 
endometrium, prostate 
Mollusks   
 Alkaloid PM1004
2
 Cancer 
 Depsipeptide Elisidepsin
2
 Cancer 
 Peptide Ziconotide
5
 Pain 
Soft corals   
 Diterpene glycoside Pseudopterosins
2
 Wound healing 
 Terpene Capnellene
1
 Inflammation 
  Gyrosanols
1
 Viral infections 
Sponges   
 Alkaloid Hymenidin
1
 Tuberculosis 
 Macrolide Eribulin mesylate (E7389)
5
 Breast cancer 
 Nucleoside Cytarabine, ara‐C5 Cancer, leukemia 
  Vidarabine, ara‐A5 Anti‐viral 
 Peptide Geodisterol sulfates
1
 Fungal infections 
 PKS/NRPS Calyculin A
1
 Nervous system 
 Polyketide Callyspongidiol
1
 Immunity 
  Plakortin
1
 Malaria 
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Marine 
organism 
Compound Target disease 
Chemical class  Name and  clinical status 
 Shikimate Homogentisic acid
1
 Malaria 
 Terpene Dysideamine
1
 Nervous system 
  Dysidine
1
 Diabetes 
 Tripeptide Hemiasterlin (E7974)
2
 Cancer 
Tunicates   
 Alkaloid Trabectedin (ET‐743)5 Cancer 
 Depsipeptide Plitidepsin
4
 Cancer 
Worms    
 
Alkaloid 3‐(2,4 dimethoxy) benzylidene‐
anabaseine (GTS‐21)3 
Cognition, Alzheimers 
disease, schizophrenia 
MMAE - Monomethylauristatin E; PKS/NRPS  - Polyketide synthases/Nonribosomal peptide synthases; 
1 
Pre-
trial; 
2 
Phase I; 
3 
Phase II; 
4 
Phase III; 
5 
approved 
 
The development of more marine natural products beyond those in the current pipeline 
promises important contributions to the medical and veterinary pharmacopeia (Mayer et al., 
2010). This milestone involves the need for strengthening the NP research, optimizing the 
technology through the use of large scale, rapid, random, sensitive and reproducible screening 
methods (Malve, 2016).  
An idea of the dimension of the research needed to obtain a compound that could 
successfully enter the biodiscovery pipeline is provided by the Pharma Sea project 
(http://www.pharma-sea.eu/), one of the current EU projects for the discovery of new 
bioactive marine compounds (Martins et al., 2014). This project aims to produce two 
compounds that could reach the preclinical evaluation. For that goal, complementary experts 
Figure 1.5. Chemical structures of the drugs isolated from algae with antitprotozoal activity and 
currently in the preclinical phase of the marine drugs pipeline: (A) bromophycolides isolated from the 
red alga Callophycus serratus and (B) the 4-acetoxydolastane isolated from the brown alga 
Canistrocarpus cervicornis (dos Santos et al., 2011; Stout et al., 2011; http://www.algaebase.org/). 
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from several scientific and economic areas (biology, genomics, natural product 
chemistry, bioactivity testing, industrial bioprocessing, legal aspects, market analysis and 
knowledge exchange) screened ca. 1,400 microbial marine strains and more than 15,000 
extracts and fractions were already tested against a broad range of antimicrobial agents and 
central nervous system diseases (Jaspars et al., 2016). This example shows the difficulty in 
obtaining a bioactive compound wich can be inserted in the pipeline approval. However, from 
the 28,000 marine molecular entities discovered and deemed as clinically useful (Blunt et al., 
2015), only seven are presently approved by the official entities (Table 1.3.), corresponding 
to 0.03% of the described natural products.  
Concernig this thesis’ aims and despite all the promising availability and novelity of the 
marine bioactive compounds described above, less extensive research has been carried out on 
the evaluation of the antiprotozoal potential of marine organisms, algae in particular. Only 
since the beginning of this century, there has been a focus on screening macroalgae for 
antiprotozoal activity, including that against Leishmania parasites (Tempone et al., 2011).  
1.1.2.2.1 Macroalgae  
Algae are cosmopolite photosynthetic organisms. Marine algae in particular have been 
used by Asian and Caribbean coastal comunities in the traditional medicine (Moo-Puc et al., 
2008), and existing ancient Japanese and Chinese records have reported its use for 
antiparasitic treatments (Tseng and Chang, 1984). Moo-Puc et al., (2008) reviewed the folk 
use of 25 green (Chlorophyta), red (Rhodophyta) and brown algae (Heterokontophyta) 
species, identifying several medicinal properties (e.g. analgesic, anti-pyretic, anti-
inflammatory, anti-neoplasic, urinary and respiratory diseases, cytotoxic and anti-
proliferative, anti-mitotic and anti-microbial) including antihelmintic (Jania capillacea, 
Gracilaria spp. and Hydropuntia cornea) and antiprotozoan (Dictyota caribaea, Laurencia 
microcladia, Sargassum fluitans) activities.  
Several studies demonstrated that macroalgae display biological properties, being promising 
sources of novel natural compounds for pharmaceutical purposes.  In spite of the interest on this 
subject, very few published articles describe the identification of bioactive compounds from 
marine algae, in contrast with the literature on terrestrial plants (Schmidt et al., 2012a,b). Screened 
bioactivities include antioxidant (Ammar et al., 2015; Vizzeto-Duarte et al., 2016a), 
antiproliferative (Vizzeto-Duarte et al., 2016b), anti-inflammatory (Dimou et al., 2016), 
antibacterial (Al-Saifa et al., 2014), antiviral (Takebe et al., 2013), nutraceutic (Vizetto-Duarte et 
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al., 2015) and also antiparasitic properties against agents responsible for neglected protozoan 
diseases as leishmaniasis (reviewed by Torres et al., 2014). 
Thus, screening efforts have explored extracts from several algae species belonging to the 
phyla Chlorophyta, Heterokontophyta and Rhodophyta for antileishmanial activity. A 
comprehensive review of these studies is presented in ANNEX 1.  
These studies report the effects of crude extracts, obtained by different sequential 
extractions of 136 macroalgae species from European, Asian, Middle-East and South 
American countries, upon axenic promastigote (P) and amastigotes (AA) forms of different 
Leishmania species. Concerning the species from the Old World, L. donovani (Lakshmi et al., 
2006; Orhan et al., 2006; Genovese et al., 2009; Allmendinger et al., 2010; Spavieri et al., 
2010a,b; Süzgeç-Selçuk et al., 2010;  Vonthron-Sénécheau et al., 2011) and L. major (Sabina 
et al., 2005; Fouladvand et al., 2011;  Sabina and Aliya, 2011; Saher and Rahman, 2013) was 
the species used by most authors. In contrast, L. infantum was only reported once using 
extracts from one alga (Ainane et al., 2014). These data also show that the choice of the 
Leishmania species in screenings for novel active compounds is often related with the origin 
of the evaluated algae. For example, L. braziliensis (Bianco et al., 2013), L. amazonensis 
(Felício et al., 2010) and L. mexicana (Freile-Pelegrin et al., 2008) are usually species from 
the New Wold (Table 1.1) against which only extracts of algae collected on Brazil and 
Mexican coasts were evaluated. These co-localization trends between parasite and algal 
sources are also apparent for the dermotropic species L. major, usually found in central Asia, 
East Africa and Middle East, against which only Pakistani and Iranian algae were used in 
screening efforts for novel anti-parasitic compounds. 
Another trend seen in these data (ANNEX 1) corresponds to the well-known 
phenomenon that marine organisms collected from different environments have different 
chemistries, which affects their biological activities (Spavieri et al. 2010a). For example, 
antileishmanial activity of three samples of Ulva lactuca and Dictyota dichotoma from 
different locations resulted in IC50 values between 5.9 and 12 μg/mL and 8.8 and 52.0 μg/mL, 
respectively, against L. donovani axenic amastigote forms, even though they were evaluated 
by means of the same screening method (Orhan et al. 2006, Spavieri et al. 2010a, Vonthron-
Sénécheau et al. 2011). The observed discrepancies may stem from several factors, ranging 
from abiotic (e.g. salinity) and biotic (e.g. predation) components (Orhan et al. 2006; Spavieri 
et al. 2010a) to the use of different extraction methods and solvents, resulting in extracts of 
diverse chemical composition. 
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Regarding the activity of algal extracts against Leishmania promastigote forms, the 
lower IC50 values for Heterokontophyta, Rhodophyta and Chlorophyta were 10.9 µg/mL, 6.25 
µg/mL, 34.0 µg/mL for Turbinaria turbinata (Freile-Pelegrin et al., 2008), Osmundea 
pinnatifida (Sabina et al., 2005; Sabina e Aliya, 2011), and Caulerpa faridii and Codium 
flabellatum (Sabina et al., 2005), respectively. The most potent activities against this parasite 
form were found in rhodophytes (ANNEX 1) with five species displaying IC50 < 25 µg/mL, 
namely Laurencia microcladia (Freile-Pelegrin et al. 2008), Bostrychia tenella (Felício et al., 
2010), Asparagopsis taxiformis (Genovese et al., 2009), Osmundea pinnatifida and Scinaia 
hatei (Sabina et al., 2005; Sabina and Aliya, 2011). Rhodophyta are known to contain a wide 
range of secondary metabolites, such as halogenated mono- and diterpenes, sterols, alkaloids, 
polyphenols and sulphated sugars (Blunt et al., 2009), some of which showing antifungal and 
antibacterial activity. Genovese et al. (2009) suggested that the inhibitory properties of the red 
algae Asparagopsis could also be due to their contents in halogenated compounds.  
From the phylum Heterokontophyta, only 6 species from 3 families have been screened. 
The most relevant results were observed with Turbinaria turbinata, Dictyota caribaea and 
Lobophora variegata, displaying antileishmanial activity with IC50 < 50 µg/mL (Freile-
Pelegrin et al. 2008).  
Chlorophyta was the phylum with less potent activities against Leishmania 
promastigotes. None of the 17 species studied had activities lower than 25 µg/mL. The lowest 
IC50 values were obtained with ethanolic extracts of Caulerpa faridii (IC50 = 34 µg/mL), C. 
racemosa (IC50 = 37.5 µg/mL) and Codium flabellatum (IC50 = 34 µg/mL; Sabina et al. 2005). 
Regarding the clinically relevant stage of the parasite, most studies used axenic 
L. donovani amastigotes. The inhibitory effect of the tested marine macroalgae extracts 
ranged between 3.8-90.9 µg/mL, 9.5-85.6 µg/mL and 5.9.39.2 µg/mL for Heterokontophyta, 
Rhodophyta and Chlorophyta, respectively.  
However, in contrast with the results observed with promastigote forms described above, 
higher activities were found in Heterokontophyta species, namely in Bifurcaria bifurcata 
(Spavieri et al., 2010a, Vonthron-Sénécheau et al., 2011), Halidrys siliquosa (Spavieri et al., 
2010a), Dictyota dichotoma and Dictyopteris polypodioides (Vonthron-Sénécheau et al., 2011). 
All these species presented extracts with IC50 < 11 µg/mL. From the reviewed data, the Ulvaceae 
appears as one of the main sources, among chlorophytes, of antileishmanial compounds for the 
axenic amastigote form (Orhan et al. 2006, Spavieri et al. 2010b).  
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Within the 19 Rhodophyta families screened for antileishmanial on axenic amastigote 
forms, only 7 (Dumontiaceae, Rhodomelaceae, Ceramiaceae, Gelidiaceae, Plocamiaceae, 
Corallinaceae, Dasyaceae) showed activities with IC50 < 25 µg/mL (ANNEX 1).  
Several metabolites such as terpenoids (Fisch et al., 2003; De-Paula et al. 2012), 
sesquiterpenes (Shimizu et al., 2015), phlorotannins (Steevensz et al., 2012) and steroids 
(Fleury et al., 1994) have frequently been reported in seaweeds. Hovewer, and despite all 
these efforts, the report of pure compounds active against Leishmania parasites isolated from 
marine algae has been scarce (Table 1.4).  
Considering the data obtained with pure compounds isolated from marine seaweeds, 
two diterpenes, 4-acetoxydolastane ((4R,9S,14S)-4α-acetoxy-9β,14α-dihydroxydolast-
1(15),7-diene) and the dolabelladienetriol diterpenes obtained from Canistrocarpus 
cervicornis (IC50 12.3 μM; dos Santos et al., 2011) and Dictyota pfaffii (IC50 43.9 μM; Soares 
et al., 2012), respectively, were shown to be active against intracellular L. amazonensis forms. 
Elatol, obtusol and triquitane were isolated from the red alga Laurencia dendroidea (dos 
Santos et al., 2010; Machado et al., 2011), being effective against the promastigote and 
intracellular amastigote forms of the same parasite species, though triquitane was less active. 
Sulphated polysaccharides, obtained from Gayralia oxysperma, Gymnogongrus griffithsiae, 
Table 1.4. Compounds isolated in marine macroalgae active against Leishmania amazonensis 
parasites  
Compound  Algae  
species 
Inhibitory concentration (μM) References 
(a-f)
 number, class and name P AA IA 
Diterpenes      
1 4-acetoxydolastane Canistrocarpus cervicornis 6.1 36.8 12.3 (d) 
2 dolabelladienetriol Dictyota pfaffii  - - 43.9 (e) 
Sesquiterpenes      
3 elatol  Laurencia dendroidea 29.1 - 13.5 (c) 
   4.0 - 0.45 (b) 
4 obtusol  14.9  9.4 (c) 
5 triquinane  195.5 - 217.4 (c) 
Sulphated polysaccharides      
 galactana iota-nu-carragenana Eucheuma denticulatum - - 10/98.0
*
 (a) 
 galactana kappa-iota-nu-
carragenana 
Gymnogongrus griffithsiae - - 10/50.0
*
 (a) 
 heteroraminana sulfatada Gayralia oxysperma - - 10/55.0
*
 (a) 
 n.n. Botryocladia occidentalis 63.7
#
   (f) 
 n.n. Caulerpa racemosa 137.4
#
   (f) 
 n.n. Solieria filiformis 34.5
#
   (f) 
P - promastigote; AA - axenic amastigote; IA - intracelullar amastigote; n.n. - no specified name; 
# 
Half inhibitory concentration (IC50; μM); 
* Maximal concentration tested (μg/mL) / % cell inhibition.  
a – Marcolino, 2010; b - dos Santos et al., 2010; c - Machado et al.; 2011; d - dos Santos et al., 2011, e - Soares et 
al., 2012; f - Pires et al., 2013. 
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and Eucheuma denticulatum (Marcolino, 2010) and Botryocladia occidentalis, 
Caulerpa racemosa, Solieria filiformis (Pires et al., 2013) also revealed inhibitory activity 
against L. amazonensis. These macromolecules had already been recognized as secondary 
metabolites with important roles in algal physiology (Pires et al., 2013) and ecology, such as 
anti-herbivore activity and possible defence against infection by microorganisms (Marcolino, 
2010; Table 1.4. Figure 1.6).   
However, a note of caution must be mentioned regarding the choice of the life cycle 
stage of the parasite for screening efforts. For example, even though the aforementioned 
diterpenes and sesquiterpenes came from the same extract, they affected amastigotes and 
promastigotes differently. This result reiforces the importance of using the intracellular 
amastigote model as the in vitro model that better mimicks the response of the vertebrate host 
and the clinically relevant stage of the parasite for the evaluation of the efficacy of NPs 
against Leishmania.  
Different bioactivity results were also reported using the same algal species, but tested 
in specific forms of the parasite. Dos Santos et al. (2011) observed a higher sensitivity of 
promastigotes (IC50 = 2.0 μg/mL) to the 4-acetoxydolastane isolated from C. cervicornis as 
compared with the intracellular form (IC50 = 4.0 μg/mL) and axenic amastigote forms (IC50 = 
12.0 μg/mL) of L. amazonensis (Table 1.4.) 
 
 
Figure 1.6. Chemical structures of diterpenes isolated from macroalgae with activity against 
Leishmania amazonensis.  
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1.2. CYSTOSEIRA ALGAE, A SOURCE OF BIOACTIVE COMPOUNDS 
The genus Cystoseira, described by C. Agardh in 1820, is included in the family 
Sargassaceae (Order Fucales; Rousseau and de Riviers, 1999). Despite the existing taxonomic 
difficulties in the classification of this genus is currently accepted that it encompasses about 40 
species, the majority occurring in the Mediterranean Sea and Atlantic-Mediterranean regions 
(García-Fernández and Bárbara, 2016; Guiry and Guiry, 2016). In the Iberian Peninsula, are 
recognized twenty-four specific and infraespecific taxa (García-Fernández and Bárbara, 2016). 
Geographical distribution of algae species and genera usually reflects its evolutionary 
history (Garbary, 2001). Algae belonging to the genus Cystoseira originally emerged in the 
Thetis Sea, located between Eurasia and Africa, 80 million years ago during the late 
Cretaceous. As a consequence of continental drift, the Mediterranean was formed, being 
intermittently connected to the Atlantic Ocean. This enabled the colonization of the 
Mediterranean by the ancestors of Cystoseira. The isolation of Mediterranean from the 
Atlantic Ocean resulted in the hipersalinization of this sea and extinction of most marine 
organisms during the Cenozoic. At the beginning of Pliocene, when the Atlantic waters re-
entered the Mediterranean through the Strait of Gibraltar, this sea was again colonized by 
Cystoseira algae. The colonization of this new but favorable ecosystem led to speciation, a 
process that is still ongoing (Piatelli, 1990 cited by Amico, 1995). 
Being among the main species responsible for the habitat formation in the intertidal and 
lower sublittoral zones (Lotze et al., 2006; Thibaut et al., 2015; Bermejo et al., 2016), 
Cystoseira plays an essential role in the conservation of biodiversity and ecosystem 
functioning (Ballesteros, 1989; Giaccone et al., 1994). Marine Cystoseira forests provide 
habitat for other algae, invertebrates and fish (Bellan and Bellan-Santini, 1972; Bulleri et al., 
2002; Cheminée et al., 2013; Bermejo et al., 2016), being a key element of the marine 
ecosystem (Ballesteros et al., 2007; Thibaut et al., 2014; Bermejo et al., 2013,2015). 
Currently, many Cystoseira species are undergoing a strong demographic decline, 
which has been attributed to both local and global pressures (Thibaut et al., 2005; Mineur et 
al., 2015; Thibaut et al., 2015; Blanfuné et al., 2016). The water turbidity, eutrophication and 
pollution are among the changes that might explain the loss of biodiversity, including habitat-
forming macrophyte species such as the Cystoseira spp. (Airoldi and Beck, 2007; Mangialajo 
et al., 2008; Sales et al., 2011). Considered as an important indicator of the marine 
environment ecological status on the Atlantic-Mediterranean regions (Ballesteros et al., 2007; 
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Díez et al., 2012), this decrease is a consequence of the sensitivity of these algae to the 
increasing anthropogenic activity (Thibaut et al., 2015; Bermejo et al., 2016).  
In addition to its undeniable bio- and ecological importance, the algae from this genus 
have shown be carriers of a large number of chemical constituents from different classes 
(Amico, 1995; Valls et al., 1993a). This chemical diversity has been explored by several 
authors to unravel the complex phylogeny of this genus, but also for biochemical (Lodeiro et 
al., 2006) and biomedical discovery purposes (Calvo et al. 1986; Spavieri et al. 2010a; Pujol 
et al. 2012; Mhadhebi et al. 2014; de los Reyes et al. 2016; Bruno de Sousa et al., 2017). 
1.2.1. SPECIES DIVERSITY AND DISTRIBUTION  
Cystoseira belong to the phylum Heterokontophyta, whose members are often called 
“brown algae”. They are known as brown due to the presence of carotenoids (e.g. fucoxanthine), 
which imparts a yellow-brownish color to plastids. Ultrastructurally, plastids contain 3-thylakoid 
lamellae and the chloroplast is surrounded by the endoplasmic reticulum, which is confluent with 
the nuclear envelope. Their mitochondria have tubular cristae; the cell walls contain alginic acid, 
fucoidine and cellulose; and the vacuoles storage β-glucan laminarin as food reserve (Gómez-
Garreta, 2003; Kadam et al., 2014). Physodes, membrane-bound vesicles, contain phlorotannins; 
and reproductive cells present two heterokont lateral flagella (Gómez-Garreta, 2003). 
Morphologically, Cystoseira have small dense clumps or tufts forming caespitose thalli 
linked to a single axis that is attached to the substratum by a conical disc or hapteron (Figure 1.7). 
The axis ends in a smooth or spinous apex. Radial (Figure 1.7.-B3) or distichous branches 
ramifications are (Figure 1.7.-C3, E3) abundant and can exhibit small spine-like or filiform 
appendages. Some characteristics are typical of specific species as, for example, the the presence 
of conical or ovoid tophules arranged along the axis or grouped in the apical zone in C. nodicaulis 
(Figure 1.7.-D3), the greenish-blue iridescence of the C tamariscifolia branches (Figure 1.7.-E2); 
and the aerocysts, either isolated or arranged in chains at the apices of the terminal branchlets of 
C. baccata (Figure 1.7.-A2) and C. usneoides (Figure 1.7.-F2).  
Concerning the reproductive structures, the receptacles are variable in shape and develop at 
the upper parts of higher order branchlets, being ocasionally bifurcate or branched and with spine-
like appendages; conceptacles, usually hermaphrodite, can be sazonally unisexual (Gómez-
Garreta et al., 2001). 
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Figure 1.7. Cystoseira specimens (columns 2 and 3) and collection sites along the Iberian Atlantic 
coast (column 1). A1-3, C. baccata with its isolated aerocysts collected in lower intertidal of Areosa - 
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Viana do Castelo, Portugal (PT), together with C. tamariscifolia (A2); B1-3, C. compressa collected in 
the upper intertidal rocky pools of S. Rafael - Albufeira, PT; C1-3, C. humilis collected in the upper 
intertidal rocky pools of Almograve - Odemira, PT; D1-3, C. nodicaulis collected in the sheltered 
coast of Santa Mariña - Coruña, Spain, and its discriminating tophules in the main thalli (D3); E1-3, 
C. tamariscifolia collected in the lower intertidal of Olhos de Água – Albufeira (E1, E3) and Areosa – 
Viana do Castelo, PT where is possible to see the blue iridescence (E2); F1-3, C. usneoides with its 
abundant and chained aerocysts collected in O Grove - Pontevedra, Spain beach cast. In A3, C3 and 
E3 it is possible to see the caespitose thalli linked to a single axis that attach to the substratum. 
A,B,C3,E and F photographs were taken by the author, D2 was a courtesy of J. Cremades and D1 was 
obtained from http://www.caminodosfaros.com. 
The easy acclimation and wide range of phenological and intra/inter species 
morphological variability of Cystoseira leds to successive alterations of the taxonomy and 
nomenclature of the genus since it was described by C. Agardh, in 1820. Aditionally, the 
ongoing active speciation, and hybridization of many of the species have often contributed to 
the occurrence of erroneous taxonomical assignments, and so the macroalgae currently 
classified as members of this genus still face challenges regarding their taxonomic assignment 
and classification (Draisma et al., 2010). 
A biological characterization of Iberian Cystoseira species together with a detailed 
taxonomic description for the identification of specimens by means of keys was published by 
Gómez-Garreta et al. (2001). Recently, García-Fernández and Bárbara (2016) have 
summaryzed the discriminative morphological features for the identification of North Atlantic 
Iberian species.  
The deep knwoledge and recognition of the morphological features of the species is of 
crucial importance for the acurate identification of the biomass used for phycochemical studies, 
justifying the need of synergistic collaborations of technicians from different areas.  
The worldwide and Iberian distribution of the species of this genus was reviewed by 
Oliveras Plá and Gómez-Garreta (1989) and Gómez-Garreta et al. (2001), respectively. 
Recently, in a study of Cystoseira assemblages in Northern Atlantic Iberia, García-Fernández 
and Bárbara (2016) summarized the distribution of the species present within the Atlantic-
Mediterranean region, indicating that 31 taxa from 24 species are present on the Iberian 
Peninsula coasts. Twenty species are only found in the Mediterranean Iberia, and two others 
are exclusive of the Atlantic Iberia, with 9 taxa being recognized as present in both 
Mediterranean Sea and Atlantic Ocean (Table 1.5.). 
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Table 1.5. Distribution of the Iberian Cystoseira species and infraespecific taxa (Adapted from 
García-Fernández and Bárbara, 2016) 
Iberian Region Cystoseira species and infraespecific taxa 
Mediterranean C. abies-marina, C. algeriensis, C. amentacea var. stricta, C. barbata,  
C. barbatula, C. brachycarpa, C. brachycarpa var. claudiae,  
C. compressa f. plana, C. crinita, C. elegans,  
C. foeniculacea f.  latiramosa, C. foeniculacea f. tenuiramosa,  
C. funkii, C. mauritanica, C. mediterranea, C. pelagosae, C. sedoides, C. spinosa, 
C. spinosa var. tenuior, C. squarrosa, C. zosteroides 
Atlantic C. baccata, C. humilis var. myriophylloides 
Atlantic-Mediterranean C. barbata f. repens, C. compressa, C. foeniculacea, C. humilis,  
C. nodicaulis, C. sauvageauana, C. spinosa var. compressa,  
C. tamariscifolia, C. usneoides 
1.2.1.1. Taxonomy and specimen assignment 
Taxonomic classification of Cystoseira is a controversial challenge (Gómez-Garreta et 
al., 1994; Ballesteros and Pinedo, 2004). The wide range of morphological plasticity, 
compounded by the active, ongoing speciation and hybridization of many species (Roberts, 
1978 cited by Draisma, 2010) has led to erroneous taxonomical assignments of specimens 
collected at different locations and seasons (Jégou et al., 2010). This has become apparent 
from inconsistencies found between taxonomical classifications based on morphologic traits 
and current molecular data.  
In order to overcome the problems in the correct identification of thalli caused by the 
morphological variability of these macroalgae, several studies tried to elucidate the genetic 
relationships of this genus and the related species using different genetic (Harvey and Goff, 
2006; Susini et al., 2007; Draisma et al., 2010; Robvieux et al., 2012; Rožić et al., 2012) and 
chemical markers (Piatelli, 1990 cited by Amico, 1995; Valls et al., 1993a; Amico, 1995; 
Valls and Piovetti, 1995; Jégou et al., 2010). However, the classification of Cystoseira 
individuals and closely related macroalgae is yet to be fully resolved. First attempts to 
determine the taxonomy of these brown algae were mostly based on morphological traits. 
Chemotaxonomic approaches soon followed, showing the potential of using the chemical 
composition as a taxonomic classification tool (Valls et al. 1993a; Amico, 1995). Trends were 
observed, and a close agreement between chemistry and morphology has been suggested 
(reviewed by Amico, 1995). The study of characteristic diterpenoids in Atlantic and 
Mediterranean Cystoseira species allowed to define a chemotaxonomic classification based 
on the presence or not of diterpenes and meroditerpenes in its chemical composition (Valls et 
al., 1993b). In another approach, the analysis of the global chemical profile and the lipophilic 
composition of 5 Britanny Cystoseira species through LC/ESI-MS
n
 (liquid 
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chromatography/electrospray ionization multistage mass spectrometry) showed to be 
concordant with the phylogenetic relationships established by the nuclear ITS2 marker (Jégou 
et al., 2010). In spite of a partial concordance between the morphologic, chemical and genetic 
classifications, the taxonomy and phylogeny of this group of brown algae is yet to be fully 
explained (Draisma et al., 2010; Jégou et al., 2010). 
Several studies have tried to elucidate the genetic relationships of this genus and related 
species using phylogenetic methods (Draisma et al., 2010; Rožić et al., 2012). Analysis of 
Fucales (Phaeophyceae) based on ribosomal DNA (rDNA) sequences led to the merging of 
the Cystoseiraceae with the Sargassaceae (Rousseau and de Reviers, 1999). In 2010, the 
polyphyly of the genus Cystoseira was demonstrated. Using mitochondrial genetic markers, 
the authors proposed the division of the genus into 6 different groups, along with other 
entities belonging to Sargassaceae (Draisma et al., 2010). Several members of the genus were 
reclassified as belonging to the genera Sirophysalis, Polycladia and Stephanocystis based on 
the conjugation of these data with the morphologic and embryonic development 
characteristics. In this study, the mitochondrial ribosomal DNA 23S subunit (mt23S) genetic 
marker proved to be useful to delineate genera (Draisma et al., 2010). Conversely, the 
mitochondrial intergenic spacer (mt-spacer) between the 23S-tRNA
Val
 intergenic spacer 
mt23S gene and the tRNA
Val
 gene, encompassing the tRNA
Lys
 gene,  was either not used for 
phylogenetic inference due to its extreme intergeneric variability (Draisma et al., 2010) or 
proved not to be suitable to resolve closely related Cystoseira (Rožić et al., 2012). As a result, 
the group of species that retained the original classification was found to be polyphyletic, 
clustering into at least three different genera.  
The mt23S genetic marker proved to be useful to define genera (Draisma et al., 2010). 
A set of 10 additional mitochondrial, plastid and nuclear markers has also been used to 
investigate the evolutionary history of brown algae at the ordinal level (Silberfeld et al., 
2010). However, to date, full infrageneric resolution of the genus and related Sargassaceae 
macroalgae has yet to be achieved and the taxonomy of the Cystoseira species is still to be 
completed. More comprehensive genetic studies are needed to fully clarify the phylogeny of 
Cystoseira. 
The results here described show the value of molecular and chemical tools in a 
taxonomical context, for the establishment of species phylogenetic relationships and also for 
sample identification (Jégou et al., 2010). The phylogeny of this genus is analysed and 
discussed in CHAPTER V. 
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1.2.2. CHEMICAL COMPOSITION AND POTENTIALITIES FOR DRUG DISCOVERY 
Chemistry of the Cystoseira species has been studied since 1976 (Fattorusso et al., 
1976). Three important reviews on the chemistry of secondary metabolites isolated from algae 
of the former Cystoseiraceae family, to which the genus Cystoseira once belonged, were 
published by Piatelli (1990) cited by Amico, 1995), and Valls and Piovetti (1995). These 
works described the chemistry and chemotaxonomy of these species, mainly based on the 
diterpenoids and meroditerpenes diversity. Recent studies show that globally the chemical 
constitution of these brown algae include diterpenoids (Ayyad et al., 2003), meroditerpenoids 
(de los Reyes et al., 2013), tetraprenyltoluquinol derivatives (Fisch et al., 2003), fatty acids, 
sterols (Andrade et al., 2013) and terpenes (Kamenarska et al., 2002) (CHAPTER II). 
The bio- and chemical diversity of this genus suggest that Cystoseira macroalgae have 
great potential for the discovery of novel compounds with biomedical relevance (Valls et al., 
1993a). Various Cystoseira species have been investigated for their pharmaceutical potential 
and, among those studies, extracts from these algae were shown to possess antibacterial 
(Bennamara et al., 1999; Süzgeç-Selçuk et al., 2010; Spavieri et al., 2010a), antifungal 
(Bennamara et al., 1999), antiprotozoal (Spavieri et al., 2010a; Süzgeç-Selçuk et al., 2010), 
antioxidant (Fisch et al., 2003; Mhadhebi et al., 2014), cytotoxic (Ayyad et al., 2003; Spavieri 
et al., 2010b), antiviral (Urones et al. 1992a), anti-proliferative (Urones et al. 1992b; 
Mhadhebi et al. 2014) and anti-inflammatory (Mhadhebi et al., 2014; de los Reyes et al., 
2013) activities. In addition, several of the compounds (e.g. phlorotannins and diterpenes) 
identified in different species of Cystoseira, but deemed as not specific to these species, 
exhibited diferent biomedical properties, such as antiviral and antitumoral (Gupta and Abu-
Ghannam, 2011; Lopes et al., 2013; Stiger-Pouvreau et al., 2014). Cystoseira indica sulphated 
polysaccharides have also shown antiviral activity (Pujol et al., 2012). In addition, Cystoseira 
fatty acids, sterol and hydrocarbons displayed specific activities against enzymes ( -
glucosidase, acetylcholinesterase and butyrylcholinesterase) and free radicals (α,α-diphenyl-β-
picrylhydrazyl - DPPH, nitric oxide, superoxide and hydroxyl; Andrade et al., 2013).   
Nevertheless, only a limited number of papers evaluating the antileishmanial activity of 
novel Cystoseira species have been published. To date, only C. baccata, C. barbata, 
C. tamariscifolia and C. crinita extracts have been tested against Leishmania parasites, showing to 
be active against L. donovani axenic amastigotes (Spavieri et al., 2010a; Süzgeç-Selçuk et al., 
2010; ANNEX 1). C. tamariscifolia was also evaluated against the VL agent, L. infantum, 
however, without interesting results (Ainane et al., 2014). Despite the lack of knowledge on the 
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antileishmanial properties of the genus Cystoseira, the published results suggest that this genus is 
a potential source of compounds with activity against Leishmania parasites. This study was 
conducted under the aims of this tesis and is described in the CHAPTERS III and IV. 
1.2.3. BIOMASS IDENTIFICATION FOR PHYCOCHEMICAL STUDIES 
Discovery of NPs requires an unequivocal identification of the investigated biological 
material and specific sampling strategies in order to efficiently survey the chemical diversity 
of the target organisms (Amico, 1995; Bucar et al., 2013; Leal et al., 2016). As important as 
the precise identification of the sampling location, the characterization of the chemical 
structure and the bioactivity of the identified molecules, the taxonomical identification of the 
biological entities used is crucial to guarantee the reproducibility of the performed research 
(Leal et al., 2016).  
The accurate taxonomic identification of the biomass is relevant for the effectiveness of 
the discovery of NPs, because compounds of interest can be specific of a given species. This 
aspect also ensures that the studied organism is not under protection programs, and therefore 
its abundance allows its exploitation (Bruno de Sousa et al., in prep.; Leal et al., 2016). 
Moreover, it allows the researchers to positively identify the biological material if additional 
sampling is necessary for large-scale isolation of the active molecules (Cordell et al., 1993). 
Thus, accuracy of the identification of biomass used for isolation and identification of NPs is 
a crucial issue for the reproducibility and reliability of the obtained results, as well as for the 
implementation of conservation measures for the target species. Classification of algal species 
is not an easy task, being in some cases difficult to define trustworthy attributes to accurately 
describe a given group of species, as for example those belonging to the genus Cystoseira 
(Gómez-Garreta et al., 2001). 
Biological classifications or taxonomy are dynamic systems that attempt to classify 
organisms according to their similarities and lack of it. Since the beginning, different 
principles have been adopted concerning the concept of species (Mayr and Bock, 2002; 
Taylor, 2009). Initially, these systems assumed that individuals morphologically similar 
and/or capable of interbreeding were nearest relatives. However, there is the perception that 
this assumption is not always correct and that there are individuals with similar morphological 
traits that can be observed in distantly related taxonomic groups, whilst the contrary may also 
be applied, since organisms with different morphologies can be more closely related than 
other individuals with a more similar morphology (Coleman, 2009). Towards the need to 
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clarify these specificities, other criteria were required to develop a different taxonomic 
classification that could clarify the diverse phylogenetic relations. Several biochemical 
approaches were developed, such as studying the taxonomy of organisms through their 
chemical profiles (Valls et al., 1993a; Jégou et al., 2010). However, the use of molecular 
genetics proposed for the first time by Zuckerkandl and Pauling (1965) became the most used 
procedures for taxonomic purposes. Since then, the development of molecular and 
bioinformatics technologies, which use DNA sequence analysis as data, has exponentially 
increased the resolution of the phylogenetic inference, bringing the ability to process, analyse 
and integrate large amounts of molecular information, very useful to elucidate the 
phylogenetic relationships between individuals and populations (Delsuc et al., 2005).  
1.2.3.1. Phylogenetic markers 
DNA sequences contain the information suitable for taxonomy and phylogenetic studies 
using appropriate bioinformatic tools. DNA sequencing and PCR related techniques are 
applied to target specific regions and comparison of homologous sequence data of the studied 
individuals making possible to access information about changes in nucleotide composition. 
Numerous parts of the genome can be compared between individuals, and some genetic 
sequences can be used as phylogenetic reference markers (Delsuc et al., 2005). 
Several molecular markers have been studied by different authors to unravel brown 
algae phylogenetic relationships and the evolutionary history of brown algae in the last 
decade. Specifically, within the Sargassaceae, the family to which the genus Cystoseira 
belongs, nuclear (Rousseau et al., 2001; Harvey and Goff, 2006; Jégou et al., 2010; Silberfeld 
et al., 2010) plastid (Cho et al., 2006; Silberfeld et al., 2010, 2014) and mitochondrial 
(Silberfeld et al. 2010, 2014; Draisma et al., 2010; Rožić et al., 2012) markers have been 
used. 
In our study, we used molecular markers that reflect the changes in three specific 
regions of the mitochondrial DNA, namely the mt23S, mt-spacer and cytochrome oxidase 
gene subunit I (COI). The mt23S and the mt-spacer are two of the most used mitochondrial 
markers (Draisma et al., 2010; Coyer et al., 2006; Rožić et al., 2012). These were combined 
with plastidial sequences coding for the photosystem II thylakoid protein D1 (psbA; Draisma 
et al., 2010; Rožić et al., 2012), enabling the authors to show the polyphyly of the Cystoseira 
genus, among other Sargassaceae genera. Phylogenetic inference using the photosystem I 
coding psaA gene confirmed the integration of Cystoseiraceae family within the Sargassaceae 
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(Cho et al., 2006). COI is a well-known molecular tool used for the identification, i.e. DNA 
barcoding, of different metazoan species (Arif and Khan, 2009; Hebert et al., 2003a; Aly, 
2014). The mutation rate of this gene is high enough to distinguish species that are closely 
related and, for that reason, it has been successfully used in the barcoding of animals (Hebert 
et al., 2003a; Rubinoff, 2006) as well as red (Saunders, 2005; Le Gall and Saunders, 2010; 
Sherwood et al., 2010a) and brown algae, including Phaeophyceae (Mattio and Payri, 2010; 
McDevit and Saunders, 2009; Saunders and McDevit, 2013). Despite its regular use, the 
utility of this marker for the intraspecific identification of Cystoseira species has not been 
evaluated to date. 
1.3. AIMS OF THIS STUDY 
Because of the high cost, toxicity, declining efficacy and parasite resistance of the 
available drugs, the need for novel drugs for treatment of leishmaniasis, which affects 
millions of people and dogs worldwide, is urgent. Marine biodiversity is nowadays 
recognized as a source of novel products, to be used alone or in combination therapies with 
available drugs, which is a promising alternative to anti-Leishmania therapy and control.  
The Cystoseira macroalgae, occurring mainly in the Atlantic-Mediterranean coasts, 
have been screened for several biomedical activities; however, few reports describe the 
evaluation of their antileishmanial potential. Despite the several studies on its chemical 
diversity, no information was available on the compounds responsible for the inhibitory 
effects of their extracts on the Leishmania parasite. Thus, a study of the antileishmanial 
potential of this algal genus was considered to be highly relevant. Biological sources used to 
obtain compounds with biomedical properties require the proper identification of that source. 
This question is especially important in species with a high degree of morphological plasticity 
such as the Cystoseira. In this genus, identification of thalli down to the species level is not 
always consensual and molecular-based techniques for the positive identification of the 
specimens used for drug screening are urgently needed.  
Therefore, the present thesis has two main objectives:  
- Identify compounds of the Cystoseira macroalgae displaying antileishmanial activity 
with potential for further development studies in the context of antileishmanial therapy and; 
- Evaluate the usefulness of mitochondrial markers, as molecular aids in the 
identification of macroalgae belonging to the Cystoseira genus in order to ensure the correct 
assignment of a sample for drug screening purposes.  
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2.1. ABSTRACT 
Cystoseira is a genus of marine brown algae belonging to the Sargassaceae family and 
composed by about 40 species, which is distributed along the Eastern Atlantic and 
Mediterranean coasts. The biological potential of Cystoseira genus has been investigated and 
antifouling, anti-bacterial, antifungal, antiviral, cytotoxic, antioxidant, antitumoral, and 
antiprotozoal activities have been reported. Chemically, the genus Cystoseira contains a wide 
variety of secondary metabolites, such as terpenoids, steroids, phlorotannins and phenolic 
compounds. Additionally, other chemical components for instance carbohydrates, 
triacylglycerols and fatty acids, pigments as well as vitamins have been isolated and identified 
in this genus. Some of the isolated compounds were associated with the reported 
pharmacological properties. Important reviews on the chemistry of secondary metabolites 
from Cystoseira are published, however, given the current importance of the natural products 
of marine origin it was considered pertinent to update these revisions in the light of current 
knowledge. In this review, we provide a comprehensive overview of the compounds isolated 
and identified after 1995 from the different species of Cystoseira, compiling more than 200 
compounds isolated, together with their therapeutic potentialities. 
 
Keywords: Macroalgae; Cystoseira; Natural products; Chemistry; Biological activity. 
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2.2. INTRODUCTION 
Marine resources represent approximately 25% of the Earth’s biodiversity (Mora et al., 
2011). The adaptation to the extremely pH, pressure, temperature and osmolarity challenging 
conditions induced the production of several secondary metabolites by the living organisms 
(Colegate and Molyneux, 2008). Among the marine organisms, macroalgae are nowadays 
receiving increasing attention due to their economic and ecological role as well as because of 
their important role in the actual panorama of drug discovery, resultant of the wide diversity 
of biological and specific molecules produced by these organisms (Bourgougnon and Stiger-
Pouvreau, 2011; Leal et al., 2016). 
Cystoseira C. Agardh, 1820 is a polyphyletic genus of marine macroalgae of the 
Sargassaceae family. Distributed along the Atlantic-Mediterranean coasts, this genus 
currently encompasses around 40 species (García-Fernández and Bárbara, 2016; Guiry and 
Guiry, 2016; Figure 1). Being essential for the biogenic structure of the marine forests these 
species ensure food and shelter to numerous species of marine organisms that co-habiting the 
rocky reefs and have economic value for man (Cheminée et al., 2013; Bermejo et al., 2016). 
Members of this genus are known to produce various secondary metabolites from different 
categories such as terpenoids, fatty acids, triacylglycerols, steroids, phlorotannins, phenolic 
compounds and polysaccharides (Amico, 1995; Valls and Piovetti, 1995). 
The bio- and chemical diversity of the genus, suggest that Cystoseira macroalgae have 
great potential for the discovery of novel compounds with biomedical relevance (Amico, 
1985a; Valls et al., 1993a). Extracts of different Cystoseira species have been evaluated for 
their several activities, such as antimycobacterial and antiprotozoal (Spavieri et al., 2010a; 
Bruno de Sousa et al., in prep.), antiviral (Pujol et al., 2012) and antifungal (Calvo et al., 
1986) properties. Additionally, cytotoxic (Spavieri et al., 2010a), antioxidant (Vizetto-Duarte 
et al., 2016a) and antitumoral (Vizetto-Duarte et al., 2016a,b) potentials were also reported. 
Four important reviews on the chemistry of secondary metabolites isolated from 
Cystoseiraceae algae, the family where the genus Cystoseira was once considered to belong, 
were published by Piatelli (1990) cited by Amico (1995), Valls and Piovetti (1995) and 
Gouveia et al. (2013a). Since these publications, relevant taxonomic changes have been 
proposed to this family that changed its position to the current family Sargassaceae (Rousseau 
and de Reviers, 1999; Cho et al., 2006). Other studies also led to the reclassification of some 
Cystoseira species from the Pacific Ocean in other genera (Draisma et al., 2010). 
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The current importance of natural products from marine origin, and in particular of the 
nutritional value and pharmacological applications of Cystoseira sp., led us to considered 
pertinent to update the available reviews regarding the global chemical constitution and 
biological aspects of these algae. Moreover, a compound of interest often has crossed 
bioativities, therefore, the knowledge of other recognized bioativities provides for a better 
understanding of the pharmacological potential of a certain species. In this scope, this review 
provides a comprehensive overview of the compounds isolated after 1995 from the different 
species from the current genus Cystoseira. 
2.3. CHEMICAL CONSTITUENTS AND BIOLOGICAL ACTIVITIES OF 
CYSTOSEIRA SP. ALGAE 
Chemical and biological aspects of 214 compounds isolated from sixteen studied 
Cystoseira species are shown in Table 2.1., in which and are compiled the compounds 
isolated from each species and some of the respective recognized biological activities. The 
metabolites found in major number were lipids followed by terpenoids (including 
meroterpenoids), steroids, carbohydrates, phlorotannins, phenolic compounds, pigments and 
vitamins. Other several compounds were identified and the respective chemical and biological 
aspects are described below. 
Table 2.1. Chemical and biological studies of genus Cystoseira. (Numbering of compounds will be 
used throughout the chapter). 
No Compound class and name Species (Origin) Reference Biological activity 
Terpenoids    
1 Cystoseirol monoacetate  C. myrica
b
  32 Cytotoxic 
2 Dictyol F monoacetate  C. myrica
b
 32 Cytotoxic 
3 Dictyone  C. myrica
b
 32 Cytotoxic 
4 Dictyone acetate C. myrica
b
 32 Cytotoxic 
5 Isodictytriol monoacetate  C. myrica
b
 32 Cytotoxic 
6 Pachydictyol     C. myrica
b
 32 Cytotoxic 
7 3,7-dimethyl-1,6-octadiene-3-ol- 2-
aminobenzoate 
C. crinita
l
 245 - 
8 Hexahydrofarnesylacetone  C. crinita
l
 245 - 
9 Dihydro-3-hydroxy-3-hydroxymethyl- 
2(3H)-furanone 
C. crinita
l
 245 - 
10 Dihydroactinidiolide C. crinita
a
 245,336 -  
11 Isololiolide C. tamariscifolia
 i
 503 Antiproliferative503,anti-germinative
232
, 
anti-cyanobacterial
525
 
Meroterpenoids    
12 14-epi-amentol triacetate Cystoseira sp.
j
 357 - 
13 Amentol Cystoseira sp.
j
 357 - 
14 Amentol chromane diacetate Cystoseira sp.
j
 357 - 
15 Cystoseirone diacetate Cystoseira sp.
j
 357 - 
16 Preamentol triacetate  Cystoseira sp.
j
 357 - 
17 Demethoxy cystoketal chromane C. tamariscifolia
 i
 
C. amentacea var. 
stricta
c
 
502 
495 
Antiproliferative 
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No Compound class and name Species (Origin) Reference Biological activity 
18 Cystoazorol A C. abies-marina
i
 191 Antioxidant, cytotoxic 
19 Cystoazorol B C. abies-marina
i
 191 Antioxidant 
20 Cystoazorone A C. abies-marina
i
 191 Cytotoxic 
21 Cystoazorone B C. abies-marina
i
 191 Cytotoxic 
22 2-[(2′E,6′E,10′E,14′Z)-5′-hydroxy-15′-
hydroxymethyl-3′,7′,11′-
trimethylhexadeca-2′,6′,10′,14′-
tetraenyl]-6-methyl hydroquinone 
C. crinita
f
 165 Antioxidant, cytotoxic 
23 2-[(2′E,6′E,10′E)-5′-oxo-13′-hydroxy-
3′,7′,11′,15′-tetra-methylhexadeca-
2′,6′,10′,14′-tetraenyl]-6-methyl 
hydroquinones 
C. crinita
f
 165 Antioxidant 
24 2-[(2′E,6′E,10′E)-5′-oxo-3′,7′,11′,15′-
tetramethyl hexadeca-2′,6′,10′,14′-
tetraenyl]-6-methyl hydroquinone 
C. crinita
f
 165 Antioxidant 
25 2-[(2′E,6′Z,10′E,14′Z)-5′-Oxo-15′-
hydroxymethyl-3′,7′,11′-
trimethylhexadeca-2′,6′,10′,14′-
tetraenyl]-6-methyl hydroquinone 
C. crinita
f
 165 Antioxidant, cytotoxic 
26 2-[(2′E,6′Z,10′E)-5′-oxo-13′-hydroxy-
3′,7′,11′,15′-tetra-methylhexadeca-
2′,6′,10′,14′-tetraenyl]-6-methyl 
hydroquinones 
C. crinita
f
 165 Antioxidant 
27 2-[(2′E,6′Z,10′E)-5′-oxo-3′,7′,11′,15′-
tetramethylhexadeca-2′,6′,10′,14′-
tetraenyl]-6-methyl hydroquinone 
C. crinita
f
 165 Antioxidant 
28 2-[(2′E,6′E)-5′-oxo-3′,7′,11′-
trimethyldodeca-2′,6′10′-trienyl]-6-
methylhydroquinone 
C. crinita
f
 165 Antioxidant 
29 2-[(2′E,6′Z)-5′-oxo-3′,7′,11′-
trimethyldodeca-2′,6′10′-trienyl]-6-
methylhydroquinone 
C. crinita
f
 165 - 
30 5-oxo-cystofuranoquinone C. crinita
f
 165 Antioxidant 
31 5-oxo-isocystofuranoquinone C. crinita
f
 165 Antioxidant 
32 2,12-diepineobalearone  C. amentacea var. 
stricta
k
 
331 - 
33 4’-methoxy-(2E)-bifurcarenone C. amentacea var. 
stricta
c
 
331 Cytotoxic 
34 Methoxybifurcarenone C. amentacea var. 
stricta
c
  
C. tamariscifolia
 h
 
331 
52, 331 
Antifungal
52
, anti-bacterial
52
 
35 Meroditerpenoid 1 C. baccata
h
 341 - 
36 Meroditerpenoid 2 C. baccata
h
 341 - 
37 Meroditerpenoid 3 C. baccata
h
 341 - 
38 Meroditerpenoid 4 C. baccata
h
 341 Antifouling 
39 Meroditerpenoid 5 C. baccata
h
 341 Antifouling 
40 Meroditerpenoid 6 C. baccata
h
 341 - 
41 Meroditerpenoid 7 C. baccata
h
 341 Antifouling 
42 Cystodione A C. usneoides
h
 133 Anti-inflammatory, antioxidant 
43 Cystodione B C. usneoides
h
 133 Anti-inflammatory, antioxidant 
44 Cystodione C C. usneoides
h
 133 Antioxidant 
45 Cystodione D C. usneoides
h
 133 Antioxidant, anti-inflammatory 
46 Cystodione E C. usneoides
h
 133 Antioxidant 
47 Cystodione F C. usneoides
h
 133 Antioxidant 
48 Cystodione G C. usneoides
j
 132 Antioxidant 
49 Cystodione H C. usneoides
j
 132 Antioxidant 
50 Cystodione I C. usneoides
j
 132 Antioxidant 
51 Cystodione J C. usneoides
j
 132 Antioxidant 
52 Cystodione L C. usneoides
j
 132 Antioxidant 
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53 Cystodione M C. usneoides
j
 132 Antioxidant 
54 Cystone A C. usneoides
j
 132 Antioxidant 
55 Cystone B C. usneoides
j
 132 Antioxidant 
56 Cystone C C. usneoides
j
 132 Antioxidant 
57 Cystone D C. usneoides
j
 132 Antioxidant 
58 Cystone E C. usneoides
j
 132 Antioxidant 
59 Cystone F C. usneoides
j
 132 Antioxidant 
60 Cystomexicone A C. abies-marina
j 
C. usneoides
h
 
165 
133 
Antioxidant 
61 Cystomexicone B C. abies-marina 
j 
C. usneoides
h
 
165 
133 
Antioxidant 
62 Usneoidone E C. usneoides
h,j
 133,132 Anti-inflammatory, antioxidant 
63 Amentadione-1′-methyl ether C. usneoides
h,j
 133,132 Antioxidant 
64 Usneoidone Z C. usneoides
h
 133 Anti-inflammatory, antioxidant 
65 6-cis-amentadione-1′-methyl ether C. usneoides
h
 133 Antioxidant 
66 (3R)-tetraprenyltoluquinone C. baccata
i
 85 Antileishmania 
67 (3S)-tetraprenyltoluquinone C. baccata
i
 85 Antileishmania 
68 (3R)-tetraprenyltoluquinol C. baccata
i
 85 Antileishmania 
69 (3S)-tetraprenyltoluquinol C. baccata
i
 85 Antileishmania 
Steroids    
70 Ergost-5-en-3β-ol C. adriatica
g
 248 - 
71 Stigmast-5-en-3β-ol C. adriatica
g
 248 - 
72 22-dehydrocholesterol C. adriatica
g
 248 - 
73 Androst-5-en-3-ol  C. crinita
l
 245 - 
74 Chol-5-en-3β-ol  C. crinita
l
 245 - 
75 23,24-dinor-chol-5-en-3β-ol  C. crinita
lz
 245 - 
76 23,24-dinor-chol-5,20-dien-3β-ol  C. crinita
l
 245 - 
77 24-isopropylcholesta-5,22-dien-3β-ol C. crinita
l
 245 - 
78 24-ethylcholesterol C. crinita
l
 245 - 
79 Isofucosterol C. crinita
l
 245 - 
80 Stigmasterol C. crinita
a 
C. adriatica
g
 
336 
248 
Anti-cancer
259
, antiviral
372,  
anti-atherosclerosis
284
,  
anti-osteoarthritic
173
 
81 Saringasterol C. adriatica
g 
C. barbata
a 
C. crinita
a
 
248 
336 
- 
82 Fucosterol C. adriatica
g 
C. barbata
a 
C. compressa
 d,k 
C. crinita
a,l 
C. nodicaulis
i 
C. tamariscifolia
 i 
C. usneoides
i
 
248 
336 
335 
24,245 
24 
Antioxidant
24,281
, cholinesterase 
inhibitor
24,529
, anti-diabetic
24,240,282
, anti-
cancer
237
, anti-obesity
242
, anti-
inflammatory
239
, anti-atopic
228
, anti-
photohaging
227,257
, anti-osteoporotic
39
, 
hepatoprotective
216
, ACE inhibitor
205
, 
antifungal
268
, cholesterol reducer
216
, 
antileishmanial
39
 
83 Chalinasterol  C. adriatica
g
 248 - 
84 Brassicasterol C. crinita
l
 245 - 
85 24-nor-chol-5-en-3β-ol  C. crinita
l
 245 - 
86 24-nor-chol-5,22-dien-3β-ol  C. crinita
l
 245 - 
87 Pregn-5-en-3-ol  C. crinita
l
 245 - 
88 Saoussazine C. compressa
k
 335 - 
89 3-keto-22-epi-28-nor-cathasterone C. myrica
b
 207 Cytotoxic 
90 Cholest-4-ene-3,6-di-one C. myrica
b
 207 Cytotoxic 
Phlorotannins and Phenolic Compounds    
91 7-phloroethol C. humilis
c
 
C. tamariscifolia
 i
 
456 
164 
Antioxidant, HAase inhibitor 
92 Fucophloroethol C. baccata
c
 
C. usneoides
i
 
456 
164 
Antioxidant, HAase inhibitor 
93 Fucodiphloroethol C. tamariscifolia
 i
 164 Antioxidant, HAase inhibitor 
94 Fucotriphloroethol C. usneoides
i
 164 Antioxidant, HAase inhibitor 
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95 Phloroglucinol C. baccata
c
 
C. compressa
j 
C. foeniculacea
j,c 
C. humilis
c
 
C. nodicaulis
i 
C. tamariscifolia
 i,c 
C. usneoides 
i
 
456 
108 
108,804
56 
33,456 
24 
24,456 
24 
Antioxidant
24,108,246
 anti-diabetic
24348
, 
cholinesterase inhibitor
24
 
96 Benzoic acid C. abies-marina
i 
C. crinita
l
 
191 
245 
Antioxidant
191
, anti-inflammatory
191
, 
antifungal
226
 
97 Phenol-2,4-bis-(1,1-dimethylethyl) C. barbata
l
 364 Anti-quorum sensing
365
, anti-biofilm
365
 
98 Ketone  C. abies-marina
j
 162 - 
Carbohydrates    
99 Mannitol C. nodicaulis
i 
C. tamariscifolia
 i 
C. usneoides
i
 
24 Antioxidant, anti-diabetic,  
cholinesterase inhibitor 
100 Fucoidans 
  
C. compressa
k 
C. crinita
k 
C. sedoides
k
 
22 
22 
22 
Anti-inflammatory, oedema inhibition, 
gastroprotective, antioxidant,  
anti-allergic
280
, anti-cancer
280
 
101 Uronic acid C. compressa
k 
C. crinita
k 
C. sedoides
k 
C. indica
e
 
22 
22 
22 
303 
Anti-herpetic
303
 
102 Xylose C. indica
e
 303 Anti-herpetic 
103 Mannose C. indica
e
 303 Anti-herpetic 
104 Fucose C. indica
e
 303 Anti-herpetic 
105 Galactose C. indica
e
 303 Anti-herpetic  
106 Glucose C. indica
e
 303 Anti-herpetic  
Triacylglycerols
*
    
107 C14:0/C16:1/C16:1 C. brachycarpa
f
 382 - 
108 C16:1/C16:1/C16:1 C. brachycarpa
f
 382 - 
109 C18:1/C18:1/C18:1 C. brachycarpa
f
 382 - 
110 C16:0/C18:1/C18:10 C. brachycarpa
f
 382 - 
111 C18:1/C18:2/C16:0 C. brachycarpa
f
 382 - 
112 C16:0/C16:0/C20:4 C. brachycarpa
f
 382 - 
113 C16:0/C16:0/C20:5, -3 C. brachycarpa
f
 382 - 
114 C16:0/C18:4, -3/C20:5, -3 C. brachycarpa
f
 382 - 
115 C14:0/C16:1/C16:0 C. brachycarpa
f
 382 - 
116 C16:0/C16:1/C16:1 C. brachycarpa
f
 382 - 
117 C16:0/C16:0/C18:1 C. brachycarpa
f
 382 - 
118 C14:0/C14:0/C16:0 C. brachycarpa
f
 382 - 
119 C14:0/C16:0/C16:0 C. brachycarpa
f
 382 - 
120 C16:0/C16:0/C16:0 C. brachycarpa
f
 382 - 
121 C16:0/C16:0/C18:0 C. brachycarpa
f
 382 - 
122 C16:0/C18:0/C18:0 C. brachycarpa
f
 382 - 
123 C16:0/C18:1/C18:0 C. brachycarpa
f
 382 - 
124 C14:0/C16:0/C18:1 C. brachycarpa
f
 382 - 
125 C14:0/C18:1/C18:1 C. brachycarpa
f
 382 - 
Saturated Fatty Acid (SFA)    
126 Caproic acid (C6:0) C. barbata
a
 366 - 
127 Pelargonic acid (C9:0) C. crinita
l
 245 - 
128 Capric acid (C10:0) C. crinita
l 
C. barbata
a
 
245 
366 
- 
129 Lauric acid (C12:0) C. barbata
a 
C. humilis
i
 
366 
504 
- 
130 Myristic acid (C14:0) C. baccata
i 
C. barbata
a,i 
C. brachycarpa
f 
C. compressa
d,i 
504 
366, 
504,382 
247,504 
- 
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C. crinita
a,l 
C. humilis
i 
C. nodicaulis
i 
C. tamariscifolia
 i
 
233,245 
504 
504 
504 
131 Pentadecyclic acid (C15:0) C. baccata
i 
C. barbata
i 
C. compressa
i 
C. crinita
l 
C. humilis
i 
C. nodicaulis
i 
C. tamariscifolia
 i
 
504 
504 
504 
245 
504 
504 
504 
- 
132 Palmitic acid (C16:0) C. baccata
i 
C. barbata
a,i 
C. brachycarpa
f 
C. compressa
d,i 
C. crinita
a,l 
C. humilis
i 
C. nodicaulis
i 
C. tamariscifolia
 i 
C. usneoides
i
 
504 
366, 
504, 
382 
247,504 
233,245 
504 
24,504 
24,504 
24 
Antifungal
241
, antiviral
279
, anti-bacterial
528
 
133 Margaric acid (C17:0) C. baccata
i 
C. barbata
a,i
 
C. brachycarpa
f
 
C. humilis
i
 
C. nodicaulis
i
 
C. tamariscifolia
 i
 
504 
366, 
504,382 
504 
504 
504 
- 
134 Stearic acid (C18:0) C. baccata
i
 
C. barbata
a,i
 
C. brachycarpa
f
 
C. compressa
d,i
 
C. crinita
a,l
 
C. humilis
i
 
C. nodicaulis
i
 
C. crinita
i
 
C. usneoides
i
 
504 
366,504 
382 
247,504 
233,245 
504 
504 
24,504 
24 
Anti-diabetic, cholinesterase inhibitor 
135 Arachidic acid (C20:0) C. baccata
i
 
C. barbata
a
 
C. compressa
i
 
C. crinita
a
 
C. nodicaulis
i
 
C. tamariscifolia
 i
 
504 
366,504 
504 
233 
504 
504 
- 
136 Heneicosylic acid (C21:0) C. barbata
 a
 366 - 
137 Behenic acid (C22:0) C. baccata
i
 
C. barbata
a,i
 
C. compressa
i
 
C. nodicaulis
i
 
C. tamariscifolia
 i
 
504 
366,504 
504 
504 
504 
- 
138 Tricosylic acid (C23:0) C. barbata
a
 366 - 
139 Lignoceric acid (C24:0) C. baccata
i
 
C. barbata
a,i
 
C. compressa
i
 
C. tamariscifolia
 i
 
504 
366,504 
504 
504 
- 
Monounsaturated Fatty Acids (MUFA)    
140 Myristoleic acid (C14:1) C. barbata
 a
 366 - 
141 Palmitoleic acid (C16:1) C. baccata
i
 
C. barbata
a,i
 
C. brachycarpa
f
 
C. compressa
d,i
 
504 
366,504 
382 
247,504 
- 
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C. crinita
a,l
 
C. humilis
i
 
C. nodicaulis
i
 
C. tamariscifolia
 i
 
233,245 
504 
504 
504 
142 Oleic acid (C18:1) C. baccata
i
 
C. barbata
a,i
 
C. brachycarpa
f
 
C. compressa
d,i
 
C. crinita
a,l
 
C. humilis
i
 
C. nodicaulis
i
 
C. tamariscifolia
 i
 
504 
366,504 
382 
247,504 
245,24 
24 
504 
504 
504 
Anti-inflammatory
188
, cancer 
preventive
188, 
anti-androgenic
188
, anti-
diabetic
340
, cholinesterase inhibitor
391
, 
antifungal
501
, anti-bacterial
105
, 
antioxidant
510
 
143 cis-10-heptadecenoic acid (C17:1) C. barbata
 a
 366 - 
144 Eicosenoic acid (C20:1) C. crinita
l
 
C. humilis
i
 
C. nodicaulis
i
 
C. crinita
i
 
245 
504 
504 
504 
- 
145 Erucic acid (C22:1) C. brachycarpa
f
 382 - 
Polyunsaturated Fatty Acids (PUFA)    
146 Hexadecatrienoic acid (C16:3) C. crinita
l
 
C. tamariscifolia
 i
 
245 
504 
- 
147 Hexadeca-4,7,10,13-tetraenoic acid 
(C16:4) 
C. crinita 
l
 245 - 
148 Linoleic acid (C18:2) C. baccata
i
 
C. barbata
a,i
 
C. brachycarpa
f
 
C. compressa
d,i
 
C. crinita
a,l
 
C. humilis
i
 
C. nodicaulis
i
 
C. tamariscifolia
 i
 
504 
366,504 
382 
247,504 
233,245 
504 
504 
504 
Anti-cancer
440
 
149 α-Linolenic acid (C18:3, n-3) C. barbata
a
 
C. crinita
l
 
366 
233,245 
Anti-inflammatory
223
, anti-bacterial
223
 
150 γ-Linolenic acid (C18:3, n-6) C. crinita
l
 
C. compressa
i
 
C. tamariscifolia 
i
 
233 
504 
504 
Anti-inflammatory
249,250
, endocrine 
precursor
398
, skin protective
250
,  
anti-rheumatoid arthritis
530
, anti-multiple 
sclerosis
327
, schizophrenia preventive
493
, 
premenstrual syndrome preventive
398
, 
infant diet supplement
504
 
151 Stearidonic acid (C18:4) C. brachycarpa
f
 
C. compressa
d
 
C. crinita
l
 
382 
247 
245 
- 
152 Eicosadienoic acid (C20:2) C. baccata
i
 
C. barbata
a,i
 
C. compressa
i
 
C. nodicaulis
i
 
C. tamariscifolia
 i
 
504 
371,504 
504 
504 
504 
- 
153 Eicosatrienoic acid (C20:3) C. baccata
i
 
C. barbata
i
 
C. compressa
i
 
C. humilis
i
 
C. nodicaulis
i
 
C. tamariscifolia
 i
 
504 
504 
504 
504 
504 
504 
- 
154 Eicosatetraenoic acid (C20:4) C. brachycarpa 
f
 382 - 
155 Arachidonic acid (C20:4) C. baccata
i
 
C. barbata
i
 
C. brachycarpa
f
 
C. compressa
i
 
504 
504 
382 
504 
Cholinesterase inhibitor
391
, endocrine 
precursor
381
, lipoprotein precursor
508
, 
hemorheologic agent
508
,  
diet supplement
508
, cardioprotective
508
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C. crinita
a
 
C. humilis
i
 
C. nodicaulis
i
 
C. tamariscifolia
 i
 
233 
504 
504 
504 
156 Eicosapentaenoic acid (C20:5) C. baccata
i
 
C. barbata
a,i
 
C. compressa
i
 
C. humilis
i
 
C. nodicaulis
i
 
C. crinita
a
 
C. brachycarpa
f
 
C. tamariscifolia
 i
 
508 
366, 
508,504 
504 
504 
233 
382 
504 
Cholinesterase inhibitor
391
, anti-
inflammatory
431
, anti-cancer
276
, 
immunomodulatory
431
, endocrine 
precursor
381
, cardioprotective
276
, anti-
atherosclerosis
79
, hyperlipidemia 
preventive
270
, schizophrenia preventive
152
, 
diet supplement
508
, anti-bacterial
223
, 
antileishmanial
500
 
157 Docosapentaenoic acid (C22:5) C. crinita
l
 245 - 
158 Docosahexaenoic acid (C22:6) C. barbata
a
 366 Cardioprotective
276
, anti-cancer
276
,  
diet supplement
508
, food additive
508
,  
anti-bacterial
223
 
Pigments and Vitamins    
159 β-carotene C. barbata
a
 366 Anti-inflammatory
33
, antioxidant
354
, 
antiproliferative
231
 
160 Astaxanthin C. barbata
a
 366 Antioxidant
356,33
, antitumoral
476
,  
anti-inflammatory
33,215
, cataract 
protective
203
, cardioprotective
155
, 
Immunomodulatory
287
, anti-
bacterial
507,269
, hepatoprotective
107
 
161 Fucoxanthin C. brachycarpa
f
 382 Anti-inflammatory
256
, antioxidant
411
,  
anti-cancer
218,231,256,264,265,351
, anti-
obesity
313,339
, anti-diabetic
339
, anti-
angiogenic
458
, antimalarial
1
, 
hepatoprotective
522
,  
ocular-protective
439
, skin-protective
490,437
 
162 Chlorophyll a C. brachycarpa
f
 382 Antioxidant
221
 
163 α-tocopherol C. barbata
a
 366 Antioxidant
258,366
, cellular signaling
81,530
,  
gene expression regulator
81,530
, 
antigenotoxic
397
 
164 Retinol C. barbata
a
 366 Anti-aging
263
 
165 Ergocalciferol C. barbata
a
 366 Citotoxic
106
, endocrine regulator
485
,  
Ca/P homeostatic
413
 
Others    
166 3-bromo-2-chloro-1-propanol  C. barbata
a
 336 - 
167 1-bromo-2-chloroethane C. barbata
a
 336 - 
168 1,1,2-trichloroethane C. barbata
a
 336 - 
169 1,1,2,2,-tetrachloroethane  C. barbata
a
 336 - 
170 Hexachlorobutadiene C. barbata
a
 336 - 
171 Dimethylformamide  C. barbata
a
 336 - 
172 Heptane C. barbata
l
 364 - 
173 Octane C. barbata
l
 364 - 
174 Undecane C. barbata
l
 364 - 
175 Tridecane C. barbata
l
 364 - 
176 Tetradecane C. barbata
l
 364 - 
177 Pentadecane C. barbata
l
 364 - 
178 Hexadecane  C. crinita
l
 245 Anti-inflammatory
371
, , thermogenic 
regulator
225
 
179 Heptadecane C. crinita
l
 245  
180 Octadecane  C. crinita
l
 245 - 
181 Nonadecane  C. crinita
l
 245 - 
182 Eicosane C. barbata
l
 364 - 
183 Heneicosane C. barbata
l
 364 - 
184 Docosane C. barbata
l
 364 - 
185 Tricosane C. barbata
l
 364 - 
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186 Tetracosane C. barbata
l
 364 - 
187 Pentacosane C. barbata
l
 364 - 
188 Hexacosane C. barbata
l
 364 - 
189 Heptacosane C. barbata
l
 364 - 
190 Octacosane C. barbata
l
 364 - 
191 Nonacosane C. barbata
l
 364 - 
192 Triacontane  C. barbata
l
 364 - 
193 Tritriacontane C. barbata
l
 364 - 
194 Tetratriacontane C. barbata
l
 364 - 
195 Pentatriacontane C. barbata
l
 364 - 
196 1-octene C. barbata
l
 364 - 
197 1-heptadecanamin C. barbata
l
 364 Anti-bacterial
459
 
198 2,4-dimethyl-1-heptene C. barbata
l
 364 - 
199 Chloroacetic acid  C. crinita
l
 245 - 
200 Chloroacetic acid, ethyl ester  C. crinita
l
 245 - 
201 1-chloro-2-ethoxy-2-methoxyethane  C. crinita
l
 245 - 
202 1-chloro-2,2-diethoxyethane  C. crinita
l
 245 - 
203 1,1-dichloro-2,2-diethoxyethane  C. crinita
l
 245 - 
204 Dimethyl disulfide  C. crinita
l
 245 - 
205 Thioacetic acid-O-ethyl ester  C. crinita
l
 245 - 
206 1,3-butanediol  C. crinita
l
 245 - 
207 2,3-butanediol C. crinita
l
 245 - 
208 Glycerol C. crinita
l
 245 - 
209 2-hydroxypropanoic acid C. crinita
l
 245 - 
210 4-hydroxypentanoic acid  C. crinita
l
 245 - 
211 2,3-dihydroxy palmitic acid, propyl ester  C. crinita
l
 245 - 
212 2-ethylhexylphtalate C. compressa
k
 335 - 
213 Cinnamic acid C. crinita
l
 245 - 
214 Proline C. nodicaulis
i 
C. tamariscifolia
 i 
C. usneoides
i
 
24 
24 
24 
Anti-diabetic, cholinesterase inhibitor 
*indicates number of carbons in side chain and presence of unsaturation to each original fatty acid from triacylglycerol. 
a 
Bulgaria; 
b
 Egypt; 
c
 France; 
d
 Greece; 
e
 India; 
f
 Italy; 
g
 Montenegro; 
h
 Morocco; 
i
 Portugal; 
j
 Spain; 
k
 Tunisia; 
l
 Turkey; 
HAase - hyaluronidase; and ACE - angiotensin-converting enzyme 
2.3.1. TERPENES 
The terpenoids cystoseirol monoacetate (1), dictyol F monoacetate (2), dictyone (3), 
dictyone acetate (4), isodictytriol monoacetate (5), and pachydictyol (6) were identified in 
Cystoseira myrica from Egypt. These compounds were tested against three different mouse 
cell lines (fibroblast NIH3T3 and the cancer cell lines SSVNIH3T3 and KA3IT), and 
displayed moderate cytotoxic activity against the KA3IT (IC50 5 μg/ml) and reduced 
cytotoxicity towards the normal cells NIH3T3 (Ayyad et al., 2003). Structures of compounds 
1-11 are presented in Figure 2.1..  
Other terpenoids, such as 3,7-dimethyl-1,6-octadiene-3-ol-2-aminobenzoate (7), 
hexahydrofarnesylacetone (8), dihydro-3-hydroxy-3-hydroxymethyl-2(3H)-furanone (9) and 
dihydroactinidiolide (10) were identified in Cystoseira crinita from Bulgaria (Milkova et al., 
1997), and Turkey (Kamenaska et al., 2002). However, no biological activity was reported to 
compounds 7-10. Furthermore, Isololiolide (11), isolated from C. tamariscifolia, proved to be 
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cytotoxic against gastric cancer cells and selectively cytotoxic on human hepatocellular 
 
 
Figure 2.1. Structures of terpenoids 1-11 isolated from Cystoseira algae 
carcinoma cells comparing with non-tumoral human fibroblasts (Vizetto-Duarte et al., 
2016b). 
2.3.2. MEROTERPENOIDS 
The meroditerpenoids 14-epi-amentol triacetate (12), amentol (13), amentol chromane 
diacetate (14), cystoseirone diacetate (15) and preamentol triacetate (16) were isolated from a 
Cystoseira sp. specimen nearby the Spanish Canary Islands (Navarro et al., 2004). 
Demethoxy cystoketal chromane (17), was found in C. tamariscifolia and C. amentacea var. 
stricta from Portugal and France respectively (Valls et al., 1996; Vizetto-Duarte et al., 2016a), 
revealing antiproliferative activity against hepatocellular carcinoma cells (Vizetto-Duarte et 
al., 2016a). Cystoazorol A (18), cystoazorol B (19), together with the 
meronorsesquiterpenoids cystoazorone A (20), cystoazorone B (21) were found for the first 
time in C. abies-marina algae collected in the São Miguel Island, Azores - Portugal (Gouveia 
et al., 2013b). Compounds 18, 20 and 21 exhibited inhibitory activity against HeLa cells and 
18 and 19 moderate antioxidant DPPH radical scavenging activity (Gouveia et al., 2013b). 
Structures of compounds 12-21 are presented in Figure 2.2.. 
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Figure 2.2. Structures of meroterpenoids 12-21 isolated from Cystoseira algae 
Tetraprenyltoluquinol derivatives 22-27, triprenyltoluquinol derivatives 28-29, and 
tetraprenyltoluquinone derivatives 30-31 were isolated for the first time in the brown alga 
C. crinita (Fisch et al., 2003). Antioxidant properties of these compounds were evaluated by 
different methods revealing that hydroquinones have powerful antioxidant activity comparable to 
that of α –tocopherol. Structures of compounds 22-31 are showed in Figure 2.3.. 
Related compounds 2,12-diepineobalearone (32), 4’-methoxy-(2E)-bifurcarenone (33) 
and the methoxybifurcarenone 34,  were isolated from C. amentacea var stricta specimens 
collected on France and Tunisia. Compound 34 was also isolated in C. tamariscifolia 
(Bennamara et al., 1999) and inhibited the development of the fertilized eggs of the common 
sea-urchin Paracentrotus lioidus (Mesguiche et al., 1997). Furthermore, this compound 
displayed antifungal activity against three tomato pathogenic fungi (Botrytis cinerea, 
Fusarium oxysporum sp. mycopersici and Verticillium alboatrum) and anti-bacterial activity 
against Agrobacterium tumefaciens and Escherichia coli (Bennamara et al., 1999).  
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Figure 2.3. Structures of meroterpenoids 22-31 isolated from Cystoseira algae 
Seven meroditerpenoids (35-38) and their derivatives (39-41) were found in the brown 
alga C. baccata harvested in Moroccan Atlantic coast. Compounds 38, 39 and 41 were not 
toxic against larvae of sea urchins and oysters, and to possess interesting antifouling activities 
(inhibition of microalgae growth, macroalgal settlement, and mussel phenoloxidase activity; 
Mokrini et al., 2008). Eighteen new meroterpenoids, cystodiones A-M (42-53) and cystones 
A-F (54-59) were isolated for the first time in the C. usneoides collected in the Moroccan and 
Spanish coasts. All these compounds and other already known meroterpoids (60-65) reveal 
radical-scavenging activity, although 42, 43, 48, 49, 63 and 65 showed strong radical-
scavenging activity. Moreover, inhibition of the production of the proinflammatory cytokine 
TNF-α in LPS-stimulated THP-1 human macrophages and anti-inflammatory activity were 
also observed in compounds 48, 56, 62 and 64 (de los Reyes et al., 2013, 2016).  
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Figure 2.4. Structures of meroterpenoids 32-69 isolated from Cystoseira. 
The novel (3R)- and (3S)- tetraprenyltoluquinones (66 and 67) together with the already 
known meroditerpenoid (3R)- and (3S)-tetraprenyltoluquinols (68 and 69), were isolated from 
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the hexane extract of C. baccata. These were the first compounds ever isolated from algae 
revealing activity against Leishmania parasites inducing cytoplasmic vacuolization and 
disruption of the mitochondrial membrane potential. The activity of this meroditerpenoids 
was evaluated against L. infantum promastigotes and amastigotes, being the compounds 68/69 
more effective (IC50 = 25.0 ± 4.1 mM) in the inhibition of the intracellular infection (Bruno de 
Sousa et al., 2017). Structures of compounds 32–69 are showed in Figure 2.4.. 
2.3.3. STEROLS AND STEROIDS  
Several steroids (70-88) were identified from different Cystoseira species. Cholesterol 
(70) initially isolated in C. compressa (Kraan, 2012) was also found in C. adriatica 
(Kapetanović et al., 2005). Cholesterol derivatives 70-72 were isolated from C. adriatica 
(Kapetanović et al., 2005), and several others i.e., androst-5-en-3-ol (73), chol-5-en-3β-ol 
(74), 23,24-dinor-chol-5-en-3β-ol (75), 23,24-dinor-chol-5,20-dien-3β-ol (76), 24-
isopropylcholesta-5,22-dien-3β-ol (77), 24-ethylcholesterol (78), isofucosterol (79) and 
stigmasterol (80) were reported from C. crinita (Milkova et al., 1997; Kamenarska et al., 
2002) although no information about the bioactivity of these compounds was described. 
Compound 80, simultaneously identified in C. adriatica (Kapetanović et al., 2005), displays 
anti-atherosclerosis, antiviral, anti-cancer and antiosteoarthritic activities (Li et al., 2015; 
Petrera et al., 2014; Kim et al., 2014; Gabay et al., 2010). The presence of saringasterol (81) 
was also confirmed in more than one Cystoseira species from the Adriatic (Kapetanović et al., 
2005) and the Black sea (Milkova et al., 1997) regions. Fucosterol (82), the characteristic 
steroid of brown algae, identified for the first time in C. compressa (Kanias et al., 1992), was 
also detected in C. barbata, C. crinita, C. nodicaulis, C. tamariscifolia, C. usneoides (Milkova 
et al., 1997; Kamenarska et al., 2002; Mighri et al., 2009; Andrade et al., 2013) and 
C. adriatica, although in the last species this compound was detected at low concentration 
(Kapetanović et al., 2005). Several activities are reported for compound 82 such as radical 
scavenging, antioxidant, acetylcholinesterase AChE, BuChE, anti-diabetic, anti-cancer, anti-
obesity, anti-inflammatory, anti-atopic, anti-photohaging, anti-osteoporotic, hepatoprotective, 
angiotensin-converting enzyme (ACE) inhibitors, cholesterol reducer, antifungal and 
antileishmanial (Hagiwara et al., 1986; Lee et al., 2003, 2004; Yoon et al, 2008; Kumar et al., 
2010; Bang et al., 2011; Hoang, et al., 2012; Andrade et al., 2013; Jung et al., 2013a,b, 2014; 
Hwang, et al., 2014a,b; Ji et al., 2014; Becerra et al., 2015). 24-methylcholesta-5,24(28)-dien-
3β-ol (83) usually known as chalinasterol was isolated from C. adriatica (Kapetanović et al., 
2005) and brassicasterol (84), 24-nor-chol-5-en-3β-ol (85), 24-nor-chol-5,22-dien-3β-ol (86), 
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and pregn-5-en-3-ol (87) from C. crinita harvested in Turkey (Kamenarska et al., 2002). 
Saoussazine (88) was isolated in a specimen of C. compressa from Tunisia (Mighri et al., 
2009).  
Other steroids such as 3-keto-22-epi-28-nor-cathasterone (89) and cholest-4-ene-3,6-di-one 
(90) were identified in C. myrica collected in the Egyptian coast (Hamdy et al., 2009). These 
compounds showed activity against human liver and colon cancer cells, with compound 89 
exhibiting a particularly higher cytotoxicity to liver cancer cells with selective activity for normal 
cells. Structures of steroids 70-90 are showed in Figure 2.5.. 
 
Figure 2.5. Structures of steroids 70-90 isolated from Cystoseira algae 
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2.3.4. PHLOROTANNINS AND PHENOLIC COMPOUNDS 
The study of three Cystoseira species (C. nodicaulis, C. tamariscifolia and C. usneoides) 
by HPLC-DAD-ESI-MS
n
, reported the occurrence of different phlorotannins belonging to 
eckol and fucophloroethol groups. Four of these phlorotannins, 7-phloroethol (91), 
fucophloroethol (92), fucodiphloroethol (93) and fucotriphloroethol (94) were identified in 
this species for the first time, revealing hyaluronidase inhibitory activity and radical 
scavenging (superoxide radical scavenging assay, as well as lipid peroxidation inhibition 
assay (Ferreres et al., 2012).  Other study demonstrated that C. humilis produce compound 91 
and C. baccata and C. nodicaulis present traces of fucols, phlorethols and fucophlorethols 
(Stiger-Pouvreau et al., 2014). The structures of compounds 91-99 are show in Figure 2.6..  
Lopes et al. (2012, 2013) evaluated, for the first time, the anti-bacterial and antifungal 
properties of phlorotannins rich extracts of C. nodicaulis, C. tamariscifolia  and C. usneoides. The 
authors demonstrated that these algae are active against different species of the yeast Candida sp. 
(C. albicans, C. dubliniensis, C. krusei, C. parapsilosis) and the dermatophyte fungus Tricophyton 
rubrum, T. mentagrophytes, Microsporum gypseum, M. canis, and Epidermophyton floccosum. 
Otherwise, no effectiveness of these crude extracts was found against Aspergillus (A. fumigatus, 
A. flavus and A. niger). Antifungal activity of C. nodicaulis against Candida cells and of 
C. usneoides against dermatophyte fungi is related with a significantly reduction of the ergosterol 
 
Figure 2.6. Structures of phlorotannins 91-98 identified in Cystoseira algae. 
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amount in the fungal cell membrane. Because of its fungistatic and fungicidal activity 
C. nodicaulis, is highlighted as very promising for the future development of antimycotic drugs. 
Additionally, the potential of Cystoseira phlorotannins against Gram-positive bacteria 
(Staphylococcus aureus, S. epidermidis, Micrococcus luteus, Bacillus cereus) and Gram-negative 
(Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium) was demonstrated. In 
particular, phlorotannins obtained from C. nodicaulis were strongly active against S. epidermidis 
and S. aureus. Extracts enriched in these compounds showed also anti-inflammatory activity, 
inducing a marked decrease in nitric oxide (NO) production in LPS-stimulated macrophages, 
especially C. tamariscifolia extract, which led to a 75% decline of NO at 8.35 mg/mL with no 
toxicity to murine RAW 264.7 cells. 
Phloroglucinol (95) isolated from C. compressa and C. foeniculacea revealed high 
antioxidant activity in comparison with the cpntent of this compound in other 12 brown algae 
species (Chkhikvishvili et al., 2000). High content of this compound were also detected in 
C. baccata, C. humilis, C. nodicaulis, C. tamariscifolia and C. usneoides (Andrade et al., 
2013; Stiger-Pouvreau et al., 2014) and its antioxidant properties was confirmed (Andrade et 
al., 2013). Acetyl- and butyrylcholinesterase activities and inhibition of the α-glucosidase 
enzyme were also attributed to phloroglucinol (95) contents of C. tamariscifolia and 
C. usneoides (Andrade et al., 2013). Benzoic acid (96) was isolated from C. abies-marina 
(Gouveia et al., 2013b) and C. crinita (Kamenarska et al., 2002). Antioxidant, anti-
inflammatory (Gouveia et al., 2013b) and antifungal (Hussain et al., 2014) activities were 
reported for compound 96. Cytotoxicity against tumor HeLa and non-tumour Vero cells was 
also evaluated although without positive results (Gouveia et al., 2013b). Phenol-2,4 bis-(1,1-
dimethylethyl) (97), identified in C. barbata, anti-intercellular bacteria communication and 
anti-biofilm activities against S. marcescens (Ozdemir et al., 2006) and the ketone (98) was 
isolated for the first time in C. abies-marina (Fernández et al., 2006). Moreover, and although 
without identifying specific compounds, phenolic compounds and phlorotannins-enriched 
fractions of Cystoseira trinodis exhibited prominent (DPPH) radical-scavenging activity 
(Sathya et al., 2013). 
2.3.5. CARBOHYDRATES  
 Mannitol (99), responsible for osmoregulation and commonly found in macroalgae, 
was identified in C. nodicaulis, C. tamariscifolia (Andrade et al., 2013) and C. usneoides 
(Andrade et al., 2013; Bruno de Sousa et al., unpublished). Because of its hydrating and 
antioxidant properties, this carbohydrate is used in numerous cosmetic and pharmaceutical 
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applications (Iwamoto and Shiraiwa, 2005). Moreover, the radical scavenging, α-glucosidase 
inhibition, AChE and BuChE activities were also reported by Andrade et al. (2013). 
Compound 99 was also tested against L. infantum promastigotes without effectiveness (Bruno 
de Sousa et al., unpublished). Fucoidans (100) were detected together with uronic acid (101) 
in C. sedoides, C. compressa and C. crinita collected in Tunisia.   
Compound 100 exhibited significant radical scavenging (DPPH) and anti-inflammatory 
activities, being found to be effective in inhibiting edema development. Moreover, compound 
100, isolated from C. sedoides and C. compressa, revealed gastro-protective activities 
(Ammar et al., 2015). The presence of the sugar acid 101 together with xylose (102), mannose 
(103), fucose (104), galactose (105) and glucose (106) was also detected in sulphated fucan-
containing fractions of C. indica that showed strong antiviral activity against herpes simplex 
virus and absence of cytotoxicity against Vero cell cultures. Moreover, it was verified that 
these fractions did not display anticoagulant activity or an inactivating effect on virions 
(Mandal et al., 2007).  
 Fucans were isolated from C. barbata harvested in Tunisia. Sulphated polysaccharides, 
identified in C. canariensis, shown to bind to myostatin protein in serum, were deemed as 
interesting for the development of drugs for muscular related diseases (Ramazanov et al., 2003). 
Other sulphated polysaccharides (mainly 3-linked-α-l-fucopyranosyl backbone, acetylated and 
C-4 sulphated derivatives) revealed a wide range of biological activities such as antioxidant, ferric 
reducing potential, chelating activity and protection activity against hydroxyl radical-induced 
DNA breakage (Sellimi et al., 2014). Structures of compounds 99-106 are shown in Figure 2.7.. 
 
Figure 2.7. Structures of carbohydrates 99-106 isolated from Cystoseira algae 
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2.3.6. LIPIDS 
Lipids fulfill some unique biological roles, as an important source of energy, and as 
constituents of cell membranes with active role in regulating trafficking cellular pathways, 
protein function and signal transduction (Ibarguren et al., 2014). In Cystoseira species, several 
types of lipids have been reported, including triacylglycerols and fatty acids. 
2.3.6.1. Triacylglycerols 
Triacylglycerols (TAGs) have an important role as intermediate compounds in several 
biosynthetic reactions. Eighteen molecular species of TAG (107-125) in the lipid fraction of 
C. brachycarpa have been identified by chromatography techniques coupled to mass 
spectrometry (Ragonese et al., 2014). TAGs are triesters that combine glycerol with three 
fatty acid molecules. In marine micro- and macroalgae, the chain lengths of fatty acid 
moieties in TAGs contain mostly 18 to 22 carbons, as is the case with eicosapentaenoic (EPA) 
and docosahexaenoic (DHA) acids. Molecular species of Cystoseira TAGs are represented in 
Figure 2.8.).  
2.3.6.2. Fatty Acids 
Several saturated (SFA; 126-139), monosaturated (MUFA; 140-144) and 
polyunsaturated (PUFA; 146-158) fatty acids were found in nine different Cystoseira species, 
namely C. baccata, C. barbata, C. brachycarpa, C. compressa, C. crinita, C. humilis, 
C. nodicaulis, C. tamariscifolia, C. usneoides (Kamenarska et al., 2002; Andrade et al., 2013; 
Ivanova et al., 2013; Panayotova and Stancheva, 2013; Ragonese et al., 2014; Vizetto-Duarte 
et al., 2015) as represented in Figures 2.9.-2.11. . 
Caproic (126), heneicosylic (136), tricosylic (138), myristoleic (140), cis-10-
heptadecenoic (143), erucic (145) and docosahexaenoic (158) acids were only reported in 
C. barbata. Although hexadeca,-4,7,10,13-tetraenoic (147) and docosapentaenoic (157) acids 
 
Figure 2.8. Structures of triacylglycerols 107-125 from Cystoseira algae 
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Figure 2.9. Structures of saturated fatty acids 126-139 identified in Cystoseira algae 
was only reported in C. crinita, and the eicosatetraenoic acid (154) in C. brachycarpa. 
Beyond their energetic role, fatty acids are involved in several biological processes, including 
the regulation of membrane structure and function, of intracellular signaling pathways and of 
the bioactive lipid mediator production, gene expression and transcription factor activity. As a 
result, they are object of greater interest due to its influence on human health, well-being, and 
disease risk (Calder, 2015). 
In addition to the recognized impact on cardiovascular diseases and its importance as 
endocrine and lipoprotein precursors, a wider range of therapeutic promising properties is 
identified in fatty acids (Radwan, 1991; Rocha Filho et al., 2011). In this work, we refer to it 
as cholinesterasic inhibitors, antioxidant,
 
anti-inflammatory, immunomodulatory, anti-
androgenic, anti-cancer, anti-diabetic, anti-atherosclerosis and hemorheologic
 
agents 
(Andrade et al., 2013; Miyazawa et al., 2005; Ren et al., 2006;  Gopalakrishna, 2011; Shultz 
et al., 1992; Ward and Singh, 2005; Kapoor and Huang, 2006; Shaikh and Edidin, 2008; Lavie 
et al., 2009; Huang, and Ebersole, 2010; Kawamura et al., 2011; Borow et al., 2015; Wei et 
al., 2016). These compounds are also useful in the treatment of premenstrual syndrome, 
hyperlipidemia, multiple sclerosis, rheumatoid arthritis, schizophrenia, skin ailments 
(Mcgregor et al., 1989; Vaddadi, 1992; Zurier et al., 1996; Kurabayashi et al., 2000; Emsley 
et al., 2003; Kawamura et al., 2011; Rocha Filho et al., 2011) as well as diet supplement for 
pregnant women and children (Ward and Singh, 2005) to ensure their correct development. 
Moreover, some of these compounds revealed activity against bacteria (Yff et al., 2002; 
Huang and Ebersole, 2010; Chen et al., 2011), fungi (Jung et al 2013c; Verma et al., 2014) 
and virus (Lee et al., 2009).  
In what concerns cholinesterase (AChE) and butyrylcholinesterase (BuChE) and anti-
radical activities (DPPH, nitric oxide, superoxide and hydroxyl), a relationship between 
chemical composition and biological activities of extracts suggest that the presence of fatty 
acids 130, 142, 155 and 156 contributes for these activities in the extracts of C. tamariscifolia, 
C. nodicaulis, and C. usneoides (Andrade et al., 2013). Anti-inflammatory, anti-cancer, anti- 
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Figure 2.10. Structures of the monounsaturated fatty acids 140-145 identified in Cystoseira algae 
diabetic, antiandrogenic, antifungal and anti-bacterial properties are also reported for 142 
(Gopalakrishna, 2011). 
Palmitic acid (138) was reported as an abundant SFA in various Cystoseira species 
(Kanias et al., 1992; Kamenarska et al., 2002; Ivanova et al., 2013; Andrade et al., 2013; 
Panayotova and Stancheva 2013; Ragonese et al, 2014; Vizzeto-Duarte et al., 2015). 
Antimicrobial activities such as antifungal, antiviral, anti-bacterial are reported for 138 (Yff et 
al., 2002; Lee et al., 2009; Jung et al., 2013c). Additionally, Vizzeto-Duarte et al. (2015) 
highlights C. compressa, C. tamariscifolia and C. nodicaulis for their low PUFA/SFA, low n-6 
PUFA/n-3 PUFA ratios and also for its favorable unsaturation, atherogenicity and 
thrombogenicity indices, suggesting the potential application of these algae in the 
nutraceutical industry. 
The n-3 PUFA 149, 156 and 158 exhibited strong anti-bacterial activity against different 
oral pathogens (Streptococcus mutans, Candida albicans, Aggregatibacter 
actinomycetemcomitans, Fusobacterium nucleatum, and Porphyromonas gingivalis), 
revealing the potential therapeutic effect for oral health improvement. γ-Linolenic acid (150), 
a metabolic precursor of 155 and prostaglandin E1, shows promising properties as an anti-
inflammatory compound (Kapoor and Huang, 2006), and a biomolecule able to improve skin 
barrier function and mild atopic dermatitis (Kawamura et al., 2011), rheumatoid arthritis 
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Figure 2.11. Structures of the polyunsaturated fatty acids 146-158 present in Cystoseira algae 
 (Zurier et al., 1996), multiple sclerosis (Mcgregor et al., 1989), schizophrenia, 
andpremenstrual symptoms (Rocha Filho et al., 2011). It is also included in infant diet 
supplements (Ward and Singh, 2005). Compound 155 is the most abundant omega-6 PUFA in 
humans. As a structural lipid, it is important for the correct development of the infants brain 
(Ward and Singh, 2005). Moreover, fatty acid 155 and other polyunsaturated derivatives are 
involved in the biosynthesis of eicosanoid hormones such as prostaglandins, thromboxanes 
and leukotrienes (Radwan, 1991) and a direct precursor of a number of eicosanoids regulating  
lipoprotein and hemorheology metabolisms, leucocyte function and platelet activation (Ward 
and Singh, 2005). Cardioprotective, anti-cancer, immunomodulatory, anti-inflammatory, 
atherosclerosis, hyperlipemia-
 
and schizophrenia-preventive, antibacterial and antileishmanial 
properties are reported for compound 156, which is also included in adult and pregnant 
women sussplements  (Kurabayashi et al., 2000; Emsley et al., 2003; Ward and Singh, 2005; 
Shaikh and Edidin, 2008; Lavie et al., 2009; Vassalo et al., 2011; Borow et al., 2015). 
Moreover, compound 156 also plays an endocrine role as precursor of the prostaglandin-3, 
thromboxane-3 and leukotriene-5 eicosanoids (Radwan, 1991). As a major structural 
component of the brain, eye retina and heart tissue, 158 is essential for the proper 
development of these organs in infants and for cardiovascular health and for cancer 
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prevention, being recommended as diet supplement for pregnant women, infants and adults as 
well (Ward and Singh, 2005; Lavie et al., 2009). This compound is also of interest for the 
food industry as additive in the manufacture of cheese, yoghurt, breakfast cereals, spreads and 
dressings (Ward and Singh, 2005). 
2.3.7. PIGMENTS AND VITAMINS 
Two carotenoids, known by their antioxidant and anti-inflammatory properties, were 
found in C. baccata, β-carotene 159 and astaxanthin 160. When evaluated for their 
antiproliferative effect on human T-cell leukemia cells these compounds revealed mild 
inhibitory activities (Panayotova and Stancheva, 2013), and compound 161 displayed 
antitumoral activity against colon cancer cells (Ishikawa et al., 2008).  
Compound 160, found in high amounts in Cystoseira, have several other applications, 
namely effects on cataracts and cardiovascular disease prevention, immune system boosting, 
anti-helycobacter pylori and liver function protection (reviewed in Higuera-Ciapara et al., 
2006 and Chena and Kotanib, 2016). Fucoxanthin (161), another recognized algal carotenoid, 
identified in C. brachycarpa (Ragonese et al., 2014) has several potential applications 
requiring antioxidant, anti-inflammatory, anti-cancer, anti-obesity, anti-diabetic, 
antiangiogenic activities, protective effects on the liver, skin and eyes and antiparasitic 
activity against Plasmodium falciparum malaria parasites (reviewed in Peng et al., 2011). 
Moreover, other phytotoxic activities, as inhibition of seed germination (Islam et al., 2017) 
and inhibition of cyanobacterial growth (Xian et al., 2006), are reported for this compound. 
Chlorophyll a (162), with recognized antioxidant properties with interesting applications for 
food purposes, was isolated from C. brachycarpa (Ragonese et al., 2014). Structures of 
compounds 159-162 are presented in Figure 2.12.. 
Three vitamins, α-tocopherol (163), retinol (164) and ergocalciferol (165), were 
identified in C. barbata (Panayotova and Stancheva, 2013). Beyond its accepted antioxidant 
activity (reactive oxygen species and reactive nitrogen species scavenging), compound 164 
also displays activities in the regulation of cellular signalling and gene expression (Brigelius- 
Flohé, 2006; Zingg, 2007). Compound 164 is broadly recognized by its anti-aging effects, 
including induction of collagen synthesis in photoaged skin and the inhibition of UV- 
activated metalloproteinases (Kong et al., 2016).  Currently recognized as a prohormone, 
compound 169 is able to inhibit leukemia cell growth (Chen et al., 2008), regulate parathyroid 
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Figure 2.12. Structures of pigments 159-162 identified in Cystoseira algae 
hormone levels (Thimachai et al., 2015) and the calcium and phosphate absorption (Sahay 
and Sahay 2012). Structures of compounds 163-165 are presented in Figure 2.13. 
2.3.8. OTHERS  
Other compounds (166-214) were identified in Cystoseira species (Figure 2.14.). 
C. barbata contains as volatile compounds mainly halogenated hydrocarbons, 3-bromo-2-
chloro-1-propanol (166), 1-bromo-2-chloroethane (167), 1,1,2-trichloroethane (168), 1,1,2,2,-
tetrachloroethane (169), hexachlorobutadiene (170), dimethylformamide (171) while the main 
volatile components of C. crinita appeared to be monoterpenoids, as for example compound 
10. As reported in literature (Milkova et al., 1997) the anti-bacterial, antifungic activity and 
toxicity against some crustaceans displayed by C. barbata extracts could be associated to the 
 
Figure 2.13. Structure of vitamins 163-165 present in Cystoseira algae composition. 
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Figure 2.14. Structures of other different compounds 166-214 isolated from Cystoseira algae 
presence of these halogenated hydrocarbons. In other study, twenty four acyclic alkanes (172-
195) were identified in the volatile oil of C. barbata (Ozdemir et al., 2006).  
The hydrocarbons 178-181 were also isolated from C. crinita (Kamenarska et al., 2002). 
Volatile fraction of C. barbata, was composed mainly of docosane (184), and tetratriacontane 
(194) followed by hexadecane (178), heptadecane (179), eicosane (182) and tricosane (185). 
Moreover three other components, 1-octene (196), 1-heptadecanamin (197) as well as 2,4-
dimethyl-1-heptene (198), were identified in C. barbata (Ozdemir et al., 2006). Antimicrobial 
activity is reported for the compound 197 (Sukatar, 2006). Halogenated and sulphur 
derivatives such as chloroacetic acid (198), chloroacetic ethyl ester (200), 1-chloro-2-ethoxy-
2-methoxyethane (201), 1-chloro-2,2-diethoxyethane (202), 1,1-dichloro-2,2-diethoxyethane 
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(203), dimethyl disulfide (204) and thioacetic acid-O-ethyl ester (205) have been reported in 
the volatile fraction of the C. crinita from the eastern Mediterranean (Kamenarska et al., 
2002). From C. crinita, other polar compounds were identified, namely the 1,3-butanediol 
(206), 2,3-butanediol (207), glycerol (208), 2-hydroxypropanoic (209) and 4-
hydroxypentanoic (210) and 2,3-dihydroxy palmitic acid, propyl ester (211; Kamenarska et 
al., 2002). Furthermore, 2-ethylhexylphtalate (212) has been identified in C. compressa from 
Tunisia (Mighri et al., 2009) and cinnamic acid (213) from C. crinita (Kamenarska et al., 
2002). The amino-acid proline (214), which has α-glucosidase inhibitory activity, acetyl- and 
butyrylcholinesterase activities, was isolated from C. nodicaulis, C. tamariscifolia and 
C. nodicaulis (Andrade et al., 2013). 
2.4. CONCLUSIONS 
Overall, the genus Cystoseira contains a wide variety of secondary metabolites, namely 
lipids, terpenoids, steroids, carbohydrates, phlorotannins, phenolic compounds, pigments and 
vitamins. Within these metabolites, 59 interesting biological properties are reported. The  
most commonly found are antioxidant, anti-inflammatory, cytotoxicity, anticancer, 
cholinesterase inhibition, anti-diabetic, and anti-herpetic activities. Antibacterial, antifungal 
and anti-parasitic activities as antimalarial and antileishmanial are also described, though with 
less detail. This comprehensive review shows that Cystoseira contain compounds with several 
biomedical potentialities, providing an extensive list of natural isolated structures that could 
be used as scaffolds to the design of novel and target-specific molecules for pharmacological 
purposes. 
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3.1. ABSTRACT 
Forty-five extracts obtained from 15 macroalgae species from Cystoseira genus 
collected on the Iberian coast were screened for activity against Leishmania (L.) infantum 
parasites. Cytotoxicity against human macrophages was also determined. Seven extracts 
displayed IC50 values ranging from 29.8 to 101.8 µg/mL against promastigote forms. Hexane 
and CH2Cl2 extracts of C. tamariscifolia and the CH2Cl2 extract of C. usneoides were the most 
active with IC50 values ranging from 29.8 to 33.6 µg/mL. Additionally, the hexane extracts 
from C. barbata and C. baccata exhibited inhibitory activities against intracellular amastigote 
forms of L. infantum with IC50 values of 5.1 and 6.8 µg/mL, respectively. A preliminary 
identification of chemical composition of the active Cystoseira extracts was performed by 
nuclear magnetic resonance
 
(NMR), gas chromatography/flame ionization detector (GC/FID), 
gas chromatography/low resolution electron ionization mass spectrometry (GC/LREIMS) and 
high resolution thin layer chromatography (HRTLC), revealing that Cystoseira extracts are 
composed of fatty acids, triacylglycerols, carotenoids, steroids, and meroterpenoids. These 
results suggest that Iberian Cystoseira macroalgae contain compounds with antileishmanial 
activity which could be explored as scaffolds to the development of novel sources of 
antiparasitic derivatives. 
 
Keywords: Leishmania (L.) infantum; antileishmanial activity; macroalgae; Cystoseira. 
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3.2. INTRODUCTION 
Leishmaniases are a group of vector-borne diseases resulting from the infection of 
mononuclear phagocytic cells by kinetoplastid parasites of the Leishmania genus, which are 
transmitted by several species of phlebotomine sand flies. With a worldwide growing annual 
incidence of about 2 million new human cases per year, these diseases are endemic in 98 
countries, affecting more than 12 million people, particularly those living in the world’s 
poorest areas, and causing chronic disability and poverty in low- and middle-income countries 
(Alvar et al., 2012). In the Mediterranean region, cutaneous and visceral clinical forms of 
human and canine leishmaniasis are caused by L. (L.) infantum, and are considered to be a 
severe public health issue (Campino et al., 2006). Presently, only a small number of drugs 
with limited effectiveness, due to growing parasite resistance, are available for controlling 
leishmaniases. In this context, the development of novel drugs continues to be important 
(Sundar and Chakravarty, 2015b). Plants are known to be a large source of bioactive 
compounds that currently continues to be explored (Al-Sokari et al., 2015) However, the 
marine environment has been recognized as another rich source of bioactive metabolites that 
could be used in antileishmanial therapy and control (Tempone et al., 2011). 
Over the last few years, screening efforts have shown that a number of extracts from 
several seaweed species belonging to the Chlorophyta, Heterokontophyta and Rhodophyta 
phyla are toxic to Leishmania parasites (Freire-Pelegrin et al. 2008; Spavieri et al., 2010a; 
Süzgeç-Selçuk et al., 2010; Sabina et al., 2005; Orhan et al., 2006; Vonthron-Sénécheau et al., 
2011; Bianco et al., 2013). These studies used different extracts of macroalgae from 
European, Asian, Middle-East and South American countries and all evaluated the effect of 
crude extracts against different Leishmania species, namely L. donovani, L. major, 
L. amazonensis and L. mexicana upon axenic promastigote and amastigote parasite forms. 
The most potent activities were found on ethanol (EtOH) extracts of Laurencia pinnatifida 
(Sabina et al., 2005) and Ulva lactuca (Orhan et al., 2006) and on the ethyl acetate (EtOAc) 
extract of the brown algae Bifurcaria bifurcata (Vonthron-Sénécheau et al., 2011). Among 
these studies, only four publications described the identification of promising molecules for 
future studies regarding the treatment of leishmaniases, namely the sesquiterpene elatol and 
obtusol isolated from Laurencia dendroidea (dos Santos et al., 2010; Machado et al., 2011) as 
well as the diterpenes 4-acetoxy-dolastane and dolabelladienetriol obtained from 
Canistrocarpus cervicornis and Dictyota pfaffii, respectively (dos Santos et al., 2011; Soares 
et al., 2012). 
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The diversity of secondary metabolites produced by Cystoseira algae (Amico, 1995) as 
well as the diversity of biological activities already reported by other authors (Spavieri et al., 
2010a; Khanavi et al., 2010; Mhadhebi et al., 2011; Tajbakhsh et al., 2011; Ibraheem et al. 
2012; Ghannadi et al., 2013) for this genus have led us to research whether these macroalgae 
could contain interesting cytotoxic compounds against Leishmania parasites. Members of this 
genus are known producers of different meroterpenoids and diterpenoids with antioxidant and 
cytotoxic activities. C. barbata, C. baccata, C. crinita and C. tamariscifolia extracts have been 
reported to be active against L. donovani (Spavieri et al., 2010a; Süzgeç-Selçuk et al., 2010). 
Although some reports have described the activity of other Sargassaceae algae against 
L. major and L. mexicana, none has reported cytotoxic bioactivities for L. infantum (Freire-
Pelegrin et al., 2008; Vonthron-Sénécheau et al., 2011).  
Taking into account the antiprotozoal potential of extracts from natural sources and the 
marine biodiversity of the Iberian coast, this study evaluated the in vitro antileishmanial 
activity and cytotoxicity of extracts of 15 macroalgal species collected on the Portuguese and 
Spanish coasts. Some of the algae tested were evaluated for the first time for this activity. In 
addition, the chemical composition of the bioactive extracts was tentatively determined by 
high field 
1
H NMR, GC/FID and GC/HREIMS spectral analysis and/or HRTLC comparison 
with standard samples. Some of the evaluated extracts exhibited inhibitory activities against 
promastigotes and intracellular amastigotes, suggesting that Iberian Cystoseira contain 
compounds with antileishmanial activity. 
3.3. EXPERIMENTAL SECTION  
3.3.1. ALGAL MATERIAL 
Samples from 15 different species belonging to the Rhodophyta, Chlorophyta and 
Heterokontophyta phyla were collected between July, 2010 and July, 2013 at different 
locations of the Portuguese and Spanish coasts (Table 3.1.). Samples were washed with 
seawater, and kept at +4 °C until they were washed with water to remove epiphytes at the 
laboratory. Biomass was freeze, dried, ground and stored at -20 °C. The 15 Voucher 
specimens are kept at Centre of Marine Sciences - MarBiotech herbarium - Faro, Portugal. 
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Table 3.1. Species, date of collection and collection site of the macroalgae 
Phylum /Species  Date Local Country 
Chlorophyta     
 Cladophora albida (Nees) Kutzing  July 2010 Olhos de Água
1 
Portugal 
Codium sp. Stackhouse  July 2010 Olhos de Água
1 
Portugal 
Heterokontophyta     
 Cladostephus spongiosus (Hudson) C. Agardh  July 2010 Olhos de Água
1 
Portugal 
Cystoseira baccata (S. G. Gmelin) P. C. Silva  July 2012 Areosa
2 
Portugal 
Cystoseira barbata (Stackhouse) C. Agardh  March 2013 Cadiz Bay
1 
Spain 
Cystoseira humilis Schousboe ex Kützing  May 2012 Almograve
3 
Portugal 
Cystoseira nodicaulis (Withering) M. Roberts  April 2013 Santa Mariña
2 
Spain 
Cystoseira tamariscifolia (Hudson) Papenfuss  July 2012 Areosa
2 
Portugal 
Cystoseira usneoides (L.) M. Roberts  September 2012 Olhos de Água
1 
Portugal 
Halopteris scoparia (L.) Sauvageau  July 2010 Olhos de Água
1 
Portugal 
Sargassum muticum (Yendo) Fensholt  July 2010 Olhos de Água
1 
Portugal 
Taonia atomaria (Woodward) J. Agardh  July 2010 Olhos de Água
1 
Portugal 
Rhodophyta 
 Peyssonnelia squamaria (S. G. Gmelin) Decaisne  July 2013 Arrifes
1 
Portugal 
 Plocamium cartilagineum (L.) P. S. Dixon  July 2012 Olhos de Água
1 
Portugal 
 Scinaia furcellata (Turner) J. Agardh  July 2013 Olhos de Água
1 
Portugal 
1
Southern coast, 
2
Northwestern coast and 
3 
Southwestern coast of the Iberian Peninsula. 
3.3.2. PREPARATION OF THE EXTRACTS 
Dried biomass was blended with hexane (1:10 w/v) by means of an IKA Ultra-Turrax 
disperser for 1 min for cell wall disruption, and after centrifugation (5000 × g, 10 min) the 
supernatants were recovered. The extraction was repeated three times. The residue was then 
sequentially extracted with CH2Cl2 and MeOH in a similar manner. All extracts were 
evaporated under reduced pressure at +40 C and stored at +4 °C. For the bioactivity assays, 
extracts were dissolved in DMSO (dimethyl sulfoxide) at the concentration of 50 mg/mL. 
3.3.3. ANTILEISHMANIAL AND CYTOTOXICITY ASSAYS 
3.3.3.1. Cytotoxicity Assay.  
Cytotoxicity of all extracts used for the antileishmanial assays was performed on human 
acute monocytic leukaemia cell line THP-1 (ATCC TIB-202). Cells were cultivated in RPMI-
1640 medium supplemented with 10% heat-inactivated foetal bovine serum (FBS), L-
glutamine (2 mM), penicillin (50 U/L) and streptomycin (0.05 mg/L) at +37 C in humidified 
atmosphere with 5% CO2. For the assay, 10
5
 THP-1 cells per well were seeded onto the 96-
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well plates. Extracts were added at concentrations ranging from 4 to 125 µg/mL for 48h, and 
cell viability was determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) colorimetric assay, as described elsewhere [51]. Cells used as 
negative control were treated with DMSO at the highest concentration used in test wells 
(0.5% v/v). Results were expressed in terms of cell viability (%) and half maximal inhibitory 
concentration values (IC50 – in µg/mL). 
3.3.3.2. Antipromastigote Assay.   
Promastigote forms of an L. infantum strain (MHOM/PT/88/IMT-151) were obtained 
from the cryobank of the ‘Instituto de Higiene e Medicina Tropical’ (Universidade Nova de 
Lisboa, Portugal) and maintained in RPMI-1640 medium supplemented with 10% FBS, L-
glutamine, penicillin and streptomycin, at 24 C. About 2 x 106 parasites per well were 
incubated in 96-well plates with the extracts at concentrations ranging from 4 to 125 μg/mL 
for 48h. Negative control cells were treated with DMSO at the highest concentration used in 
test wells (≤1% v/v). Amphotericin B (0.2 µg/mL), miltefosine (12.7 µg/mL) and pentamidine 
(0.5 µg/mL) were used as positive controls. The effect of the extracts on parasite viability was 
assessed by the MTT colorimetric assay. Results were expressed in terms of cell viability (%) 
and IC50 values (µg/mL). 
3.3.3.3. Activity against intracellular amastigotes.  
L. infantum intracellular amastigotes (MHOM/MA(BE)/67) were collected from the 
spleen of heavily infected donor hamsters and used to infect primary peritoneal mouse 
macrophages (PMM). PMM (3 × 10
4
 per well) were seeded on 96-well plates, and incubated 
for two days for cell attachment. Then, 5 × 10
5
 amastigotes were added to each well (infection 
ratio about 16 amastigotes per cell) and infected macrophages were further incubated at 37 C 
for 2 h. The extracts at concentrations ranging from 0.25 to 64.0 µg/mL were added and the 
plates were further incubated at 37 C and 5% CO2. After 5 days, intracellular amastigote 
burdens were microscopically assessed upon Giemsa staining and the inhibitory concentration 
conferring a 50% reduction of the intracellular amastigote burden compared to the non-treated 
infected positive controls (CC50) was determined. In addition, cytotoxicity of the extracts was 
evaluated on PMM cells and carried out as previously described (Mokrini et al., 2008). For 
the latter tests, the reference drug (miltefosine) was used as positive control. 
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3.3.3.4. Microscopic Analysis.  
Leishmania promastigotes were incubated with the extracts (125 µg/mL) and with 
amphotericin (0.2 µg/mL) for 48h. After incubation and centrifugation, parasites were 
smeared on microscope slides, fixed with methanol and stained with Giemsa solution and 
observed using a Zeiss AXIOMAGER Z2 microscope, equipped with a cool SNApHQ2 
camera and AxioVision software version 4.8 (Carl Zeiss MicroImaging GmbH, Göttingen, 
Germany).  
3.3.3.5. Apoptosis detection through Annexin V-FITC staining. 
Promastigotes (4 x 10
6
/mL) cultured in RPMI medium with DMSO (0.1%) were treated 
with Cystoseira extracts at IC50 concentrations for 48h. Negative and positive controls cells 
were treated with DMSO at the highest concentration used in test wells (≤ 1% v/v) and 
amphotericin B (0.6 µg/mL), respectively. Apoptotic effect of the tested extracts on 
L. infantum promastigotes was evaluated by flow cytometry using the Annexin V-FITC 
(fluorescein isothiocyanate) Apoptosis Kit - KA0714 (Abnova) in accordance with the 
manufacturer's recommendations. Briefly, treated and control promastigotes were washed 
with culture medium and resuspended in 500 μL binding buffer and stained with 5 μL of 
annexin V-FITC (10 mg/mL) and 5 μl of propidium iodide (PI; 50μg/ml) and incubate at 
room temperature for 5 min in the dark. Results were obtained by flow cytometry using a 
FACS Calibur Flow Cytometer (Becton-Dickinson, East Rutherford, NJ, USA) using the Cell 
Quest software (BD Biosciences, San Jose, CA, USA) for acquisition and result analysis. Ten 
thousand events were analysed and apoptosis evaluated based on the geometric mean of the 
fluorescence intensity detected in channels 1 (for annexin) and 2 (for PI) (Farias et al., 2013). 
3.3.4. CHEMICAL CHARACTERIZATION OF CYSTOSEIRA EXTRACTS. 
3.3.4.1. NMR analysis.  
Hydrogen nuclear magnetic resonance (
1
H NMR) spectra were recorded on a Bruker 
Avance III 500 spectrometer, using 5 mm TXI probe, operated at 500.13 MHz for 
1
H nucleus. 
Approximately 10 mg of each sample was dissolved in 0.6 mL of CDCl3 with 
tetramethylsilane (TMS) as a standard reference with a chemical shift H = 0.00 ppm. Spectra 
were obtained at +25 C, with 64 scans, 2 dummy scans, using a 90 degree high power pulse 
of 8.3 µs, a recycle delay of 1s, and 64 K data points covering a spectral width of 7684 Hz. 
All spectra were processed using Topspin 3.2 software. 
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3.3.4.2. HPTLC Analysis.  
All studied crude extracts were submitted to comparative high resolution thin layer 
chromatography (HRTLC; PF254, Merck) in SiO2 (silicon dioxide) for investigating the 
presence of secondary metabolites. Different solvents were employed as the mobile phase and 
ceric sulphate/p-anysaldehyde as a post-derivatization agent. All planar chromatographic 
analyses were developed using different standard samples.  
3.3.4.3. GC/FID and GC/LREIMS analysis 
Gas chromatography with flame ionization detector (GC/FID) chromatograms were 
recorded on a Shimadzu GC-2010 gas chromatograph equipped with an FID-detector and an 
automatic injector (Shimadzu AOC-20i) using a RtX-5 capillary column (5% phenyl, 95% 
polydimethylsiloxane, 30 m × 0.32 mm × 0.25 μm film thickness; Restek, USA). These 
analyses were performed by injecting 1.0 μL of a 1.0 mg/mL solution of crude hexane extract 
in hexane in a split mode (1:30) employing helium as the carrier gas (1 mL/min) under the 
following conditions: injector and detector temperatures of +270 C and 300 C, respectively; 
oven programmed temperature from 120–290 °C at 8 °C/min, holding 20 min at 290 C. Gas 
chromatography–low resolution electron ionization mass spectrometry (GC/LREIMS) 
analysis was conducted in a Shimadzu GC-17A chromatograph interfaced with a MS-QP-
5050A mass spectrometer operating using ionization voltage of 70 eV and an ion source 
temperature of +350 °C with the same conditions described above. Helium was used as the 
carrier gas.  
3.3.5. STATISTICAL ANALYSIS 
The antileishmanial and cytotoxic assays were conducted in triplicate and the results 
were expressed as mean and standard error of the mean (SEM). The IC50 values were 
calculated using sigmoid regression on the logarithm of the concentration-response data in the 
GraphPad Prism V 5.0 software. 
3.4. RESULTS 
From the 45 extracts evaluated, seven were active against L. infantum promastigotes 
(Table 3.2.). The majority of the bioactive extracts belong to Cystoseira species. 
C. tamariscifolia hexane (IC50 = 31.2 µg/mL) and CH2Cl2 (IC50 = 29.8 µg/mL) extracts and 
C. usneoides CH2Cl2 (IC50 = 33.6 µg/mL) extract were the most active against this parasite 
form. 
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Table 3.2. Inhibitory concentrations of algal extracts against L. infantum and THP-1 cells 
Species 
Extract/ 
Compound 
IC50 (μg/mL)
a
 
Promastigotes 
CC50 (μg/mL)
b
 
Amastigotes 
IC50 (μg/mL)
a
 
THP-1 
Cladophora albida Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
Cladostephus spongiosus Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
Cystoseira baccata Hexane 
CH2Cl2 
MeOH 
94.1 ± 1.5 
>125 
>125 
5.1 ± 0.0 
- 
- 
>125 
76.2 ± 3.9 
>125 
Cystoseira barbata Hexane 
CH2Cl2 
MeOH 
78.7 ± 3.2 
>125 
>125 
6.8 ± 0.0 
- 
- 
79.5 ± 2.3 
>125 
>125 
Cystoseira humilis Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
Cystoseira tamariscifolia Hexane 
CH2Cl2 
MeOH 
31.2 ± 0.9 
29.8 ± 0.5 
>125 
- 
- 
- 
30.9 ± 0.4 
19.9 ± 0.5 
>125 
Cystoseira nodicaulis Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
Cystoseira usneoides Hexane 
CH2Cl2 
MeOH 
59.9 ± 0.2 
33.6 ± 0.6 
>125 
- 
- 
- 
16.6 ± 0.3 
12.6 ± 0.4 
45.0 ± 0.4 
Codium sp. Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
Dictyota spiralis Hexane 
CH2Cl2 
MeOH 
48.3 ± 0.7 
>125 
>125 
- 
- 
- 
- 
- 
- 
Halopteris scoparia Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
Peysonnelia squamaria Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
Plocamium cartilagineo Hexane 
CH2Cl2 
MeOH 
101.8±2.8 
>125 
>125 
- 
- 
- 
51.6±0.1 
>125 
>125 
Sargassum muticum Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
Scinaria funcellata Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
Taonia atomaria Hexane 
CH2Cl2 
MeOH 
>125 
>125 
>125 
- 
- 
- 
>125 
>125 
>125 
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Species 
Extract/ 
Compound 
IC50 (μg/mL)
a
 
Promastigotes 
CC50 (μg/mL)
b
 
Amastigotes 
IC50 (μg/mL)
a
 
THP-1 
Positive controls Amphotericin B 
Miltefosine 
Pentamidine 
  0.2 ± 0.0 
12.7 ± 1.8 
  0.5 ± 0.1 
- 
8.8 ± 0.0 
- 
- 
8.8 ± 0.0 
- 
a
IC50 - Inhibitory concentration of extract / compound causing 50% reduction of the promastigote and human 
acute monocytic leukaemia cell line THP-1 cells growth; 
b
CC50 - Inhibitory concentration of extract / compound 
causing 50% reduction of the intracellular amastigote burden compared to the non-treated infected controls. IC50 
and CC50 values represent the mean ± standard error of the mean of three experiments performed in triplicate. 
 
The effect of the extracts on promastigote forms was also analyzed by optical 
microscopy, revealing the occurrence of several morphological changes of the parasites 
(Figure 3.1.). The exposure of L. infantum promastigotes to extracts from C. barbata (Figure 
3.1.D) resulted in motility loss, cell shrinkage, abnormal round cell shapes, vacuolated and 
slightly denser cytoplasm as well as reduction of flagellar length in parasite cells. In contrast, 
control cells and cells treated with the inactive hexane extract from C. nodicaulis (Figure 
3.1.C) were indistinguishable regarding the typical elongated cell morphology, flagellar 
length and motility, similar to negative control - RPMI medium (Figure 3.1.A). 
Phosphatidylserine externalization assay did not reveal an apoptotic effect of any 
Cystoseira extract on promastigotes upon a 48 h of treatment (data not shown). From the 
active Cystoseira extracts, those obtained in hexane from C. baccata and C. barbata 
 
 
Figure 3.1. Effect of C. nodicaulis and C. barbata hexane extracts (125 µg/mL, 48h) on the 
morphology of L. infantum promastigotes. Control cells cultured in RPMI medium alone (A) treated 
with the control drug amphotericin B (0.2 µg/mL; B), and treated with C. nodicaulis (C) or C. barbata 
(D) extracts. Bright field images; the scale bar corresponds to 5 µm. 
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displayed the lowest toxicity against THP-1 mammalian cells (IC50 = 79.5 µg/mL and > 125 
µg/mL, respectively - Table 3.2.). This lower toxicity allowed for the testing of the latter 
extracts on the intracellular model. When assayed towards the intracellular amastigote form of 
the parasite infecting the peritoneal mouse macrophages (PMM), hexane extracts from 
C. baccata and C. barbata revealed a CC50 of 6.8 and 5.1 µg/mL, respectively (Table 3.2.). 
Moreover, these extracts were as cytotoxic to PMM as the reference drug miltefosine (IC50 = 
8.8 µg/mL). 
The 
1
H NMR spectral analysis of the C. baccata, C. barbata, C. tamariscifolia, and 
C. usneoides crude extracts (ANNEXES 2-3) revealed the occurrence of different classes of 
metabolites present in each studied extract (Table 3.3.). The chemical analysis of the 
bioactive hexane extracts suggest the presence of fatty acids, triacylglycerols, carotenoids, 
and steroids, except those from C. barbata and C. usneoides, which were also composed of 
meroterpenoids. In all obtained spectra, an intense singlet at H 1.2, a deformed triplet at H 
0.8 and a multiplet at H 5.3 were indicative of the presence of unsaturated fatty acids. 
Analysis of GC/FID using standard samples of arachidonic and eicosapentaenoic acids 
allowed the characterization of these fatty acids in the studied crude hexane extracts. 
Additionally, these spectra displayed singlets at H 0.68, broad doublets at H 5.4 and 
multiplets at H 3.5, characteristics of steroids. Furthermore, the presence of singlets at range 
H 0.9 - 1.8 associated to the unresolved signals at H 5.9 - 6.4 suggested the presence of 
carotenoid derivatives in all studied hexane extracts, except for that of C. usneoides. The 
occurrence of steroids and carotenoids was confirmed by GC/LREIMS. Analysis of mass 
spectra of main peaks followed by comparison of obtained data with those available in the 
system indicated the presence of steroids cholesterol (m/z 386), sitosterol (m/z 414), 
stigmasterol (m/z 412) and fucosterol (m/z 412) as well as carotenoids -carotene (m/z 536) 
and lutein (m/z 568). Particularly, in the hexane extracts of C. barbata and C. usneoides, 
overlapping peaks at H 6.5 (m), 5.3 (m) and 3.2 (m) were observed. In addition, singlets at H 
3.7 (methoxyl group attached to the aromatic ring), 2.2 (methyl group at the aromatic ring) 
and 1.7-0.9 (methyl groups of the geranyl unit) characteristic of meroterpenoids were also 
detected. Analysis of crude extract by HRTLC (SiO2 - Hex:EtOAc 4:1) using standard 
samples available in our laboratory allowed the identification of E- and Z-usneoidones as 
main derivatives.  
Similarly to hexane extracts, the 
1
H NMR spectra of CH2Cl2 extracts from C. barbata 
and C. usneoides showed multiplets at H 6.5, 5.3 and 3.2 as well as singlets at H 3.7, 2.2 and  
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Table 3.3. Class of metabolites found in Cystoseira extracts 
Species Extracts Class of metabolites
1
 Species Extracts Class of metabolites
1
 
C. baccata Hexane FA, CAR, ST C.  tamariscifolia Hexane FA, ST, CAR 
 CH2Cl2 MT, FA  CH2Cl2 TAG, FA 
C. barbata Hexane FA, CAR, ST, MT C. usneoides Hexane MT, FA, ST 
 CH2Cl2 MT, FA  CH2Cl2 MT, FA 
1FA - fatty acids, TAG - triacylglycerols, CAR - carotenoids, ST - steroids, MT - meroterpenoids 
 
1.7-0.9, assigned to hydrogens of meroterpenoid derivatives. These spectra also displayed 
intense peaks at H 1.2 (s), 0.8 (br t) and 5.3 (m), indicating that meroterpenes are present in 
the crude extracts in a mixture with unsaturated fatty acids. Differently, the 
1
H NMR spectra 
of CH2Cl2 extracts from C. tamariscifolia showed intense peaks related to fatty acids, 
suggesting that these compounds are the main metabolites. Additionally, the occurrence of 
triacylglycerol derivatives (esterified fatty acids) in this extract could be inferred due to the 
presence of characteristic peaks at H 4.0 - 4.5 in the 
1
H NMR spectra. In the case 
1
H NMR 
spectrum of CH2Cl2 extract from C. baccata the presence of signals at H 1.2 and 5.3 
associated to less intense peaks at H 6.4 (m), 5.3 (m), 3.7 (s), and 2.3 (s) was indicative of 
fatty acids and meroterpenoids. Despite of GC/LREIMS analyses having been conducted for 
these extracts, the obtained data did not allow the unequivocal identification of main 
derivatives. 
3.5. DISCUSSION 
In this work, the IC50 range on Leishmania promastigote forms of the Cystoseira active 
extracts was close to those obtained for crude extracts of other algae of the same phylum, 
namely Dictyota caribaea (Dictyotaceae), Lobophora variegata (Dictyotaceae), Turbinaria 
turbinata (Sargassaceae) and Sargassum oligocystum (Sargassaceae) (Freire-Pelegrin et al., 
2008; Fouladvand et al., 2011). Moreover, the alterations observed in the promastigotes 
morphology (Figure 3.1.) were similar to those observed by other authors after treatment of 
different Leishmania species with extracts from some marine sponges (Kahla-Nakbi et al., 
2010). Loss of motility and cellular vacuolization could be consequence of starvation 
processes caused by a deficient mitochondrial activity, autophagic mechanisms or 
cytoplasmic organelle disruption induced by the action of the extracts, as described by other 
authors (Lockshin and Zakeri, 2004; Monte Neto et al., 2011). Furthermore, 
phosphatidylserine externalization assay on L. infantum promastigotes upon a 48h-treatment 
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did not reveal an apoptotic effect of the tested extracts (data not shown). These results 
together with the extensive vacuolization observed by microscopy suggest that some crucial 
organelles, such as mitochondria, are compromised. Thus, the observed cytotoxic effect might 
not be associated with programmed cell death. As Leishmania parasites have a single 
mitochondrion, the role and stability of the membrane potential of this organelle are vital for their 
survival. Hence this organelle is usually considered as an indicator of cellular dysfunction and 
therefore an interesting target for chemotherapeutic studies (Souza et al., 2009).  
Being an easier and affordable model, axenic forms of Leishmania are often used for the 
screening of drug candidates (Tempone et al., 2011). However, due the identification of 
differences in drug susceptibility of the different parasite forms, it is recommended that the 
most promising products be evaluated on intracellular amastigotes, the clinically relevant 
stage of the parasite that recreate the pathophysiological conditions of the disease (Cos et al., 
2006). In this study, despite of the potent activity of C. usneoides and C. tamariscifolia 
extracts against promastigotes, their high toxicity against mammalian cells (Table 3.2.) 
prevented their use in intracellular assays. Therefore, hexane extracts from C. baccata and 
C. barbata were further tested for an inhibitory effect towards the intracellular amastigote. In 
fact, both extracts were more active on the intracellular form than on promastigotes, 
reinforcing the evidence that compounds with potential therapeutic interest against this 
parasite are present in these algae. The obtained results show higher activity (IC50 ≤ 6.8 
µg/mL) of the C. baccata and C. barbata hexane extracts compared to those already described 
for other macroalgae from the Cystoseira genus against intracellular Leishmania amastigotes. 
For example, Süzgeç-Selçuk et al. (2010) reported that the crude MeOH extracts of 
C. barbata and C. crinita displayed IC50 values within 23.5 and 70.0 μg/mL towards 
L. donovani intracellular amastigotes. Other examples reported in the literature are the 
CHCl3/MeOH extracts of C. baccata and C. tamariscifolia, which exhibited activities towards 
L. donovani axenic amastigotes with IC50 values of 15.7 and 19.6 μg/mL (Spavieri et al., 
2010a). Thus, the results obtained in this study compare favourably with those of similar 
reports published elsewhere.   
Since Cystoseira extracts were the most promising, their chemical profiles were 
investigated (Table 3.3.). Previous studies focusing on different bioactivities from species of 
the Cystoseira genus identified diterpenoids, meroditerpenoids, phlorotannins, and sterols 
(Mokrini et al., 2008; Mighri et al., 2009). C. baccata reveal mainly the presence of 
meroditerpenoids (Cos et al., 2006), C. barbata halogenated hydrocarbons and sterols 
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(Milkova et al., 1997) and C. tamariscifolia phloroglucintriacetates, phlorotannins and 
meroditerpenoids (Bennamara et al., 1999; Lopes et al., 2012). However, none of these 
studies reported any antileishmanial activity  
In this study, different analytical methods (NMR, HRTLC, GC/FID and GC/LREIMS) 
were used to give preliminary chemical evidence about the composition of active crude 
extracts. Thus, the obtained data revealed the presence of unsaturated fatty acids such as 
arachidonic and eicosapentaenoic (EPA) acids in the hexane extracts of the active Cystoseira 
species. This result is in agreement with other authors that have previously detected these 
compounds in different macroalgae of this genus (Vizetto-Duarte et al., 2015). Conjugated 
EPA was found to be effective against L. donovani promastigotes without affecting 
macrophages, probably by inhibiting the L. donovani topoisomerase (Vassallo et al., 2011). 
The triacylglycerols 1,3-dilinoleoyl-2-olein and 1,3-dioleoyl-2-linolein isolated from Moringa 
stenopetala revealed activity against promastigote (IC50 values of 0.08 and 242.5 µg/mL, 
respectively) and amastigote (IC50 values of 40.0 and 26.8 µg/mL, respectively) forms of 
L. aethiopica (Bekele et al., 2013). Moreover, a triacylglycerol obtained from Theobroma 
glandiflorum seeds induced a decrease in the size of cutaneous lesions in Golden hamsters 
infected with L. amazonensis identical to the one observed in the animals treated with kojic 
acid, a known antifungal agent (Rodrigues et al., 2014b). 
In the present study, steroids such as cholesterol, sitosterol, stigmasterol and fucosterol 
were also found in the hexane extracts of all studied species and were already reported as 
main metabolites in nonpolar extracts of C. adriatica (Kapetanović et al., 2005). Fucosterol, 
isolated from the brown alga Lessonia vadose, was found to be particularly active against 
both L. infantum promastigotes (IC50 = 45 µM) and intracellular amastigotes (IC50 = 10 µM) 
(Becerra et al., 2015). In addition, sitosterol was one of the two main compounds found in the 
MeOH extract of the fungi Lactarius pubescens, which demonstrated activity against several 
Leishmania species (da Silva et al., 2014). Other authors have described that this sterol 
reduced the viability of L. amazonensis (Torres-Santos et al., 2004; Pulivarthi et al., 2015). 
Sitosterol, described as candidate for cancer chemotherapy, promotes significant the arrest of 
the second subphase of the cell cycle interphase (G2/M) and endoreduplication by favoring 
the microtubule polymerization by the Bcl-2 and PI3 K/Akt signaling pathways (Moon et al., 
2008). A docking study also suggested that sitosterol displays a potent activity against the 
trypanothione reductase of L. infantum, an enzyme specific to the Kinetoplastida parasites 
(Gundampati et al., 2013). Thus, it is possible that the activity of evaluated hexane extracts 
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tested in this study against Leishmania parasites may be due to the presence of sitosterol and 
other related steroids. 
Meroterpenoids are common among marine organisms (Menna et al., 2013). The 
presence of meroterpenoids E- and Z-usneoidones in the analyzed extracts was also 
previously reported in Cystoseira (Urones et al., 1992a). Potent activities of other 
meroterpenoids, namely prenylated hydroquinones isolated from the leaves of Piper 
crassinervium (Piperaceae), were described against the epimastigote forms of Trypanosoma 
cruzi, a trypanosomatid phylogenetically and biochemically closed to Leishmania (Lopes et 
al., 2008). Analysis of 
1
H NMR spectra suggested the presence of meroterpenoids in the 
CH2Cl2 active extracts from C. barbata, C. baccata and C. usneoides but associated to the 
presence of fatty acids. Meroterpenoids are a class of secondary metabolites, mainly isolated 
from brown algae, which have already been described as having cytotoxic, antiviral, 
antibacterial and antioxidant properties (de los Reyes et al., 2013). Nonetheless, the 
antileishmanial effect of these compounds remains poorly studied. Meroterpenoids isolated 
from extracts of the marine sponge Callyspongia sp. inhibit Leishmania adenosine 
phosphoribosyltransferase, an important component of the purine salvage pathway essential 
for the parasites survival (Gray et al., 2006). As the presence of these metabolites were 
confirmed in the majority of the active Cystoseira extracts, further assessment of these 
metabolites as antileishmanial agents should be carried out in the near future. 
3.6. CONCLUSIONS  
Several macroalgae species have already been identified as sources of activity against 
protozoan agents responsible for neglected diseases, namely chagas disease, african 
trypanosomiasis and leishmaniasis (Torres et al., 2014). In this study, 15 marine macroalgae 
species from the Iberian coast were evaluated for their potential against Leishmania infantum 
parasites. Among the evaluated macroalgae, the Cystoseira genus stood out with four species 
(C. baccata, C. barbata, C. nodicaulis and C. tamariscifolia) displaying significant activity 
against this parasite. The activity of these species against promastigote forms was similar if 
not better than those described for other extracts of algae of the same phylum, suggesting the 
presence of compounds with therapeutic potential against Leishmania parasites. The 
observation of several morphological alterations and lack of externalization of 
phosphatidylserine in treated promastigotes indicate that these extracts might compromise the 
metabolism of vital organelles, such as mitochondria. Moreover, the chemical characterization 
of the Cystoseira active against the parasites revealed that hexane extracts are composed of 
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fatty acids, triacylglycerols derivatives, carotenoids, and steroids, whereas the CH2Cl2 extracts 
contain fatty acids and meroterpenoids. According to recent reports, the identified compounds 
might be involved in the antileishmanial activity here evaluated. Taken together, the results of 
this study indicate for the first time that the Cystoseira extracts might be used as source of 
compounds with activity agains L. infantum, which could be explored as scaffolds to the 
development of antiparasitic derivatives. In particular, the selective activity found in 
C. baccata and C. barbata against intracellular amastigotes suggests that they should be 
chosen for further study, since they exhibited higher antileishmanial activity as compared to 
results described in similar reports on bioactivities found in macroalgae.  
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4.1. ABSTRACT 
The development of novel drugs for the treatment of leishmaniases continues to be 
crucial to overcome the severe impacts of these diseases on human and animal health. Several 
bioactivities have been described in extracts from macroalgae belonging to the Cystoseira 
genus. However, none of the studies has reported the chemical compounds responsible for the 
antileishmanial activity observed upon incubation of the parasite with the aforementioned 
extracts. Thus, this work aimed to isolate and characterize the molecules present in a hexane 
extract of Cystoseira baccata that was found to be bioactive against Leishmania infantum in a 
previous screening effort. A bioactivity-guided fractionation of the C. baccata extract was 
carried out and the inhibitory potential of the isolated compounds was evaluated via the MTT 
assay against promastigotes and murine macrophages as well as direct counting against 
intracellular amastigotes. Moreover, the promastigote ultrastructure, DNA fragmentation and 
changes in the mitochondrial potential were assessed to unravel their mechanism of action. In 
this process, two antileishmanial meroditerpenoids, (3R)- and (3S)-tetraprenyltoluquinol 
(1a/1b) and (3R)- and (3S)-tetraprenyltoluquinone (2a/2b), were isolated. Compounds 1 and 2 
inhibited the growth of the L. infantum promastigotes (IC50 = 44.9 ± 4.3 and 94.4 ± 10.1 µM, 
respectively), inducing cytoplasmic vacuolization and the presence of coiled multilamellar 
structures in mitochondria as well as an intense disruption of the mitochondrial membrane 
potential. Compound 1 decreased the intracellular infection index (IC50 = 25.0 ± 4.1 µM), 
while compound 2 eliminated 50% of the intracellular amastigotes at a concentration > 88.0 
µM. This work identified compound 2 as a novel metabolite and compound 1 as a 
biochemical isolated from Cystoseira algae displaying antileishmanial activity. Compound 1 
can thus be an interesting scaffold for the development of novel chemotherapeutic molecules 
for canine and human visceral leishmaniases studies. This work reinforces the evidence of the 
marine environment as source of novel molecules. 
 
Keywords: Leishmania infantum; macroalgae; Cystoseira baccata; meroterpenoids; 
tetraprenyltoluquinol; tetraprenyltoluquinone. 
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4.2. INTRODUCTION 
Leishmaniases are a group of infectious diseases caused by obligate intracellular 
protozoa of the Leishmania genus. Endemic in 98 tropical and subtropical countries and 
affecting 12 million people, leishmaniases may entail cutaneous, mucocutaneous and diffuse 
forms as well as the potentially fatal visceral form (Alvar et al., 2012). Visceral leishmaniasis 
causes considerable morbidity in 200-400 thousand individuals every year, with extreme 
suffering and financial loss, especially in the poorest populations of the Indian subcontinent 
(Mondal et al., 2014). Currently, leishmaniases are among the most neglected tropical 
diseases, facing problems of resistance of the parasite to the available therapeutic molecules. 
The need for the discovery and development of alternative drugs allowing more efficient and 
effective treatments is thus quite urgent (Freitas-Junior et al., 2012).  
Nowadays, marine natural products are recognized as powerful reservoirs of novel, 
chemically diverse molecules with wide applicability to health sciences (Tempone et al., 
2011). Occurring worldwide, mainly in the rocky substrates of the Mediterranean Sea and the 
adjoining Atlantic coasts, Cystoseira C. Agardh (1820) genus encompasses 39 species of 
brown macroalgae (Guiry and Guiry, 2016). Several bioactivities such as anti-inflammatory, 
antiproliferative, antioxidant (Mhadhebi et al., 2011), enzyme inhibitory (Ghannadi et al., 
2013), cytotoxic (Khanavi et al., 2010), antifungal (Lopes et al., 2013), antiviral (Ibraheem et 
al., 2012), antibacterial (Tajbakhsh et al., 2011) and antiprotozoal (Spavieri et al., 2010a) have 
been detected in this algal genus. Despite the extensive chemical studies available for the 
Cystoseira genus, there have been only a few reports describing the antileishmanial potential 
effects of its crude extracts, and no information was found on the compounds responsible for 
the inhibitory effects on the Leishmania parasites (Amico, 1995; de los Reyes et al., 2013). As 
part of ongoing research on the identification of antileishmanial compounds from the 
Cystoseira genus, this work describes the bioactivity-guided fractionation of the hexane 
extract from Cystoseira baccata and the effect of the extract, fractions and isolated 
compounds on the promastigote and amastigote forms of Leishmania infantum.  
4.3. MATERIAL AND METHODS 
4.3.1. GENERAL EXPERIMENTAL PROCEDURES 
Optical rotations were measured in a JASCO DIP-370 digital polarimeter (Na filter, λ = 
588 nm). UV spectra were recorded using a UV/visible Shimadzu 1650-PC 
spectrophotometer. IR spectra were obtained with a Shimadzu IR Prestige-21 
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spectrophotometer. 
1
H, 
13
C, DEPT, COSY, HSQC, HMBC and NOESY NMR spectra were 
recorded in a Bruker Avance III 500 spectrometer, operating at 500 and 125 MHz, to 
1
H and 
13
C nuclei, respectively. CDCl3 (Aldrich) was used as the solvent with TMS as the internal 
standard. HRESIMS spectra were measured with a Bruker Daltonics MicroTOF QII 
spectrometer while LRESIMS spectra were recorded on a VG Platform II spectrometer. Silica 
gel (Merck, 230–400 mesh) and Sephadex LH-20 (Amersham Biosciences) were used for 
column chromatographic separation, while silica gel 60 PF254 (Merck) was used for analytical 
(0.25 mm) and preparative TLC (1.0 mm).  
4.3.2. ALGAL MATERIAL 
Cystoseira baccata biomass was collected in July 2012 in Areosa, Viana do Castelo, 
Portugal (41º42’27.60’’N, 8º51’44.90’’W). After collection, biomass was cleaned and 
cryodesiccated. Voucher specimen (MB-1) was deposited within the Laboratory of the Marine 
Biotechnology Group - MarBiotech at the Centre of the Marine Sciences of the University of 
Algarve (Faro, Portugal).  
4.3.3. EXTRACTION AND ISOLATION OF COMPOUNDS 
Dried and powdered biomass (120 g) was exhaustively extracted with hexane in a 
Soxhlet apparatus. After evaporation of the solvent under reduced pressure, 1.3 g of crude 
extract were obtained. Part of this extract (0.6 g) was subject to column chromatography over 
SiO2 eluted with hexane containing increasing amounts of EtOAc (up to 100%), followed 
with CHCl3 containing increasing amounts of MeOH (up to 100%), generating 13 fractions 
(1-13). As fraction 10 (370.0 mg) displayed activity towards promastigote forms of 
L. infantum, it was fractionated over SiO2 column, and eluted with hexane:EtOAc 1:1 yielding 
6 sub-fractions (A-F). Bioactive sub-fraction E (195 mg) was purified in a Sephadex LH-20 
column being eluted with hexane:CH2Cl2 1:4, CH2Cl2:Me2CO 3:2 and 1:1 (Cardellina II, 
1983) originating 4 groups (E1-E4). Bioactive group E4 (65.3 mg) was subjected to 
preparative TLC (hexane-EtOAc, 7:3, twice) to afford compounds 1a/1b (23.2 mg; 0.30%) 
and 2a/2b (2.5 mg; 0.04%) (Figure.4.1.). 
3R – tetraprenyltoluquinol (1a) and 3S – tetraprenyltoluquinol (1b). Yellowish oil; 1H 
NMR and 
13
C NMR (500 MHz, CDCl3) data, see Table 4.1.; LRESIMS m/z 441 [M+H]
+
 and 
463 [M + Na]
+
 (calcd for C28H41O4, 441, and C28H40O4Na, 463, respectively). 
CHAPTER IV 
103 
 
3R – tetraprenyltoluquinone (2a) and 3S – tetraprenyltoluquinone (2b). Colourless oil; 
[α]D
25
 = + 0.06 (c 0.15, CHCl3); UV (MeOH) max (log ) 352 (2.0), 248 (3.4) nm; IR (KBr) 
max 3400, 1670, 1480, 1180, 1060 cm
-1
; 
1
H and 
13
C NMR (500 MHz, CDCl3), see Table 4.1. 
and Figure. 4.2.; HRESIMS (positive mode) m/z 455.2776 [M+H]
+
 and 477.2604 [M+Na]
+
 
(calcd for C28H39O5 and C28H38O5Na, 455.2797 and 477.2616, respectively). 
4.3.4.  PARASITES, MAMMALIAN CELLS AND ANIMAL MAINTENANCE 
L. infantum strain (MHOM/PT/88/IMT-151) promastigotes were obtained from the 
cryobank of the Instituto de Higiene e Medicina Tropical (Universidade Nova de Lisboa, 
Portugal) and cultivated in M199 medium supplemented with 10% foetal bovine serum 
(FBS), penicillin (10 U/L), streptomycin (0.01 mg/L) and 2% of human male urine at 25 ºC. 
Peritoneal macrophages from BALB/c mice were cultivated in RPMI-1640 medium 
supplemented with 10% FBS, L-glutamine (2 mM), penicillin (50 U/L) and streptomycin 
(0.05 mg/L) at 37 ºC in humidified atmosphere with 5% CO2. BALB/c mice were obtained in 
the Animal Facility of the School of Medicine of São Paulo University – Brazil. These 
animals were maintained in accordance with the institutional guidelines regarding the welfare 
of experimental animals and with the approval of the Animal Ethics Committee of São Paulo 
University (322/12).  
4.3.5.   ACTIVITY AGAINST LEISHMANIA PROMASTIGOTES 
For the determination of the antileishmanial activity, L. infantum promastigotes in 
stationary phase (2×10
6
 parasites/mL) were incubated with the hexane extract at a 
concentration of 250 μg/mL for 24h on 96-well plates. Using the same methodology, the 
fractions obtained during the bioactivity-guided fractionation were tested at a concentration of 
50 μg/mL. At a later stage, compounds 1 and 2 were added at concentrations ranging from 0.9 
to 227.0 and 0.9 to 220.0 μM, respectively. Parasites treated with miltefosine at the half 
maximal inhibitory concentration (IC50 = 23.1 μM) were used as positive control. 
Promastigotes incubated with M199 medium were used as negative control. Parasite viability 
was determined by the MTT colorimetric assay (Dutta et al., 2005; Dal Picolo et al., 2014). 
Briefly, after incubation plates were centrifuged at 10 ºC, using an RCF of 1479 × g for 10 
min, washed three times with PBS, and supernatants discarded. Afterwards, 50 μL of MTT (5 
mg/mL in PBS) were added to each well and plates were re-incubated at 37 ºC for 2 h. Upon 
incubation, 50 μL of SDS were added to each well and plates were incubated for 18 h in order 
to dissolve the formazan crystals. Absorbance was measured at 590 nm using a Thermo 
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Scientifc Multiskan™ FC Microplate Photometer. Results were expressed in terms of parasite 
viability (%) relative to non-treated parasites and the half maximal inhibitory concentration 
(IC50; µM). 
4.3.6.  ULTRASTRUCTURAL ALTERATIONS OF THE PROMASTIGOTES 
 L. infantum promastigotes in stationary phase (2 x 10
6
 cells/mL) were incubated at 25 
ºC for 24 h on 96-well plates with compounds 1 and 2 at their IC50 values, i.e. 44.9 µM of 
94.4 µM, respectively. Non-treated promastigotes were used as negative control. After 
incubation, the plate was centrifuged at 1479 × g for 10 min at 4 ºC, and washed with PBS 
three times. Pellets were fixed in 0.1% tannic acid dissolved in 2.0% glutaraldehyde in a 0.15 
M phosphate buffer pH 7.2 and incubated for 1h at 4°C. These were afterwards contrasted in 
1% osmium tetroxide and a 0.5% uranyl acetate solution for 12 h; then the samples were 
embedded in araldite resin (Yamamoto et al., 2015). Ultrathin sections (70 nm), obtained with 
a ultramicrotome Reichert and double contrasted with 2% uranyl acetate and 0.5% lead 
citrate, were examined using a JEOL 1010 transmission electron microscope.  
4.3.7.  PROMASTIGOTES DNA INTEGRITY 
To detect whether the compounds induced fragmentation on L. infantum nuclear DNA, 
promastigote forms in stationary phase of growth (2 x 10
8
 cells) were incubated with IC50 
concentrations of compounds 1 (44.9 µM), 2 (94.4 µM) and hydrogen peroxide (6.2 M) as 
an inductor of DNA damage in parasites (Das et al., 2001b) for 24 h at 25 ºC. Non-treated 
cells were used as control. After incubation, plates were centrifuged at 1479 × g for 10 min at 
4 ºC, and the supernatants discarded. Parasites pellets were extracted with a Macherey-Nagel 
nucleoSpin® Blood kit according with the manufacturer recommendations and ran on a 2% 
agarose gel, 100 V for 90 min. 
4.3.8.  PROMASTIGOTE TRANSMEMBRANE MITOCHONDRIAL POTENTIAL 
In order to evaluate the influence of compound 1 on the promastigote mitochondrial 
membrane potential (ΔΨm, parasites in the stationary phase (2×106 parasites/mL) were 
incubated with compound 1 and miltefosine at their IC50 values (44.9 and 23.1 µM, 
respectively) for 24h on 96-well plates. Mitochondrial membrane potential was evaluated 
using the widefield automated microscope Mitoscreen Kit (BD Biosciences) according to the 
manufacturer’s recommendations (Levy et al., 2014; Yamamoto et al., 2015). Briefly, cells 
were incubated with working solution, containing the JC-1 (5,5,6,6-tetrachloro-1,1,3,3-
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tetraethylbenzimidazolylcarbocyanine iodide) fluorochrome, for 15 min at 37 °C in an 
atmosphere of 5% CO2. ΔΨm induces the uptake of JC-1 monomers into the functional 
mitochondria. Once inside the organelle, JC-1 monomers aggregate, exhibiting high levels of 
red fluorescence and ΔΨm is assessed through the determination of the presence of JC-1 
fluorochrome inside the mitochondria. ImageXpress
®
 Micro XLS Widefield High-Content 
Analysis System and transfluor MetaXpress software were used to determine the presence of 
J-aggregates in nine sites per well and three wells per treatment. ΔΨm was expressed as a 
percentage of J-aggregates per cell. 
4.3.9.  CYTOTOXICITY AGAINST MURINE MACROPHAGES 
To determine the compounds toxicity in vitro, murine peritoneal macrophages were 
seeded in RPMI-1640 at a density of 10
6
 cells/mL and incubated overnight at 37 ºC in 
humidified atmosphere with 5% CO2, allowing the cells to adhere to the plate background. 
Compounds 1 and 2 were tested for 24h at concentrations ranging from 0.9 to 227.0 and 0.9 to 
220.0 μM, respectively. Miltefosine control cells were incubated with RPMI-1640 medium at 
concentrations from 3.8 up to 490.7 μM. Cell viability was evaluated by the MTT 
colorimetric assay (Ferrari et al., 1990; Dal Picolo et al., 2014), as described above, for the 
determination of the activity against Leishmania promastigotes. Absorbance was measured at 
590 nm using a Thermo Scientific Multiskan™ FC Microplate Photometer. Results were 
expressed in terms of the cytotoxic concentration causing a 50% decrease in cell viability 
(CC50; µM) relative to non-treated cells (100 %). 
4.3.10. ACTIVITY AGAINST LEISHMANIA INTRACELLULAR AMASTIGOTES AND NO 
PRODUCTION 
Peritoneal macrophages of BALB/c mice were collected by intraperitoneal lavage, 
seeded on 24-well plates (10
5
 cells/mL) and incubated at 37ºC with 5% CO2 during 2h for cell 
attachment. Afterwards, L. infantum promastigotes in stationary phase were added to each 
well at an infection ratio of 10 promastigotes per cell, being further incubated at 37 ºC for 
24h. Infected macrophages were treated with compounds 1 and 2 at concentrations ranging 
from 7 to 90 μM to determine the corresponding IC50. Supernatants were collected for nitric 
oxide (NO) determination after 24h and intracellular amastigote burden was microscopically 
assessed upon Giemsa staining for determination of the infection index (% of infected 
macrophages × internalized amastigote forms / macrophage; Passero et al., 2015) and the 
inhibitory concentration allowing 50% reduction of the infection index (IC50) was estimated. 
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Miltefosine was used as positive control. Culture supernatants of treated and control 
macrophages were used for NO determination that was performed using the Measure-iT
TM
 
High-Sensitivity Nitrite Assay Kit in accordance with the manufacturer's recommendations 
(Life Technologies). The NO concentration was determined using a calibration curve 
prepared with several known concentrations (2.75, 5.5, 11, 22, 33, 44 and 55 μM) of nitrite as 
standard. Results were expressed as NO production (μM) and compared with untreated 
infected and non-infected macrophages. The selectivity index (SI) was obtained by 
calculating the ratio of the CC50 of the macrophage by the IC50 of the intracellular 
amastigotes. 
4.3.11. STATISTICAL ANALYSIS 
Bioassays results were expressed as mean ± standard error of the mean (SEM) of 
replicates samples from at least two independent assays. The IC50 values were calculated 
fitting the data as a non-linear regression using a dose-response inhibitory model, in the 
GraphPad Prism V 5.0 program. Student’s t-test was used to determine whether differences 
between means were significant at different levels (p < 0.05 and p < 0.01). 
4.4. RESULTS AND DISCUSSION 
The hexane extract from the C. baccata was incubated with promastigote forms of 
L. infantum for 24h, and cell viability was determined by means of the MTT assay. As this extract 
decreased the viability of the parasite by 74% at a concentration of 250 μg/mL, it was selected for 
further study. Bioactivity-guided fractionation afforded compounds 1 and 2 (Figure 4.1.).  
Compound 1 was obtained as an optically active oil []D = + 17.8 (CHCl3, c 2.7). 
Structural evidence was obtained by analysis of NMR (
1
H, 
13
C and DEPT 135), HREIMS 
spectra and comparison with those data previously reported in the literature to (3R)-(1a) and 
(3S)-(1b) tetraprenyltoluquinol, previously isolated from C. baccata (Valls et al., 1993b). In 
addition, some corrections in the attributions of chemical shifts of C-18 and C-19 in 
13
C NMR 
spectrum were carried out, based on the HMBC spectral analysis (Table 4.1., ANNEX 4-10). 
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Figure 4.1. Structures of the tetraprenyltoluquinols (1a-1b) and tetraprenyltoluquinones (2a-2b) 
isolated from C. baccata 
Compound 2, also obtained as an optically active colourless oil []D = + 0.06 (CHCl3, 
c 0.15), appeared to be homogeneous on the TLC chromatograms, revealing that it is a 
mixture of closely related derivatives. The 
1
H NMR spectrum of compound 2 revealed some 
similarities with compound 1 - two peaks assigned to hydrogens of aromatic ring at H 7.15 
(d, J = 3.0 Hz, H-3’) and 7.00 (d, J = 3.0 Hz, H-5’), one methoxyl group at H 3.78 (s) as well 
as five singlets assigned to methyl groups at H 1.20 (H-20), 1.25/1.26 (H-17), 1.13/1.11 (H-
16), 1.09/1.04 (H-18), and 0.91/0.83 (H-19). 
13
C and DEPT 135 NMR spectra confirmed the 
presence of aromatic ring due the peaks at range C 151.9 – 114.6 (C-1’ – C-6’), and one 
methoxyl group at C 55.7. Additionally, peaks assigned to a carbonyl group at C 192.2/192.1 
(C-1), to carbinolic carbons at C 81.3/81.2 (C-3) and 71.0 (C-15) as well as an -
unsaturated carbonyl carbon at C 153.3/154.3 (C-5), 133.5/134.0 (C-13) and 208.0/208.1 (C-
12) were observed. Finally, HRESIMS showed the [M+H]
+
 and [M + Na]
+
 quasi-molecular 
ion peaks at m/z 455.2776 and 477.2604, respectively, indicating the molecular formula 
C28H38O5. The connectivity between hydrogens and carbon atoms was revealed by analysis of 
the HMBC spectrum as showed in Figure 4.2. (ANNEX 11-18). The correlations between 
signals at H 7.15 (H-3’) and 2.56/2.57 (H-2) with C 192.2/192.1 (C-1) as well as between H  
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Compound 1a 1b 2a 2b 
Position δC, type H (J in Hz) δC, type H (J in Hz) δC, type  (J in Hz) δC, type H (J in Hz) 
1 22.7, CH2 2.79, (m) 22.6, CH2 2.79, (m) 192.2, C - 192.1, C - 
2 32.5, CH2 1.80, (m) 33.6, CH2 1.80, (m) 47.8, CH2 2.56, (m) 48.6, CH2 2.57, (m) 
3 76.4, C - 76.2, C - 81.3, C - 81.2, C - 
4 43.6, CH2 2.66, (s) 45.2, CH2 2.66, (s) 44.1, CH2 2.70, (s) 44.8, CH2 2.70, (s) 
5 153.7, C - 154.5, C - 153.3, C - 154.3, C - 
6 44.3, CH2 2.57, (m) 44.7, CH2 2.57, (m) 44.1, CH2 2.60, (d, 4.0) 44.1, CH2 2.63, (d, 4.0) 
2.60, (m) 2.60, (m) 2.68, (d, 4.0) 2.68, (d, 4.0) 
7 44.8, C - 44.8, C - 44.9, C - 44.9, C - 
8 35.0, CH2 1.54, (m) 35.0, CH2 1.54, (m) 35.0, CH2 1.54, (m) 35.0, CH2 1.54, (m) 
1.73, (m) 1.73, (m) 1.73, (m) 1.73, (m) 
9 18.8, CH2 1.74, (m) 18.8, CH2 1.74, (m) 18.8, CH2 1.74, (m) 18.8, CH2 1.74, (m) 
10 29.3, CH2 1.46, (m) 29.3, CH2 1.46, (m) 29.4, CH2 1.40, (d, 13.0) 29.7, CH2 1.42, (d, 13.0) 
11 54.9, C - 54.9, C - 54.9, C - 54.9, C - 
12 208.5, C - 208.9, C - 208.0, C - 208.1, C - 
13 132.9, C - 133.3, C - 133.5, C - 134.0, C - 
14 39.4, CH2 2.45, (d, 15.0) 39.9, CH2 2.45, (d, 15.0) 39.4, CH2 2.54, (d, 15.0) 39.6, CH2 2.54, (d, 15.0) 
2.73, (d, 15.0) 2.73, (d, 15.0) 2.59, (d, 15.0) 2.59, (d, 15.0) 
15 70.8, C - 71.1, C - 71.0, C - 71.0, C - 
16 28.8, CH3 1.12, (s) 28.8, CH3 1.14, (s) 29.1, CH3 1.11, (s) 29.1, CH3 1.13, (s) 
17 30.5, CH3 1.24, (s) 31.6, CH3 1.19, (s) 30.8, CH3 1.25, (s) 31.3, CH3 1.26, (s) 
18 21.1, CH3 1.09, (s) 21.1, CH3 1.03, (s) 21.1, CH3 1.04, (s) 21.1, CH3 1.09, (s) 
19 22.4, CH3 0.91, (s) 22.5, CH3 0.83, (s) 22.4, CH3 0.83, (s) 22.5, CH3 0.91, (s) 
20 24.1, CH3 1.28, (s) 24.5, CH3 1.28, (s) 23.9, CH3 1.20, (s) 24.2, CH3 1.20, (s) 
1' 145.2, C - 145.3, C - 167.8, C - 167.8, C - 
2' 120.4, C - 120.4, C - 119.6, C - 119.6, C - 
3' 111.1, CH 6.45, (d, 3.0) 111.2, CH 6.46, (d, 3.0) 114.6, CH 7.15, (d, 3.0) 114.6, CH 7.16, (d, 3.0) 
4' 152.6, C - 152.6, C - 151.9, C - 151.9, C - 
5' 115.2, CH 6.59, (d, 3.0) 115.3, CH 6.60, (d, 3.0) 104.5, CH 7.00, (d, 3.0) 104.5, C 7.01, (d, 3.0) 
6' 127.0, C - 127.2, C - 126.5, C - 126.5, C - 
Me-6' 16.6, CH3 2.16, (s) 16.8, CH 2.17, (s) 16.2, CH3 2.21, (s) 16.4, CH3 2.23, (s) 
OMe-4' 55.6, CH3 3.73, (s) 55.6, CH 3.74, (s) 55.7, CH3 3.78, (s) 55.7, CH3 3.78, (s) 
 
 
 
 
 
 
Figure 4.2. HMBC of the tetraprenyltoluquinones (2a-2b) isolated from C. baccata 
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2.70 (H-4) withC 81.3/81.2 (C-3) and 133.5/134.0 (C-13) indicated that compound 2 
1
H and 
13
C NMR data (500 and 125 MHz, CDCl3, /ppm) for compounds 1 (a/b) and 2 (a/b) 
contained one additional carbonyl group at C-1. Based on these results, it was possible to 
identify 2 as epimers of (3R)-(2a) and (3S)-(2b) tetraprenyltoluquinones. 
In vitro antiparasitic activity and cytotoxic studies of the compounds 1 and 2 were 
evaluated by the colorimetric MTT method against promastigote forms of L. infantum and 
murine macrophages, respectively (Table 4.2.). Compound 1 displayed an IC50 value of 44.9 
± 4.3 µM against promastigote forms of L. infantum. The cytotoxicity against mouse 
peritoneal macrophages (CC50 = 126.6 ± 21.1 µM) was similar to that of the reference drug, 
miltefosine (130.3 ± 17.2 µM). Compound 2 showed lower activity against the promastigote 
forms (IC50 = 94.4 ± 10.1 µM), and higher toxicity to the mouse peritoneal macrophages 
(CC50 = 84.5 ± 12.5 µM).   
To assess the alterations induced by the compounds on the promastigotes forms of 
L. infantum, transmission electron microscopy images were acquired (Figure 4. 3.). Important 
changes were observed with both treatments, including loss of the typical fusiform shape 
(Figure 4.3.A). Ultrastructural analysis revealed morphologic changes in parasites treated 
with the IC50 concentrations of both compounds 1 (Figures 4.3.B and 4.3.C) and 2 (Figures 
4.3.D and 4.3.E). Moreover, cellular vacuolization was observed, which might be a 
consequence of cytoplasmic organelle disruption (Figures 4.3.B and 4.3.D). When treated 
with compound 1, parasites presented coiled multilamellar structures within the mitochondria 
(Figure 4.3.C). These structures have been shown to be a consequence of starvation processes 
caused by deficient mitochondrial activity or autophagic mechanisms caused by the action of 
chemical compounds on these organelles (Lockshin and Zakeri, 2004). If left unchecked, both 
processes may result in the removal of the damaged organelles as well as cell death 
(Nishikawa et al., 2010). Previous studies have described similar structures in promastigotes 
of different Leishmania species treated with distinct natural products (Monte Neto et al., 
2011). Compound 2 induced noticeable changes in the ultrastructure of the cell, in particular 
the occurrence of pyknotic nuclei, which was accompanied by the disappearance of the 
chromatin associated with the nuclear inner membrane (Figure 4.3.D).  
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Figure 4.3. Effect of compounds 1 and 2 on the ultrastructure of L. infantum promastigotes. Parasites 
were treated with 1a/1b (44.9 µM) and treated with compound 2a/2b (94.4 µM). N – nucleus, FP - 
flagellar pocket, K – kinetoplast, M – mitochondrion, V – vacuole, * - disappearance of the chromatin 
associated with the nuclear inner membrane 
Overall, these compounds seem to induce parasite death through different mechanisms. 
Other reports have shown that Leishmania apoptosis occurs in response to different drugs 
(Holzmuller et al., 2002). In order to evaluate if the alterations observed in the nuclei were 
associated with DNA fragmentation and consequently with programmed cell death, 
promastigote DNA was analysed through horizontal electrophoresis. This analysis did not 
reveal any fragmentation of the genomic DNA when promastigote forms of L. infantum were 
treated with the IC50 concentrations of compounds 1 and 2 (Figure  4.5.A), suggesting that 
the observed cytotoxic effect might not be associated with programmed cell death. Although 
chromatin condensation culminating in nucleolytic pyknosis is usually accompanied by 
macronuclear DNA digestion, generating oligonucleosomal fragments of low molecular 
weight (Kobayashi and Endoh, 2003), non-nucleolytic pyknotic processes have also been 
described previously (Burgoyne, 1999).   
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Figure 4.4. Effects of compounds 1 (Comp1) and 2 (Comp2) on the nuclear DNA fragmentation (A) 
and mitochondrial membrane potential (B) of L. infantum promastigotes. Parasites were treated with 
1a/1b (44.9 µM) and 2a/2b (94.4 µM). Hydrogen peroxide (6.2 M) (A) and miltefosine (23.1 µM) 
(B) and untreated parasites (A and B) were used as controls. *, p < 0.05; **, p < 0.01. 
As Leishmania cells have a single mitochondrion, the proper functioning of 
mitochondria, including the stability of their membrane potential, is vital for the survival of 
the parasite. This organelle is usually considered as a good indicator of cellular dysfunction 
and therefore is an interesting target for chemotherapeutic studies (Souza et al., 2009). 
Because the variation of the mitochondrial membrane potential (ΔΨm) in different 
Leishmania species exposed to various drugs has been reported (Britta et al., 2014) and that 
changes were observed in the morphology of the mitochondria of promastigotes treated with 
compound 1, the ΔΨm in cells incubated with the latter chemical was evaluated. This was 
carried out in order to elucidate possible mechanisms of cell death induced by the compound 
displaying the most potent activity against L. infantum promastigotes. This parameter was 
determined by assessing the presence of JC-1 fluorochrome inside the mitochondria using a 
widefield automated microscope. ΔΨm induces the uptake of JC-1 monomers into the 
functional mitochondria. Once inside the organelle, JC-1 monomers aggregate, exhibiting 
high levels of red fluorescence. At the IC50, compound 1 induced a significant (p ≤ 0.01) 
decrease in fluorescence-emitting cells (133.3 ± 8.5 J-aggregates/well) as compared to non-treated 
(762.5 ± 36.7 J-aggregates/well) promastigotes (Figure 4.5.B), corresponding to a disruption of 
83% of the ΔΨm. This effect was higher than that observed with miltefosine (216.0 ± 22.6 J-
aggregates/well), which disrupted the ΔΨm by only 72%. Interestingly, similar drops in ΔΨm 
coupled with changes in the mitochondrial ultrastructure have also been detected when using an 
iron chelator against L. (V.) braziliensis (Mesquita-Rodrigues et al., 2013). 
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When tested against L. infantum-infected macrophages the tetraprenyltoluquinol (1) 
applied at concentrations of 34 and 66 µM decreased the infection index by 64.5% and 66.3%, 
respectively, showing an IC50 of 25.0 ± 4.1 µM and a selectivity index of 5.04 against the 
peritoneal macrophages (Figure 4.5A; Table 4.2). 
Only five compounds isolated from marine algae with antileishmanial activity have 
been reported previously (Machado et al., 2011; dos Santos et al., 2010, 2011; Soares et al., 
2012). However, none of the studies was about Cystoseira macroalgae. Reported 
sesquiterpenes obtusol (IC50 = 9.4 μM; Machado et al., 2011) and elatol (IC50 = 13.5 μM and 
0.45 μM) from the red alga Laurencia dendroidea  (Machado et al., 2011; dos Santos et al., 
2010) showed strong activity against L. amazonensis intracellular amastigotes. However, the 
triquinane sesquiterpene isolated from the same algae was significantly less effective (IC50 = 
217.4 μM; Machado et al., 2011). In addition, 4-acetoxydolastane and dolabelladienetriol, 
isolated from the brown alga Canistrocarpus cervicornis (IC50 = 12.3 μM; dos Santos et al., 
2011) and Dictyota pfaffii (IC50 = 44.0 μM; Soares et al., 2012), respectively, were also tested 
against the same species and form of Leishmania. Therefore, the activity of compound 1 was 
in the range of that reported for the aforementioned diterpenes.  
Despite the lower activity of compound 2 against promastigotes (IC50 = 94.4 ± 10.1), it was 
higher than the effect reported for triquinane (IC50 = 195.5 μM) on promastigotes. However, 
similarly to what has been reported for triquinane (Machado et al., 2011), the treatment with the 
tetraprenyltoluquinone (2) did not decrease the infection index (Figure. 4.5A). 
During the infection by Leishmania, NO is released by macrophages to eliminate 
intracellular amastigotes (reviewed by de Almeida et al., 2003). In addition, NO production 
can be triggered by natural compounds, including those from algae (Robertson et al., 2015). 
In the present study, infected peritoneal macrophages treated with compounds 1 and 2 
produced low or undetectable amounts of NO as compared to controls. The NO released when 
the lowest concentrations (8.4 and 17 µM) were applied to the cells was residual, suggesting 
Table 4.2. Effect of the compounds 1 and 2 against L. infantum promastigotes and intracellular 
amastigotes and mouse peritoneal macrophages  
Compounds Promastigotes
a
 
Intracellular 
amastigotes
a
 
Peritoneal 
macrophages
b
 
SI
c
 
1 44.9 ± 4.3 25.0 ± 4.1 126.6 ± 21.1 5.04 
2   94.4 ± 10.1 > 88.0   84.5 ± 12.5 <0.96 
Miltefosine 23.1  ± 0.0 20.3 ± 1.3 130.3 ± 17.2 6.42 
a
IC50 - Half maximal inhibitory concentration in µM; 
b
CC50 - Cytotoxic concentration that causes the death of 
50% of the viable cells in µM; 
c
SI – Selectivity index concerning the activity against the intracellular amastigotes. 
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Figure 4.5. Effect of compounds 1 and 2 on the L. infantum intracellular amastigotes (A) and on the 
nitric oxide production (mM) of the infected mouse peritoneal macrophages (B) after a 24-h treatment 
with different concentrations (µM). Untreated non-infected macrophages (CTL+), untreated infected 
macrophages (CTL inf) and infected macrophages treated with a reference drug, miltefosine, were 
used as controls. 
that the leishmanicidal effect observed for 1 was not related to NO production by the host 
macrophages (Figure 4.5.B) and that these compounds did not display an immunomodulatory 
effect.  These results are in agreement with Machado et al. (2011) who observed that 
triquinane, elatol and obtusol did not promote enhanced NO levels, indicating that 
leishmanicidal effect of these compounds might be mediated by a mechanism that does not 
involve the release of this signalling molecule by the host cell.  
In conclusion, this is the first report describing the identification of compounds from 
Cystoseira macroalgae displaying activity against Leishmania parasites. In addition, the 
isolation of tetraprenyltoluquinone (2) as a novel metabolite from algae of the Cystoseira 
genus is described. Concerning the particular chemical structure of these compounds, our data 
suggest that the presence of the carbonyl group in C-1 could play a role in the antileishmanial 
activity of the compounds 1 and 2. Although not as active as miltefosine, 
tetraprenyltoluquinol (1) displayed significant antileishmanial activity and could be 
considered as an interesting scaffold for the development of novel chemotherapeutic 
molecules for canine and human visceral leishmaniases studies. Furthermore, this work 
reinforces the evidence of the marine environment as source of novel molecules. 
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5.1. ABSTRACT 
Cystoseira C. Agardh is a common brown alga widely distributed throughout the 
Atlantic and Mediterranean whose taxonomical assignment of specimens is often hampered 
by intra- and interspecific morphological variability. In this study, three mitochondrial 
regions, namely cytochrome oxidase subunit 1 (COI), 23S rDNA (23S), and 23S-tRNA
Val
 
intergenic spacer (mt-spacer) were used to analyse the phylogenetic relationships of 22 
Cystoseira species (n = 93 samples). A total of 135 sequences (48 from COI, 43 from 23S and 
44 from mt-spacer) were newly generated and analysed together with Cystoseira sequences (9 
COI, 31 23S and 35 spacer) from other authors. Phylogenetic analysis of the three markers 
identified three well-resolved clades and corroborated the polyphyletic nature of the genus 
found in previous studies. Resolution of taxa within the three clades containing sequences of 
specimens classified as Cystoseira increased significantly when the inclusion of sequencing 
data from individuals of related genera was minimized. COI and mt-spacer markers resolved 
the phylogeny of some of the Cystoseira species, such as the C. baccata, C. foeniculacea and 
C. usneoides. Furthermore, trends between phylogeny, embryonic development and available 
chemotaxonomic classifications were identified, showing that phylogenetic, chemical and 
morphological data should be taken into account to study the evolutionary relationships 
among the algae currently classified as Cystoseira. 
 
Keywords: Brown algae; Cystoseira; mitochondrial markers; phylogeny. 
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5.2. INTRODUCTION 
Cystoseira (Fucales, Heteronkonphyta) brown algae are key elements of the marine 
seascape along warm-temperate North African and European coasts (Ballesteros et al., 2007; 
Thibaut et al., 2014; Bermejo et al., 2013, 2015). They form marine forests with a complex 
three-dimensional structure and provide a habitat for other algae, invertebrates and fish 
(Bellan and Bellan-Santini, 1972; Bulleri et al., 2002; Cheminée et al., 2013; Bermejo et al., 
2016), playing a key role in the determination of biodiversity patterns and ecosystem 
functioning (Benedetti-Cecchi et al., 2001; Bulleri et al., 2002). Currently, many Cystoseira 
species are undergoing a strong demographic decline attributed to both local and global 
pressures (Thibaut et al., 2005; Mineur et al., 2015; Thibaut et al., 2015). Moreover, it has 
been suggested that this loss of biodiversity might be caused by the sensitivity of these 
species to increased water turbidity, eutrophication and pollution (Airoldi and Beck, 2007; 
Mangialajo et al., 2008; Sales et al., 2011), as consequence of the increasing anthropogenic 
activity near the Atlantic and Mediterranean coastal areas (Mineur et al., 2015; Thibaut et al., 
2015). Because of the ecological importance of species assemblages dominated by Cystoseira 
and the deterioration of their populations during the past decades, the Mediterranean species 
of this genus are protected under the Barcelona Convention (Annex II, COM/2009/0585 FIN) 
and reforestation has been proposed as a management action to improve the conservation 
status of these species (Susini et al., 2007; Sales et al., 2011; Gianni et al, 2013).  
 The importance of the genus Cystoseira is further underscored by the observation that 
its members produce several potentially bioactive metabolites such as terpenoids, fatty acids, 
triacylglycerols, steroids, phlorotannins, and polysaccharides (Amico, 1995). Indeed, 
antioxidant, anti-inflammatory, antiproliferative, antifungal, antiviral, antibacterial and 
antiprotozoal activities have been reported to occur in Cystoseira algae with increasing 
frequency (Calvo et al., 1986; Spavieri et al., 2010a; Mhadhebi et al., 2011; Pujol et al., 2012; 
de los Reyes et al., 2016; Vizetto-Duarte et al., 2016a; Bruno de Sousa et al., 2017). This wide 
range of bioactivities detected in extracts of these algae might be explained by the bio- and 
chemical diversity of the genus (Amico, 1985b; Valls et al., 1993b). 
The accuracy of the taxonomic identification of the biomass used for the isolation and 
identification of natural compounds is, however, an important issue concerning the 
reproducibility and reliability of the results as well as for the implementation of conservation 
measures for the target species (Leal et al., 2016). Taxonomic classification within the genus 
Cystoseira is challenging and controversial (Gómez-Garreta et al., 1994; Ballesteros and 
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Pinedo, 2004). Erroneous taxonomical assignments are frequent due to the wide 
morphological variability of Cystoseira individuals, in addition to there being many species 
that are still undergoing active speciation and hybridization (Roberts, 1978; Cormaci et al., 
1992; Draisma et al., 2010). This has become especially apparent due to frequent conflits 
between classification of specimens based on morphology and molecular data. 
Chemotaxonomic classifications based on the presence or absence of specific chemicals (e.g. 
meroterpenoids) have also been attempted (Piatelli, 1990 cited by Amico, 1995; Valls et al., 
1993b; Amico, 1995; Valls and Piovetti, 1995; Jégou et al., 2010). In addition, analysis of the 
global chemical profile and the lipophilic composition of five Cystoseira species from 
Brittany have been found to be in agreement with the phylogenetic relationships established 
by the ITS2 region (Jégou et al., 2010). However, congruence between morphology, 
chemistry and molecular taxonomy at the species level is yet to be achieved (Draisma et al., 
2010), and the results obtained so far have not fully resolved the phylogeny of Cystoseira 
(Jégou et al., 2010). 
Several authors have previoulsly attempted the elucidation of the relationships within 
this genus and with related genera using phylogenetic methods (Barceló-Martí et al., 2001; 
Draisma et al., 2010; Rožić et al. 2012). Analysis of Fucales (Phaeophyceae) Kylin based on 
large subunit (LSU) and small subunit (SSU) of the ribosomal DNA sequences led to the 
merging of the Cystoseiraceae and Sargassaceae families (Rousseau and de Reviers, 1999). 
The mitochondrial 23S ribosomal subunit (23S) proved to be useful for defining genera in the 
Fucales (Draisma et al., 2010) and in addition a set of 10 additional mitochondrial, plastid and 
nuclear markers has also been used to investigate the evolutionary history of brown algae at 
the ordinal level (Silberfeld et al., 2010). Other analysis including also organellar markers 
revealed that the genus Cystoseira was composed of at least six distinct evolutionary lineages, 
and clearly polyphyletic, although only 3 lineages (see below) were eventually classified as 
separated genera (Draisma et al., 2010). Based on morphologic, embryonic development 
characters and genetic data, several members of the genus were reclassified as belonging to 
the genera Sirophysalis (Tropical Indo-West-Pacific), Polycladia (eastern Indian Ocean) and 
Stephanocystis (N Pacific; Draisma et al., 2010). All other Cystoseira species, despite forming 
at least three separate NE Atlantic-endemic clades, retained the original classification. 
Currently, the genus Cystoseira encompasses approximately 40 species, the majority of which 
occurs in the Mediterranean and Atlantic-Mediterranean regions (García-Fernández and 
Bárbara, 2016; Guiry and Guiry, 2016). However, to date, full infrageneric resolution of the 
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genus and their position among related Sargassaceae genera has not been established. 
Therefore the taxonomy of the Cystoseira species is still unclear.  
The mitochondrial gene coding for cytochrome oxidase subunit 1 (COI) is a well-
known molecular tool used for the identification of different metazoan species (Arif and 
Khan, 2009; Hebert et al., 2003b; Sanaa, 2014). Although the COI gene was used in the study 
of red (Sherwood et al. 2010b) and brown algae (Mattio and Payri, 2010; McDevit and 
Saunders, 2009; Saunders and McDevit, 2013), the utility of this marker for the infrageneric 
identification of Cystoseira individuals has not been evaluated so far. With the purpose of 
improving the resolution of the Cystoseira species identification and clarify their phylogenetic 
relationships, a comprehensive study combining sequence information on the using 
cytochrome oxidase subunit 1 (COI), 23S rDNA (23S), and 23S-tRNA
Val
 intergenic spacer 
(mt-spacer) was undertaken. The results of this study confirm the polyphyly of the genus. 
Although the resolution of several Cystoseira species were improved with the addition of the 
protein-coding COI gene as suggested by previous authors (Draisma et al., 2010), other 
closely related taxa (e.g. C. tamariscifolia and C. amentacea) remained unresolved. 
5.3. MATERIAL AND METHODS   
5.3.1. SAMPLING 
Overall, this study includes 93 samples of Cystoseira and 210 sequences belonging to 
31 species of the Sargassaceae family (Cystoseira: 22 species; Bifurcaria: 1 species; 
Polycladia: 2 species; Sirophysalis: 1 species; Stephanocystis: 4 species and Turbinaria: 1 
species; ANNEX 19).  
Fifty-nine samples from 16 Cystoseira (55 individuals) species and Bifurcaria bifurcata 
(4 individuals) were collected along the Atlantic and Mediterranean coasts (Figure 5.1.), and 
mtDNA markers were specifically amplified. The samples, collected by the authors or kindly 
provided by expert coleagues, were morphologically classified using the taxonomic 
characteristics following Gómez-Garreta et al. (2001) and Guiry and Guiry (2016). After 
washed with tap water, a small portion of the biomass was separated, silica-dried and stored at 
room temperature for subsequent DNA extraction.  
Additional sequences of Cystoseira (9 COI, 31 23S and 35 mt-spacer) and other 
Sargassaceae (3 COI, 8 23S and 8 mt-spacer) species deposited in the public GenBank database at 
the National Center for Biotechnology Information (NCBI) were included in the analyses (Benson  
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Figure 5.1. Geographical distribution of the Cystoseira samples used in this study. Symbols do not 
reflect the number of samples used for each location. Green dots represent GenBank sequences and the 
red dots data obtained from this study. The boxes show the archipelagos of (a) Madeira, (b) Azores, 
(c) Canary, (d) Cape Verde and (e) Balearics. 
et al., 2013; Figure 5.1.). Similarly, sequences from 4 species of the Fucaceae family (4 COI, 
4 23S and 4 IGS) were also obtained from GenBank and used as outgroups. 
5.3.2. DNA EXTRACTION, AMPLIFICATION AND SEQUENCING 
Genomic DNA was extracted from the silica gel-dried algal tissue using the method 
described by Doyle and Doyle (1987). The primers for amplification of the COI and 23S 
fragments were described by Lane et al. (2007) and Draisma et al. (2010), respectively. 
Moreover, primer pairs for amplification of the mt-spacer fragment were designed specifically 
for this study. Primer information, such as locus names, nucleotide sequences, and references 
are provided in Table 5.1.  
Mt23S and mt-spacer were PCR-amplified in a final volume of 20.5 μL reactions 
containing 5 μL of genomic DNA (~10 ng/mL), 4 μL 5×PCR Buffer, 4 μL dNTP mix (1 mM 
of each dNTP), 2 μL 25 mM MgCl2, 0.6 μL Taq DNA polymerase (GoTaq® DNA 
Polymerase, Promega), 0.5 μL of 10 μM 23S forward (mt23S-FB) and reverse (mt23S-RB) 
primers or 0.25 μL of 10µM mt-spacer forward (mt-spacer-F) and reverse (mt-spacer-R) 
primers. COI amplifications were perfomed in a 12-µL mix containing 2 μL of genomic 
DNA, 1.25 μL 5×PCR Buffer, 0.6 μL dNTP mix (1 mM of each dNTP), 1.25 μL 25 mM  
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Table 5.1. Molecular markers used in this study - locus name and target region, forward and reverse 
primer sequences, and references. 
Target region Primer Sequence References 
23S 
mt23S-FB 5'-AGCGTAACAGCTCACTGACCTA-3'  Draisma et al. 
(2010) mt23S-RB 5'-CTGTGGCGGTTTAAGGTACGGTT-3'  
mt23S(partial)-IGS-
tRNA
Lys
-IGS-tRNA
Val
 
tRNALys-FW 5'-GGGGTGAAAAATATCACTTTGA-3' 
This study tRNALys-RV 5'-AACCCAAGACCCTCGGATTA-3' 
COI 
GazF2 5'-CCAACCAYAAAGATATWGGTAC-3' 
Lane et al. (2007) 
GazR2 5'-GGATGACCAAARAACCAAAA-3' 
 
MgCl2, 0.1 μL Taq DNA polymerase, 0.25 μL of 10 μM COI forward (GazF2) and 
reverse (GazR2) primers. Amplifications were performed using an Applied Biosystems 2720 
Thermal Cycler with the following conditions: 95 ºC for 6 min; 10 cycles of 95 ºC for 30 s, 64 
ºC (decreasing  0.5 °C per cycle) for 30 s, 72 ºC for 60 s; 35 cycles of 95 ºC for 30 s, 59 ºC for 
30 s, 72 ºC for 60 s; and a final elongation step of 10 min at 72 ºC for the 23S and mt-spacer 
fragments; for COI, samples were incubated at 95 ºC for 2 minutes; 5 cycles of 95 ºC for 30 s, 
45 ºC for 30 s and 72 ºC for 1 min; 35 cycles of 95 ºC for 30 s, 46.5 ºC for 30s and 72 ºC for 1 
min; and a 72 ºC elongation step for 7 min. PCR amplicons were screened for specific 
fragment size on 2 % agarose gel electrophoresis and subsequently purified using a E.Z.N.A.
® 
MicroElute Cycle-Pure Kit (Omega Bio-Tek, USA) purification kit. Amplified fragments 
were sequenced using the Sanger method at the Molecular Biology Core Laboratory, Centre 
of Marine Sciences (Algarve University, Faro), in an 3130XL Genetic Analyzer (Applied 
Biosystems) using PCR primers in cycle sequencing reactions. 
5.3.3. SEQUENCE VALIDATION AND GENETIC DIVERSITY 
New sequences were compared with GenBank data using the basic local alignment 
search tool BLASTn (Altschul et al., 1990) to confirm the proximate identity of their 
biological source (i.e. that they were from Sargassaceae). GenBank accession numbers of the 
sequences are indicated in ANNEX 19.  
Sequences were also organized in two datasets: one including only sequences from 
individuals of the Cystoseira genus, and the second comprising the same data plus those from 
the Sargassaceae and Fucales. 
The 23S and mt-spacer sequences were aligned with the CLC Sequence Viewer V.7.6.1 
(Quiagen), using the default settings. For COI, sequences were aligned with transAlign 
software (Bininda-Emonds, 2005) using ClustalW multiple sequence alignment (Higgins et 
al., 1996). Alignments were further inspected with CLC Sequence Viewer V.7.6.1 and 
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manually improved before a final curation step with Gblocks v.0.91b software (Talavera and 
Castresana, 2007) available at the Phylogeny.fr web service (Dereeper et al., 2008). Gap 
positions within the final blocks option were allowed and a maximum of 8 contiguous non-
conserved positions were considered with a minimum block length of 5 nucleotides (nt). The 
concatenated matrix was obtained using Seaview v.4.5.3 (Gouy et al., 2010). 
The number of polymorphic and phylogenetically informative sites of the aligned 
sequences was estimated for each marker using DnaSP v.5.10.1 software (Librado and Rozas, 
2009). Haplotype identification was carried out for each mitochondrial marker using the same 
software and the respective Median-Joining (MJ) network of haplotypes was constructed 
using NETWORK version 4.5.10 software (Bandelt et al., 1999). Genetic distance analyses 
between Cystoseira sequences for each species were perfomed using MEGA5 software 
(Tamura et al., 2011). The pairwise distances for intra- and interspecific frequencies were 
estimated using the Kimura 2-parameter model (Kimura, 1980). The rate variation among 
sites was modeled with a gamma distribution (shape parameter = 6). All ambiguous positions 
were removed for each sequence pair. 
5.3.4. PHYLOGENETIC RELATIONSHIPS 
Phylogenetic analysis was carried out using Maximum likelihood (ML) and Bayesian 
inference (BI). The substitution models that best fit the data were selected using MrModeltest2 
v.2.3 (Nylander, 2004) and PAUP* v.4.0b10 (Swofford, 2003) by applying the Akaike 
information criterion (AIC; Akaike 1974). The substitution models selected were: GTR+I+Γ4 
[general time-reversible (GTR) model with a proportion of invariant sites (I) and among-site rate 
variation modelled by a discrete gamma distribution with 4 categories (Γ4)] for 23S, HKY+I+G 
[Hasegawa-Kishino-Yano model (HKY)] for COI and GTR+Γ4 for the mt-spacer. 
ML analysis was performed using RaxML v.7.0.4 (Stamakis, 2006) with 400 bootstrap 
replicates, assuming the best-fitting models. Posterior probabilities were determined by 
Markov Chain Monte Carlo (MCMC) sampling in MrBayes v.3.1.2 (Huelsenbeck and 
Ronquist, 2001; Ronquist and Huelsenbeck, 2003). MrBayes analyses were also conducted 
using the best-fitting models, using 6 chains for 10,000,000 generations, sampling every 
1,000
th
 generation, and default settings for the remaining options. Convergence of the MCMC 
and burn-in were determined through the analysis of the generations vs. log probability plot 
using the trace analysis tool TRACER v1.6 (Rambaut A., Suchard M.A., Xie D. and 
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Drummond A.J., 2014; http://beast.bio.ed.ac.uk/Tracer). The initial burn-in step discarded 
20% of the samples. 
After inferring the phylogeny for each marker (COI, 23S, mt-spacer) topological 
congruence between gene trees was visually assessed. Subsequently, the sequences obtained 
for the 3 markers were concatenated and analyzed by ML and BI as described before. ML and 
BI best consensus trees for each marker dataset (COI, 23S, mt-spacer, and concatenated COI-
23S-mt-spacer) were generated and edited with the graphical viewer FigTree v.1.3.1 
(Rambaut and Drummond, 2009).  
5.4. RESULTS 
5.4.1. ALIGNMENT CHARACTERIZATION  
Overall, sequences from 92 Cystoseira samples belonging to 22 species from the 
Atlantic (Macaronesian and Iberian Peninsula south and west coasts) and the Mediterranean 
(Adriatic, Alboran, Balearic and Tyrrhenian seas) regions were included in this study (Figure 
5.1.). Among these, the 55 Cystoseira samples collected for this study generated 135 new 
sequences representing a sequencing success of 87.3 % (48 sequences), 78.2 % (43 sequences) 
and 80.0 % (44 sequences) for COI, 23S and mt-spacer loci, respectively.  
The conjoint analysis of Cystoseira sequences obtained during this study and from 
GenBank (56 COI, 74 23S and 79 mt-spacer sequences) resulted in alignments with 656, 391, 
258 nt for COI, 23S and mt-spacer, respectively. Upon phylogenetic analysis, three lineages 
(Cystoseira-I, -II, -III) with support values close to the maximum (BS = 100; PP = 1) were 
identified (Figures 5.2.-5.4. and ANNEXES 20-27). Detailed information of the alignment 
results obtained for each marker and phylogenetic group is shown in Table 5.2.. Longer 
alignment lengths and higher number of conserved positions were observed for COI (656 nt; 
86.1 %) and 23S (391 nt; 81.7 %) loci, and the lowest for mt-spacer (258 nt; 52.7 %).  
Concatenation of the 3 loci (COI-23S-mt-spacer) consisted of a 1305-nt alignment with 
78% of conserved positions. Depending upon the marker considered, 15.6-24.0% of 
polymorphic sites (PS) and 14.3-22.5% of parsimony informative (PI) sites were identified 
(Table 5.2.). Group Cystoseira-II showed the highest number of variable PS (7.9-13.2%) and 
PI (5.6-11.2%) for all loci, except for the 23S marker, where 6.4 % of PS were found (Table 
5.3.). Group Cystoseira-III showed the lowest PS (2.6-7.0 %) and PI (2.3-6.2 %) values for 
23S and mt-spacer loci, respectively. 
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Figure 5.2. Cystoseira groups defined by the phylogenetic analysis. Green dots represent the species 
belonging to the Group I (Cystoseira tamariscifolia, C. amentacea and C. amentacea var. stricta, 
C. funkii, C. mediterranea, C. brachycarpa var. brachycarpa, C. crinita, C. barbatula, C. zosteroides, 
Cystoseira RB105 and Cystoseira sp. 1); yellow  dots represent the species belonging to the Group II 
(C. mauritanica, C. barbata f. repens, C. spinosa and C. spinosa var. tenuior, C. barbata, 
C. nodicaulis, C. granulata, C. elegans, C. squarrosa, C. usneoides, C. baccata, C. abies-marina, 
C. sonderi, Cystoseira sp. 2 and Cystoseira sp. MP14); red dots represent the species belonging to the 
Group III (C. compressa and C. compressa var. pustulata, C. humilis, C. humilis var. myriophyoides 
and C. foeniculacea, Cystoseira sp. MP1, Cystoseira sp. MP2 and Cystoseira sp. MP31). 
Interspecific evolutionary divergence of  Cystoseira, when considered only the species 
that have information for all the 3 markers, ranged from 0 to 4.4 % in COI, 0-10.7 % in 23S 
and 0-10.9 % in the mt-spacer (Table 5.4. and ANNEXES 28-30). Highest amount of 
interspecific variation was observed in the Cystoseira-III (0-10.9 %), whereas Cystoseira-I 
species showed the lowest range of distances (0-1.1 %). Concerning intraspecific variation, 
lower values were observed, with a maximum of 3.9 % for the mt-spacer loci, followed by 
23S (2.2 %) and COI (0.0 %). When considering all the samples included in the phylogenetic 
analysis, the inter- and intraspecific divergences were slightly higher (0.0-13.8%; 0.0-7.6%), a 
result of the higher heterogeneity of the species included. COI marker showed maximum 
interspecific genetic variability (0-4.4 %) and low intraspecific genetic variability (0.0-0.6 %). 
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Figure 5.3. Maximum likelihood phylogenetic tree obtained with RAXML and based on the 
concatenated COI-23S-IGS sequences of samples from the Sargassaceae family. Values on the 
branches represent maximum likelihood bootstrap support values (≥ 75) on the left, and Bayesian 
posterior probabilities (≥ 90%) on the right. 
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Figure 5.4. Maximum likelihood phylogenetic tree obtained with RAXML and based on the 
concatenated COI-23S-mt-spacer sequences of samples from the Cystoseira genus. Values on the 
branches represent maximum likelihood bootstrap support values (≥ 75) on the left, and Bayesian 
posterior probabilities (≥ 90%) on the right. 
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Table 5.2. Number of Cystoseira species and samples included in this study. Alignment 
characteristics (with gaps) are also shown for each marker and phylogenetic group. 
 Parameters All species Group I
1
 Group II
2
 Group III
3
 
COI     
 Species  13 3  7  3 
 Number of samples (sequences)  58  18  25  15 
 Alignment length (nt)  656  656  656  656 
 Conserved sites
a
 565 (86.1%) 648 (98.7%) 604 (92.0%) 535 (81.6%) 
 Polymorphic sites 114 (17.4%) 8 (1.2%) 52 (7.9%) 30 (4.6%) 
    Singleton variable sites 4 (0.6%) 1 (0.2%) 4 (0.6%) 2 (0.3%) 
    Parsimony informative sites 110 (16.7%) 7 (1.1%) 48 (7.3%) 28 (4.3%) 
23S     
 Species  20  8  9  3 
 Number of samples (sequences)  73  31  29  13 
 Alignment length (nt)  391  391  391  391 
 Conserved sites
a
 317 (81.7%) 335 (85.7%) 331 (84.7%) 352 (90.0%) 
 Polymorphic sites  61 (15.6%) 25 (6.4%) 22 (5.6%) 10 (2.6%) 
 Singleton variable sites 5 (1.3%) 10 (2.6 %) 0 (0%) 1 (0.3%) 
 Parsimony informative sites  56 (14.3%) 15 (3.8%) 22 (5.6%) 9 (2.3%) 
IGS     
 Species  21  7  11  3 
 Number of samples (sequences)  79  35  33  11 
 Alignment length (nt)  258  258  258  258 
 Conserved sites
a
 136 (52.7%) 183 (70.9%) 141 (54.6%) 168 (65.1%) 
 Polymorphic sites 62 (24.0 %) 25 (9.7%) 34 (13.2%) 18 (7.0%) 
     Singleton variable sites 4 (1.6%) 7 (2.7%) 5 (1.9%) 2 (0.8%) 
     Parsimony informative sites 58 (22.5%) 18 (7.0%) 29 (11.2%) 16 (6.2%) 
1Group I - available individuals belonging to Cystoseira tamariscifolia, C. amentacea and C. amentacea var. stricta, 
C. funkii, C. mediterranea, C. brachycarpa var. brachycarpa, C. crinita, C. barbatula, C. zosteroides, and Cystoseira sp. 
1; 2Group II - available species belonging to C. mauritanica, C. barbata  var. repens, C. spinosa and C. spinosa var. 
tenuior, C. barbata, C. nodicaulis, C.granulata, C. elegans, C. squarrosa, C. usneoides, C. baccata, C. abies marina, 
C. sonderi, Cystoseira sp. 2 and Cystoseira sp. MP14; 3Group III - available species belonging to C. compressa and 
C. compressa var. pustulata, C. humilis, C. humilis var. myriophyoides and C. foeniculacea, Cystoseira sp. MP1, 
Cystoseira sp. MP2 and Cystoseira sp. MP31. aPercentage calculated relative to the alignment length. 
 
A total of 16 COI, 26 23S and 37 mt-spacer haplotypes were identified, in 58, 73 and 79 
Cystoseira sp. individuals, respectively. Several haplotypes were exclusive to each Cystoseira 
group, and the Median-Joining analysis revealed three cleary independent networks 
correspondent to Cystoseira-I, -II and –III groups for each marker (ANNEXES 31-33). Only 
21 haplotypes out of the 79 found were shared among at least two species of the same group.  
Among all, the Cystoseira-I species were those with the highest number of shared haplotypes 
(n= 11), followed by the Cystoseira-II species (n= 5), and Cystoseira-III with only 5 shared 
haplotypes per locus that are spread within the sub-groups . 
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Table 5.3. Comparison of the different Cystoseira phylogenetic groups defined in this study with the groups identified by other authors based on genetic, 
chemical and morphological traits. 
Reference This study Draisma et al. (2010) Amico (1995)
2
 Valls et al. (1993b)
3
 Piatelli (1990)
4
 Amico et al. (1985b)
5
 da Colombo et al. (1982)
6
 
Type of data Phylogeny Chemistry Morphology 
Species
1
 COI, 23S, IGS 23S Lipophylic, diterpenoid and meroditerpenoid content  Anatomic traits   Embryo germination  
C. amentacea Cystoseira-IA Cystoseira-5 VI IIIB / IIIC VII I I 
C. funkii Cystoseira-IA Cystoseira-5 - - - - - 
C. mediterranea Cystoseira-IA Cystoseira-5 VII IIIB / IIIC VII I I 
C. tamariscifolia Cystoseira-IA Cystoseira-5 VII IIIB / IIIC VII I I 
C. barbatula Cystoseira-IB Cystoseira-5 III IIIA III - - 
C. brachycarpa Cystoseira-IB Cystoseira-5 II II II II I 
C. crinita Cystoseira-IB Cystoseira-5 III IIIA III II I 
C. zosteroides Cystoseira-IC Cystoseira-5 IV IIIB IV III I 
C. baccata Cystoseira-IIA Cystoseira-6 V IIIB - IV* II 
C. barbata Cystoseira-IIA Cystoseira-6 I I III II I 
C. elegans Cystoseira-IIA Cystoseira-6 V IIIA / IIIB V III I 
C. granulata Cystoseira-IIA - - - - - - 
C. mauritanica Cystoseira-IIA - - - - III - 
C. nodicaulis Cystoseira-IIA - - - - III I 
C. spinosa Cystoseira-IIA Cystoseira-6 V IIIB V III I 
C. squarrosa Cystoseira-IIA - IV - IV III - 
C. usneoides Cystoseira-IIA Cystoseira-6 IV - - III - 
C. abies-marina Cystoseira-IIB Cystoseira-6 - - - II - 
C. sonderi Cystoseira-IIB - - - - - - 
C. compressa Cystoseira-IIIA Cystoseira-4 I I I IV III 
C. humilis Cystoseira-IIIA Cystoseira-4 I I I IV III 
C. foeniculacea Cystoseira-IIIB Cystoseira-4 - IIIA III IV III 
1 Conspecifity of taxa used by different authors (Guiry and Guiry, 2016): C. amentacea = C. stricta; C. brachycarpa = C. balearica = C.  caespitosa; C. barbata= C.  susanensis; C. nodicaulis 
= C. granulata; C. spinosa = C. jabukae; C. squarrosa = C. spinosa var. squarrosa; C. foeniculacea = C. Ergovicii; 2 Chemical groups based on the meroditerpenoids composition: Group I = no 
lipophilic secondary metabolites; Group II = linear diterpenoids; Group III = linear meroditerpenoids; Group IV = tetrahydrofurans, furans and pyran ring; Group V = cyclic meroditerpenoids; 
Group VI = Bicyclo[3.2.0]heptane ring system; Group VII = Rearranged meroditerpenoids; 3 Valls et al.’s chemical groups: Group I - No diterpenoids; Group II - Linear diterpenoids; Group III – 
Meroditerpenoids: III.A - Linear meroditerpenoids; III.B - Cyclic rneroditerpenoids; III.C - Rearranged meroditerpenoids; 4 Piatelli (1990)’s chemical groups on the chemical composition (Valls 
and Piovetti, 1995): Group I - no lipophilic secondary metabolites; Group II - linear diterpenoids; Group III - open-chain meroditerpenoids; Group IV - tetrahydrofurans and furans;  Group V - 
cyclopentane ring; Group VI – bicyclo[4.3.0]nonane ring system; Group VII – bicyclo[3.2.0]heptane ring system; 5 Morphological groups based on the receptacle, conceptacle and axis 
characteristics: Group I = C. ericaefolia  (C. amentacea, C. mediterranea, C. tamariscifolia); Group II = C. crinito-selaginoides (C. abies-marina, C. barbata, C. brachycarpa, C. crinita); Group 
III = C. spinifero-opuntioides (C. elegans, C. mauritanica, C. nodicaulis, C. spinosa, C.squarrosa, C. zosteroides); Group IV (*VI) = C. discors-abratanifolioides (C. baccata, C. compressa, 
C. foeniculacea, C. humilis), 6 Da Colombo et al (1982) identified morphological groups based on the embryo characteristics (see Amico et al., 1985b): Group I – Spherical embryo germination 
and 4 primary rhizoids; Group II - Spherical embryo germination and 4 primary rhizoids and different segmentation sequence; Group III – Ovoid embryo germination with 8 primary rhizoids. 
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Table 5.4. Evolutionary divergence between COI, 23S and mt-spacer Cystoseira sequences 
Markers - Group 
All Cystoseira samples  Cystoseira  with information of the 3 markers* 
Interspecific Intraspecific    Interspecific Intraspecific   
COI - I 0.0 -  1.1 0.0 - 0.3  0.0 -  1.1 0.0 
COI - II 0.0 -  6.8 0.0 - 0.5  0.0 -  3.8 0.0 - 0.5 
COI - III 0.0 -  4.4 0.0 - 1.0  0.0 -  4.4 0.0 - 0.6 
23S - I 0.0 -  4.9 0.0 - 2.2  0.0 -  2.3 0.0 - 2.2 
23S - II 0.0 -  3.1 0.0 - 1.6  0.0 -  3.1 0.0 - 1.6 
23S - III 0.0 - 11.0 0.0 - 0.3  0.0 - 10.7 0.0 - 0.3 
mt-spacer - I 0.0 -  9.6 0.0 - 7.6  0.0 -  4.4 0.0 - 2.6 
mt-spacer - II 0.0 - 13.8 0.0 - 3.9  0.0 -  8.9 0.0 - 3.9 
mt-spacer - III 0.0 - 11.4 0.0 - 1.5  0.0 - 10.9 0.0 - 0.8 
* samples without species identification were excluded 
5.4.1. PHYLOGENETIC ANALYSIS  
Maximum likelihood and Bayesian inference analyses of the Sargassaceae (Figures 
5.3.) and Cystoseira-only (Figures 5.4.) concatenated datasets confirm the subdivision of 
Cystoseira in 3 well-suported clades (Cystoseira-I-III; Figures 5.3., 5.4. and ANNEXES 20-
25). This subdivision was congruent among analyses using single mitochondrial markers 
(ANNEXES 22-27). Overall, the Cystoseira-III group, which includes C. discors-
abratanifolioides species (C. compressa, C. foeniculacea, C. humilis; Amico et al., 1985b), 
clearly branched off Cystoseira-I (C. amentacea, C. barbatula, C. brachycarpa, C. crinita, 
C. funkii, C. mediterranea, C. tamariscifolia, C. zosteroides) and -II (C. abies-marina, 
C. baccata, C. barbata, C. elegans, C. mauritanica, C. nodicaulis, C. sonderi, C. spinosa, 
C. squarrosa, C. usneoides; Table 5.3). However, these results suggest that Cystoseira-I and -
II are more closely related as compared to Cystoseira-III, sharing a common branch with 
maximum support (BS = 100; PP = 1; Figure 5.4.). Nonetheless Cystoseira-I and -II are 
paraphyletic when Bifurcaria is included in the analysis, as was observed with the Cystoseira-
III taxa that clustered together with other genera from the Indio-Pacific region previously 
classified as Cystoseira (BS = 74; PP = 0.86), such as Polycladia, Sirophysalis and 
Stephanocystis (Draisma et al., 2010).  
Cystoseira-I could be divided into two subgroups Cystoseira-IA and -IB (Figures 5.3. 
and 5.4.). Cystoseira-IA (C. amentacea, C. funkii, C. mediterranea, C. tamariscifolia) formed 
a well-supported cluster (BS = 96; PP = 1) using mt-spacer sequences (ANNEXES 26-27), 
although without significant statistical support in the 23S analysis (ANNEXES 24-25). 
Within this group, C. mediterranea formed a cluster that was ML-supported in the COI tree 
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(BS = 99; PP = 0.93; ANNEXES 22-23), while C. tamariscifolia and C. amentacea remained 
unresolved. Subgroup Cystoseira-IB (C. barbatula, C. brachycarpa, C. crinita) was 
significantly supported in the concatenated datasets analysis (BS = 92; PP = 0.96; Figure 5.3-
5.4.); however, in the 23S tree, support was highly significant (BS = 99; PP = 1; ANNEXES 
24-25). This result suggests that C. crinita, C. barbatula and C. brachycarpa are indeed 
closely related. In addition, Cystoseira-I taxa clustered together with a well-supported 
Bifurcaria bifurcata cluster (BS = 94; PP = 1; Figures 5.3 and ANNEX 20), confirming that 
they are sister taxa. 
Cystoseira-II branched into two well-supported subgroups, Cystoseira-IIA (BS = 100; 
PP = 1) and Cystoseira-IIB (BS = 98/99; PP = 1; Figures 5.3-5.4). This high support is 
mainly due to the inclusion of the COI and mt-spacer markers (ANNEXES 22-23). Analysis 
of the concatenated dataset showed that Cystoseira-IIA (C. baccata, C. barbata, C. elegans, 
C. mauritanica, C. nodicaulis, C. spinosa, C. squarrosa, C. usneoides) encompassed two 
well-resolved species, namely C. usneoides (BS = 98/97; PP = 0.93/0.91) and C. baccata (BS 
= 100; PP = 1) (Figure 5.3-5.4.). Maximum support of the C. baccata clade was also obtained 
in the COI tree (ANNEXES 22-23), whereas in the 23S tree the branch support values were 
lower (BS = 89; PP = 0.92; ANNEXES 24-25). C. usneoides cluster was supported by the 
ML analysis using the COI (BS = 96; PP = 0.54; ANNEXES 22-23) and 23S (BS = 94; PP = 
0.92; ANNEXES 24-25) loci. In addition, Cystoseira-IIA included an unresolved 
heterogeneous set of species (Figure 5.3-5.4.) although the COI locus allowed the resolution 
of a C. nodicaulis cluster (BS = 86; PP = 0.99; ANNEXES 22-23). However, the presence of 
a well-supported heterogeneous cluster (BS = 98/88, PP = 1) encompassing 3 sequences 
acquired from the GenBank and classified as C. spinosa, C. elegans, C. squarrosa from the 
Adriatic and nearby Sicily Mediterranean coasts was not in agreement with the results of 
sequences of the same species obtained in the Spanish south Mediterranean coast 
(ANNEX 19). Sister to Cystoseira-IIA, Cystoseira-IIB contained C. abies-marina and 
C. sonderi and formed a well-supported cluster (BS = 99/98; PP = 1; Figures 5.3-5.4.) 
although this topology was not detected in the 23S analysis (ANNEXES 24-25).   
Within the Cystoseira-III group, C. foeniculacea formed a clade with maximum support 
(BS = 100; PP = 1), sister to C. compressa and C. humilis as defined by all markers (Figure 
5.3.-5.4. and ANNEXES 20-21). Although without significant support values (BS = 80/67, 
PP = 0.95/0.74 in Figure 5.3. and 5.4., respectively), C. compressa branched off 
C. compressa var. pustulata and C. humilis. These results are in agreement with some authors 
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(G mez-Garreta et al., 2001; Giaccone and Bruni, 1973) that consider 
C. compressa var. pustulata a synonym of C. humilis var. humilis. These relations are better 
defined in the COI trees (ANNEXES 22-23) that suggest the occurrence of 3 independent 
clades: C. compressa (BS = 90, PP = 0.9), C. humilis (BS = 94, PP = 0.95) and 
C. compressa var. pustulata (BS = 96, PP = 1). Notwithstanding, the importance of COI to 
clarify the infrageneric phylogeny and improve the identification of Cystoseira samples is 
highlighted by Cystoseira sp. MP2 and Cystoseira sp. MP31. Even though these individuals 
were classified tentatively as belonging to other taxa, the trees based on COI sequencing data 
strongly suggested that they should be classified as C. humilis and C. compressa var. 
pustulata, respectively (Figures 5.3.-5.4. and ANNEXES 22-23).  
5.5. DISCUSSION 
The present study represents a comprehensive survey of the diversity of the genus 
Cystoseira, based on 92 samples from 22 different Cystoseira species and other 
Cystoseiracea. To the best of our knowledge, this is the first study using COI, 23S and mt-
spacer sequences to investigate the phylogeny of the genus Cystoseira. In particular, this work 
contributed with 48 COI, 43 23S and 44 mt-spacer sequences from a wide geographic area 
(Figures 5.1.-5.2.), enlarging significantly the number of available sequences in GenBank. 
Additionally, emphasis was given to the C. ericaefolia group (C. tamariscifolia, C. amentacea 
and C. mediterranea), whose phylogeny is still poorly clarified. 
Compared to previous studies (Draisma et al., 2010; Silberfeld et al., 2010), Cystoseira 
sequences used in the present work had a relatively low number of phylogenetically 
informative sites (16.7% PI sites for COI, 14.3 % for 23S and 22.5% for mt-spacer). This 
might be explained by our focus on Cystoseira and the limited use of sequences of related 
genera in order to minimize the number of gaps in alignments of highly variable regions, such 
as the mt-spacer. Analyses of the interspecific divergence show results similar to values 
described for other algae (Saunders, 2005; Kucera and Saunders, 2008).  
Fucales seem to have low zygote dispersal (Clayton, 1990; Guern, 1962) and, as a 
result, it is predicted that macrophytes belonging to this order show low intra-population 
genetic diversity, but larger differentiation among diferent regional populations (Coleman and 
Brawley, 2005; Susini et al., 2007). The inclusion of a wider array of closely related genera 
suggests, however, that Cystoseira-I and Cystoseira-III maintain more phylogenetic closely 
relations with species of other genera (Bifurcaria, Policladia, Stephanocystis and 
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Syrophysalis) than with the Cystoseira of the other groups (Figures 5.3.), making this genus, 
as noted by Draisma (2010), polyphyletic. Therefore, our results suggest that Atlantic-
Mediterranean Cystoseira, currently defined, are not a natural group from an evolutionary 
point of view correspondig a distinct groups that should be taxonomically separated in 3 
different genera.  
The comparison of our results with those of other studies, including genetic, chemical 
and morphological information (Colombo et al., 1982 cited by Amico et al., 1985b; Amico et 
al., 1985b; Piatelli, 1990 cited by Valls and Piovetti, 1995; Valls et al., 1993b; Amico, 1995; 
Draisma et al., 2010; Table 5.3.), led to identification of similarities between species of these 
groups. Phylogenetic results corroborate the polyphyletic nature of the Cystoseira genus 
described previously (Rousseau and de Rivers, 1999; Draisma et al., 2010). A direct 
correspondence between our classification and that proposed by Draisma et al. (2010) was 
found, namely Cystoseira-I, Cystoseira-II and Cystoseira-III map to Cystoseira-5, Cystoseira-
6, and Cystoseira-4, respectively. Concerning the morphology of some reproductive and 
support structures (receptacle, conceptacle and axis) described by Amico et al. (1985b), our 
group Cystoseira-I matches their Groups I and II. Moreover, Amico’s Group III, known as 
C. spinifero-opuntioides, corresponded to the Cystoseira-II taxa of the present work. The only 
exception was C. zosteroides, which branches off early in trees either obtained in this study 
(Figures 5.4. and ANNEXES 24-27) or as described by Draisma et al. (2010), though often 
without statistical support. Amico’s Group IV (C. discors-abratanifolioides) seems, however, 
to be heterogeneous, containing Cystoseira-II (C. baccata) and Cystoseira-III (C. compressa, 
C. humilis and C. foeniculacea) algae. Group III of da Colombo and colleagues (1982), based 
on criteria related to embryo germination (Amico et al., 1985b), matches Cystoseira-III taxa. 
Although Draisma et al. (2010) discarded any connection between phylogeny and the 
published chemotaxonomic classifications, careful comparison between all traits can detect 
some trends. For example, linear diterpenoids and rearranged meroterpenoids (Piatelli, 1990 
cyted by Valls and Piovetti, 1995; Valls et al., 1993b; Amico, 1995) are exclusive to 
Cystoseira-I taxa, which have been identified as the most developed group of species (Valls et 
al., 1993b), in agreement with the results obtained in this phylogenetic study. Unlike 
Cystoseira-I and –II algae, all Cystoseira-III taxa lack diterpenoids and lipophilic secondary 
metabolites, being thus defined not by presence of a given class of chemicals, but by its 
absence. Similar trends can even be observed at the sub-group level (Table 5.3.). For 
example, Cystoseira-IA and -IB taxa match chemical Groups VI/VII and Groups II/III as 
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described by Amico (1995), respectively. Another example would be the fact that Cystoseira 
II-B algae are restricted to Amico’s chemical Groups I, IV and V. Interestingly, only 
C. zosteroides, which branches early off the remaining Cystoseira-I taxa, shares a similar 
chemical profile to Cystoseira II-A algae, namely C. squarrosa and C. usneoides. Taken 
together, these results suggest that there might be a closer relationship between phylogenetic, 
chemical and morphological classifications than previously thought. 
The mt-spacer locus described as having high resolving power for Fucus spp. (Coyer et 
al., 2006) was considered to be useful only at a generic level for Sargassaceae (Draisma et al., 
2010) and insufficiently informative to differentiate between the closely related C. spinosa 
and C. squarrosa species (Rožić et al., 2012). Despite these arguments and the high 
variability of mt-spacer, that can generate large gaps if the choice of taxa to include in the 
alignment is too divergent, C. barbata, C. baccata and C. abies-marina (Cystoseira-II), and 
C. foeniculacea (Cystoseira-III) were resolved from their closest relatives with significant 
support in mt-spacer trees.  
Another question addressed by the present work is the difficulty to distinguish the 
closely related species C. tamariscifolia, C. amentacea and C. mediterranea only based on 
morphological criteria alone. Morphological plasticity, crypticism and seasonal variability in 
the appearance of these species often hinders and, in some cases, even prevents the accurate, 
unambiguous taxonomical assignment of the samples (Ballesteros and Catalán, 1981; Gómez-
Garreta et al., 1994; Ballesteros and Pinedo, 2004). Thus, this reinforces the need for novel 
tools able to differentiate these species, especially in places where they coexist (Ballesteros 
and Catalán, 1981).  Although the analyses using the 3 markers under study did not support 
the resolution of C. tamariscifolia from C. amentacea and, the COI trees show a well-
supported cluster of C. mediterranea. Moderately high interspecific divergences with low 
intraspecific variations, as verified in the studied Cystoseira COI sequences, are considered to 
be prerequisites of a marker to be considered a suitable DNA barcode (Saunders and Kucera, 
2010), thereby these results suggest that the COI could be useful to differentiate Cystoseira 
species, and in particular C. mediterranea from C. tamariscifolia and C. amentacea. 
Even though other mitochondrial markers have been used to analyse the phylogeny of 
brown algae, the results of this study are consistent with those of Silberfeld et al. (2010), and 
also with those of Draisma et al. (2010) and Rožić et al. (2012) that studied 23S, mt-spacer 
and/or psbA loci. In certain cases, individual markers were shown not to be sufficiently 
informative to infer relationships between species (Draisma et al., 2010; Rožić et al., 2012). 
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Therefore, multi-gene datasets have been used to try to achieve greater phylogenetic 
resolution (Rousseau and de Reviers, 1999; Lane and Mayes, 2006; Draisma et al., 2010; 
Silberfeld et al., 2010; Vaidya et al., 2011; Lam et al., 2016). The phylogenetic trees obtained 
from the combined datasets used in this work (only Cystoseira samples, and Cystoseira 
together with other Sargassaceae) were congruent with previous phylogenies of Fucales 
(Philips et al., 2005; Cho et al. 2006; Harvey and Goff, 2006; Draisma et al., 2010; Rožić et 
al., 2012). Even though COI, 23S and mt-spacer markers resolved several taxa, the 
polyphyletic nature of the genus Cystoseira is a clear obstacle for further taxonomic 
resolution. As shown by Rousseau and de Reviers (1999) and Draisma et al. (2010), the 
Sargassaceae family includes a few polyphyletic genera, such as Cystoseira, Sargassum and 
Bifurcaria, and consequently there is still much to define within this family.  
In spite of the current limitations, the comparative phylogenetic analysis of several 
Sargassaceae with three genetic markers and the divergence analysis enabled the authors to 
assign previously unidentified samples (Cystoseira sp. 1, Cystoseira sp. 2, Cystoseira sp. 
MP1, Cystoseira sp. MP14, Cystoseira sp. MP2, Cystoseira sp. MP31) to their respective taxa 
at the species level. In particular, we were able to classify the following samples: 
Cystoseira sp. 1 as C. crinita (Cystoseira-I); Cystoseira sp. 2 as C. spinosa, 
Cystoseira sp. MP14 as C. abies-marina (Cystoseira-II); and Cystoseira sp. MP31 as 
C. compressa var. pustulata, Cystoseira sp. MP1 and Cystoseira sp. MP2 as C. humilis 
(Cystoseira-III). 
5.6. CONCLUSIONS 
Comprising 22 different Cystoseira species and infra-generic taxa currently accepted, 
this work shows that the identification of the Cystoseira species using molecular markers is 
more effective when only closely related species are chosen in order to minimize the number 
and extension of gaps in the alignment of highly variable regions. The combined use of 
genetic markers with more conserved evolutionary signals allowed for a better resolution of 
the taxonomic relationships within this group of species. Gien the high variability of mt-
spacer, this marker can be used in combination with COI to distinguish the majority of the 
Cystoseira species, resolving the phylogeny of several species of different groups, namely 
C. barbata and C. baccata (Cystoseira-II), and C. foeniculacea (Cystoseira-III). Even though 
there are quite a few exceptions, our results and the chemotaxonomic classifications suggest 
that the relationships of the phylogenetic, chemical and morphological classifications should 
not be promptly discarded. Moreover, our results suggest that European Cystoseira, as 
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currently defined, should be split into 3 separate genera, to reflect their different evolutionary 
histories, relationships with other genera, and genetic divergence.  
Overall, these results strongly suggest that a combined effort should be carried out to 
further elucidate the observed relationships between taxonomy, chemical profiles, anatomical 
traits and phylogeny in order to clarify the phylogenetic relations of the studied three groups 
of Cystoseira. 
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6.1. FINAL CONSIDERATIONS 
This work constitutes a pioneer study about the antileishmanial potentialities of the 
algae belonging to Cystoseira genus. In this context, our main aim was to identify algae 
metabolites active against Leishmania parasites. The decision to focus on Cystoseira species 
was taken after an initial screening of 15 red, green, and brown algae species that strongly 
indicated that algae from this genus contained compounds with antileishmanial potentialities 
(Chapter III). The comprehensive review carried out showed that Cystoseira contain 
compounds with several biomedical potentialities; however, the antileishmanial activity had 
never been described before for these species (Chapter II). Our work allowed to isolate two 
meroditerpenoid coumpounds from C. baccata with antileishmanial activity: one with an 
unknown tetraprenyltoluquinone structure, and the other previously isolated 
tetraprenyltoluquinol active against Leishmania intracellular amastigotes (Chapter IV). 
Considering that currently only 11 algal compounds are reported as active against these 
parasites (dos Santos et al., 2010; dos Santos et al., 2011; Machado et al., 2011; Soares et al. 
2012), our results are extremely useful. Being the identification of the biomass origin a 
primordial issue in drug screening studies, the controversial taxonomical assignment of 
Cystoseira specimens raised questions concerning the accuracy of the identification of the 
samples used in this study. In this context, this project also evaluated the usefulness of 
mitochondrial markers for identification of Cystoseira species, complementing the previously 
published information on the genetics of these species, namely with major contributions for 
the knowledge of the COI region (Chapter V).  
The focus of this study on the search for natural products active against Leishmania 
parasites is justified by the imperative need for molecules that overcome or inhibit the 
development of these parasites, in order to develop novel and effective antileishmanial 
therapies. Parasite resistance, limited therapeutic indexes, and considerable toxicities of the 
existing antileishmanial drugs have been entailing new challenges to the fight against 
leishmaniasis (Croft et al., 2006). In this sense, WHO (2013b) pointed out the need to 
reinforce the natural products drug research, traditionally recognized as having a large 
medical importance worldwide. Research on marine natural products (NPs) is nowadays 
accepted as a promising route to discover novel therapies against several diseases that needs 
to be enlarged in order to increase the chances of finding a candidate with strong and effective 
properties, in particular against leishmaniasis. In this context, our work constitutes a relevant 
contribution in line with the current needs and recommended priorities, providing natural 
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isolated structures that could be used as scaffolds for the design of new and target-specific 
bioactive molecules. 
Afecting 12 million people in 98 developing and developed countries (Alvar et al., 
2012), leishmaniasis is in active geographical expansion with 1.3 million human cases 
registered annually worldwide over the past two decades, being strongly associated with 
poverty, migration phenomena, and climatic and environmental changes (WHO, 2015a). In 
the Old World, L. infantum is the causative agent of visceral (VL), cutaneous (CL) and canine 
(CanL) leishmaniases, and the most relevant Leishmania species due to the fact that VL and 
CanL are potentially fatal if left untreated (Assimina et al., 2008; CFSPH, 2009). Endemic in 
all the southern European countries, infection by L. infantum has an annual burden in the 
Mediterranean Region of about 900 VL (Alvar et al., 2012) and more than 2.5 million CanL 
cases (Moreno and Alvar, 2002). With dogs as major host, and an increasing risk of infection 
in Europe (Ready, 2010, Mansueto et al., 2014) this zoonosis constitutes a serious and 
challenging public health and veterinary issue. 
Algae contain hundreds of metabolites, and the search for the highly desired active NPs 
is a complex and long process (Bucar et al., 2013). The structure of the natural bioactive 
compounds is often complex, hindering its identification as well as isolation, and insufficient 
yields and purity can also become a limitation (Cechinel and Yunes, 1998). Therefore, the 
extraction and separation processes are challenging essential tasks for the success of the NPs 
isolation. Extract composition and bioactivity are strongly influenced by the polarity of the 
solvents and the solubility of the present molecules. In our case, antileishmanial activity was 
mostly detected in the hexane and CH2Cl2 extracts (Chapter III), corroborating published data 
which suggests that, in general, the active anti-protozoal compounds were found in non-polar 
fractions of the studied marine seaweeds (Vonthron-Sénécheau et al., 2011). Nonetheless, it is 
known that several other factors influence the ability to extract compounds of interest from a 
given sample (biomass amount; matrix solubility; stability of the interest compounds; solvents 
toxicity, volatility, viscosity and purity; artefacts presence; Bucar et al., 2013), and our review 
confirmed that antileishmanial activity can be found in extracts obtained with different 
solvents (ANNEX 1). 
Concerning the drug screening for anti-leishmanial purposes, bio-guided fractionation 
assays are usually used in order to achieve an efficient isolation of the antileishmanial activity 
(Tempone et al., 2011). Therefore, dried biomass samples, collected at various sites of the 
Portuguese and Spanish coast, and morphologically identified, were efficiently extracted using 
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different organic solvents of increasing polarity (Hexane, CH2Cl2 and MEOH) using Soxhlet 
extractors. Forty-five extracts from 15 marine algae species were obtained and submitted to bio-
guided fractionation for evaluation of its antileishmanial and cytotoxic activities. Fractionation 
assays were sequentially repeated until attainment of less complex fractions and isolation of the 
purified compounds, using liquid-solid (silica and Sephadex) and thin layer chromatography 
techniques (Chapters III and IV). The random screening of organic extracts to identify the 
molecules responsible for a biomedical activity requires fast, simple, and reproducible bioassays 
that allow to quantify the activity of interest (Sereno et al., 2007).  
Bioassays for evaluation of the NPs efficiency can involve the manipulation of the 
different Leishmania forms: promastigotes and amastigotes (Tempone et al., 2011). The use 
of axenic promastigotes is widely used by many authors as an easier, faster, and low-cost 
alternative for preliminary screenings (Tempone et al., 2011), and were therefore chosen to 
evaluate the efficacy of the crude extracts/fractions on reducing the viability of L. infantum in 
the early stages of the fractionation process. The use of the MTT method and the axenic 
promastigote model allowed to determine the antileishmanial effect and the cytotoxicity 
against mammalian cells of a large number of extracts and fractions in order to select the less-
toxic and most active algal fraction. As a result, seven of the 45 studied extracts displayed 
considerable activities against Leishmania promastigote forms (IC50 29.8 to 101.8 µg/mL). 
Among these, Cystoseira genus stood out, with four species (C. baccata, C. barbata, 
C. nodicaulis and C. tamariscifolia) displaying significant activity against this parasite form, 
being the hexane and CH2Cl2 extracts of C. tamariscifolia, and the CH2Cl2 extract of 
C. usneoides the most active (IC50 29.8 to 33.6 µg/mL) and similar to those described in 
literature for other algae (Freire-Pelegrin et al., 2008; Fouladvand et al., 2011; Chapter III).  
Because of the intracellular requirement of Leishmania amastigotes infection, the in 
vitro amastigote–macrophage model is considered the gold standard to determine the drug 
sensitivity profile of an antileishmanial compound (Croft et al., 2011; Tempone et al., 2011). 
For these assays, macrophage susceptibility to the studied drug has to be firstly assessed, in 
order to find the most selective fractions/compounds, which ones are toxic to the parasite, and 
which are less or non-toxic to macrophages. In our case, the high toxicity revealed by the 
C. usneoides and C. tamariscifolia extracts against human acute monocytic leukaemia THP-1 
cells prevented their use in the intracellular assays, even displaying potent anti-promastigote 
activities; on the other hand, the selectivity exhibited by the C. baccata and C. barbata 
hexane extracts allowed to proceed with the study of its effect towards the intracellular 
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amastigote model (Chapter III). In fact, these extracts were more active above the parasite 
intracellular form (IC50 ≤ 6.8 µg/mL) than on promastigotes (IC50 ≥ 78.7 µg/mL), proving the 
existence of differences in drug susceptibility of both parasite forms, and furthermore 
reinforcing the importance of using the clinically relevant stage of the parasite for the 
selection of the active and less toxic compounds. 
The composition of the Cystoseira crude extracts that displayed antileishmanial activity was 
also investigated. This preliminary characterization showed that hexane extracts are composed of 
fatty acids, triacylglycerols derivatives, carotenoids, and steroids, whereas the CH2Cl2 extracts 
contain fatty acids and meroterpenoids, complementing the information published, as can be 
verified in the data compiled in Chapter II. According to recent reports, those compounds might 
be involved in the antileishmanial activity here evaluated. In particular, unsaturated fatty acids, 
such as the eicosapentaenoic acid; steroids, such as fucosterol and sitosterol; and different 
meroterpenoids, such as the ones detected in our Cystoseira extracts, were recently found to be 
responsible for reducing the viability of viscerotropic and dermotropic Leishmania species, as 
discussed in Chapter IV. These results suggest that identified metabolites may be related with the 
antileishmanial activity of the extracts here studied. However, a more detailed characterization of 
these metabolites should be carried out in the near future, in order to clarify their potentialities as 
antileishmanial agents. 
Among all the other extracts presenting antileishmanial activity, C. baccata hexane 
extract was selected because of its lower toxicity against the mammalian cells, and the lower 
complex profile of its fractions. Bioactivity-guided fractionation of this extract allowed to 
isolate two meroditerpenoids with antileishmanial activity: (3R)- and (3S)-
tetraprenyltoluquinol; and (3R)- and (3S)-tetraprenyltoluquinone. In practice, our work led to 
the identification of 4 compounds, since each of the mentioned meroditerpenoids was isolated 
as a mixture of two inseparable epimers (Chapter IV). Elucidation of the isolated compounds 
constituted a major challenge for us, in that it required the decoding of the information 
obtained from the different NMR (
1
H, 
13
C, DEPT 135º, HMBC, HSQC), UV and mass 
spectrometry spectra (ANNEXES 2-18). Tetraprenyltoluquinol was previously isolated from 
C. baccata by Valls et al. (1993b); however, due to the use of the additional HMBC spectral 
analysis, our study introduced some corrections to the structural elucidation, thus 
complementing the information already published. Concerning the tetraprenyltoluquinone, a 
comprehensive literature review allowed to conclude that it corresponds to an unidentified 
structure so far, being therefore a novel metabolite, here described for the first time.  
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Both isolated meroditerpenoids inhibited the growth of L. infantum parasites. The 
tetraprenyltoluquinol was shown to be the most effective in reducing the promastigote 
viability and intracellular amastigote infection index (IC50  44.9 and  25.0 µM, 
respectively) followed by the tetraprenyltoluquinone (IC50  94.4 µM and > 88.0 µM, 
respectively). Assessment of its effect on mouse peritoneal macrophages showed that 
tetraprenyltoluquinol has a similar cytotoxicity (CC50  126.6 µM) to that of the reference 
drug miltefosine, largely used in the treatment of the VL and CL. Moreover, the 
tetraprenyltoluquinone showed to exert a higher toxic effect (CC50   84.5 µM), without 
compromising its intracellular evaluation (Chapter IV). These results clearly suggest that 
these compounds, in particular the tetraprenyltoluquinol, may be interesting as scaffolds for 
the development of novel chemotherapeutic molecules, namely for canine, and human 
visceral leishmaniases studies.  
This study also provides relevant information for the identification of the mechanism of 
action of the Cystoseira extracts and the isolated compounds. Several morphological 
alterations and lack of externalization of phosphatidylserine were observed in promastigotes 
treated with the achieved active extracts, indicating that the observed toxic effect 
compromised the metabolism of vital organelles, such as mitochondria (Chapter III). These 
results were corroborated by the electron microscopy data that proved the mitochondrial 
commitment of the promastigotes treated with the isolated compounds (Chapter IV). 
Published data indicate that cytoplasmic vacuolization and the presence of coiled 
multilamellar structures observed in the mitochondria, as well as the disruption of the 
mitochondrial membrane potential could be a consequence of starvation processes of a 
deficient mitochondrial activity, autophagic mechanisms or cytoplasmic organelle disruption 
(Lockshin and Zakeri, 2004; Monte Neto et al., 2011) induced by the tested compounds. 
These results are relevant, since this organelle is usually considered an indicator of cellular 
dysfunction and is therefore a very interesting target for chemotherapeutic studies (Souza et 
al., 2009), particularly against Leishmania parasites that only have a single mitochondrion, 
vital for their survival. 
Taken together, our results about the pharmaceutical potencialities of macroalgae 
indicate, for the first time, that Cystoseira extracts might be used as a source of compounds 
active against L. infantum which could be explored as scaffolds for the development of novel 
antileishmanial drug leads. The selective activity identified in C. baccata and C. barbata 
against intracellular amastigotes suggests that they should be chosen for further studying, 
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since they exhibited higher antileishmanial activity as compared to results described in similar 
reports on bioactivities found in macroalgae. In the context of the isolation of NPs, we can say 
that this study reinforces the evidence of the marine environment as source of novel 
molecules, and that Cystoseira algae are in fact a source of products potentially useful to fight 
against parasitic diseases such as Leishmaniasis. 
Concerning, the usefulness of the mitochondrial markers for the correct identification of the 
Cystoseira samples, phylogenetic and population genetics approaches were followed to 
investigate the genetic relationships between different Atlantic-Mediterranean Cystoseira species.  
Informational variability of a chosen marker influences its usefulness. In this study, 
three mitochondrial regions (COI, 23S and mt-spacer) with distinct evolutionary signals were 
chosen based on previous studies that generated Cystoseira sequences available at the 
GenBank database. Using the combined information of these genetic markers, the 
relationships between 22 Atlantic-Mediterranean Cystoseira species (n = 92), were analysed 
using Maximum likelihood and Bayesian inference methods as well as population genetics. 
The dataset comprised 55 samples specifically collected for this study, including those used in 
the chemical study, and generated 135 new sequences for the 3 markers (48 COI, 43 23S and 
44 mt-spacer); other GenBank sequences were included, resulting in a global dataset of 210 
Cystoseira sequences (58 COI, 73 23S and 79 IGS).  
Phylogenetic and population genetics results were concordant indicating that Atlantic-
Mediterranean Cystoseira species are clearly divided in three distinct Cystoseira natural 
groups (Cystoseira-I, -II and –III). The results are in agreement with the polyphyletic nature 
of Cystoseira previous described by Draisma et al. (2010). Moreover, the observation that 
Cystoseira-I, and –III are more closely related with other Sargassaceae genera, namely the 
Bifurcaria, and the Indo-Pacific Policladia, Stephanocystis and Syrophysalis than between 
what is observed the three Cystoseira groups is an indicator that the currently defined 
Cystoseira genus should be revised and probably divided into distinct genera. 
Given the high variability of the mt-spacer, this marker allowed to distinguish the 
majority of the Cystoseira species and helped resolving the phylogeny of several species of 
different groups, namely C. barbata and C. baccata (Cystoseira-II), and C. foeniculacea 
(Cystoseira-III). Concerning the COI region, moderately high interspecific divergences and 
low intraspecific variations were observed; therefore, our results suggested its usefulness in 
differentiating among Cystoseira species, namely the highly similar species C. mediterranea 
from the C. tamariscifolia and C. amentacea.  
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Concluding, the attained results on Cystoseira genetics allowed to confirm the 
identification of the samples used in the chemical studies, validating the suitability of the 
studied mitochondrial markers for the identification of several Cystoseira species within each 
group (Cystoseira-I, -II and –III) and providing a reliable method structure for the study of the 
taxonomy, evolution and speciation history of this genus. Furthermore, the comparison 
between phylogenetic, chemotaxonomic and morphological classifications, previous 
published, showed congruent results between the different methodologies suggesting that 
these approaches should not be promptly discarded. 
6.2. FUTURE PERSPECTIVES 
This study constitutes a preliminary effort on the research of Cystoseira natural 
products for antileishmanial purposes, and we are certain that future investigations can further 
complement the knowledge here acquired.  
The effect of the tetraprenyltoluquinol isolated in this study on Leishmania parasites 
justifies its further investigation, namely evaluating its in vivo antileishmanial efficacy on a 
mouse model; and clarifying what mechanisms are beyond the mitochondrial commitment 
and exploring other possible mechanisms of action. Moreover, the effect of 
tetraprenyltoluquinol should be evaluated against other Leishmania species, since different 
species reveal different drug responses and sensitivities. Regarding these issues, 
collaborations have been established, allowing to proceed with the testing of these molecules 
in other Leishmania species from both the Old and the New Worlds. Additionally, it would be 
interesting to expand the knowledge about the bioactive potentialities of this compound by 
testing it against other parasites such as the protozoan Trypanossoma species, responsible for 
the American and the African trypanosomiases. 
All the active extracts obtained in this study should continue to be explored so as to find 
more compounds potentially active against Leishmania or other parasitic diseases. Particularly the 
extracts of C. nodicaulis and C. tamariscifolia, which have been discarded because of their low 
selectivity, may show pleasant surprises upon further fractionation, since the extracts are complex 
mixtures of compounds with different activities that mask each other. Moreover, other non-fully 
explored C. baccata and C. barbata fractions can be further investigated in order to isolate and 
identify more bioactive compound(s). For the chemical investigation a collaboration was 
established with a research group on the organic chemistry of NPs which will allow to continue 
the work of isolation and structural elucidation of coumpounds that could reinforce the contribute 
of this work for the fight against Leishmaniasis. 
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Concerning the identification of the Cystoseira samples, our results suggest that a combined 
phylogenetic/taxonomic/chemical approach should be carried out to further elucidate the 
phylogenetic relationships of the studied Cystoseira species. In particular, a more extensive 
sampling, to include specimens of all the studied species from different geographic origins, would 
allow to complement the genetic information obtained in this study with sequences of all the 
species for the three markers used here. Moreover, ecological data should also be investigated 
once these species have a large geographical intraspecific variability. In this sense, collaborations 
were arranged regarding expertise in DNA barcoding, morphological identification of Cystoseira 
specimens, biogeography and population genetics that could support future studies. 
Finally, despite the potentialities displayed by COI, 23S and mt-spacer regions for the 
identification of the different Cystoseira species, we are certain that further studies using 
nuclear markers, such as the nuclear internal transcribed spacer (ITS), would lead to a more 
comprehensive perspective on the genetic relationships and evolutionary history of the 
Cystoseira.  
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 Antileishmanial activities identify in marine algae extracts  ANNEX 1.
Phylum 
    Family 
Algal  
species 
Crude  
extract  
IC50 
(μg/mL) 
Tested 
organism 
Parasite 
form  
References 
(a-p)
 
Chlorophyta       
 
Acrochaetiaceae Avrainvillea cf digitata DCM:H2O >100 L. mexicana P
1
 d 
Anadyomenaceae Anadyomene saldanhae Me2CO 50/87.9
*
 L. braziliensis P
1
 n 
Caulerpaceae Caulerpa faridii EtOH 34.0 L. major P
1
 a, o 
Caulerpa cupressoides ME2CO 50/51.7
*
 L. braziliensis P
1
 n 
Caulerpa racemosa EtOH 37.6 L. major P
1
 a, o 
 MeOH 22.7 L. donovani AA
3
 l 
Cauluerpa sertularioides H2O hot 
H2O cold 
85.0 
125.0 
L. major P
2
 h 
Cladophoraceae Cladophora glomerata EtOH 39.2 L. donovani AA
3
 c 
Cladophora rupestris CF:MeOH 20.2 L. donovani AA
3
 k 
Codiaceae Codium bursa MeOH 31.71 L. donovani AA
3
 l 
Codium elongatum - na
*
 L. donovani - b 
Codium flabellatum EtOH 34.4 L. major P
1
 a, o 
Codium fragile CF:MeOH 16.6 L. donovani AA
3
 k 
Codium iyengarii EtOH 60.4 L. major P
1
 a, o 
Codium tomentosum EtOAc 
EtOH 
9.7/0.0
*
 
9.7/29.0
*
 
L. donovani AA3
 
m 
Halimedaceae Halimeda incrassata DCM:H2O >100 L. mexicana P
1
 d 
Halimeda tuna DCM:H2O >100 L. mexicana P
1
 d 
Udoteaceae Penicillus dumetosus DCM:H2O >100 L. mexicana P
1
 d 
Penicillus lamourouxii DCM:H2O >100 L. mexicana P
1
 d 
Rhipocephalus phoenix f. 
brevifolius 
DCM:H2O >100 L. mexicana P
1
 d 
Udotea conglutinata DCM:H2O >100 L. mexicana P
1
 d 
Udotea flabellum DCM:H2O >100 L. mexicana P
1
 d 
Ulvaceae Ulva clathrata EtOAc 
EtOH 
9.7/7.0
*
 
9.7/0.0
*
 
L. donovani AA
3
 m 
Ulva fasciata EtOH 50.0 L. major P
1
 a, o 
Ulva intestinalis CF:MeOH 14.9 L. donovani AA
3
 k 
Ulva lactuca EtOAc 
EtOH 
9.7/11.0
*
 
9.7/26.0
*
 
L. donovani AA
3
 m 
 CF:MeOH 12.0 L. donovani AA
3
 k 
 EtOH 5.9 L. donovani AA
3
 c 
 EtOH 64.8 L. major P
1
 a, o 
Ulva rigida EtOH 65.7 L. major P
1
 a 
Heterokontophyta      
 
Acinetosporaceae  Pylaiella littoralis CF:MeOH 47.1 L. donovani AA
3
 j 
Chordaceae  Chorda filum CF:MeOH 21.1 L. donovani AA
3
 j 
Chordariaceae Leathesia difformis CF:MeOH 77.4 L. donovani AA
3
 j 
Dictyotaceae Canistrocarpus cervicornis ME2CO 50/85.8
*
 L. braziliensis P1 n 
Dictyopteris polypodioides EtOAc 10.8 L. donovani AA3 m 
Dictyota sp.  DCM:MeOH 50/93.3
*
 L. braziliensis P
1
 n 
Dictyota dichotoma EtOAc 8.8 L. donovani AA
3
 m 
CF:MeOH 42.4 L. donovani AA
3
 j 
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Phylum 
    Family 
Algal  
species 
Crude  
extract  
IC50 
(μg/mL) 
Tested 
organism 
Parasite 
form  
References 
(a-p)
 
Dictyota caribaea DCM:H2O 24.4 L. mexicana P
1
 d 
Lobophora variegata DCM:H2O 49.9 L. mexicana P
1
 d 
Padina sp. ME2CO 50/80.9
*
 L. braziliensis P
1
 n 
Padina perindusiata DCM:H2O >100 L. mexicana P
1
 d 
Fucaceae Ascophyllum nodosum CF:MeOH 66.3 L. donovani AA
3
 j 
Fucus ceranoides CF:MeOH 25.3 L. donovani AA
3
 j 
Fucus serratus EtOAc 
EtOH 
9.7/14.0
*
 
9.7/15.0
*
 
L. donovani AA
3
 m 
CF:MeOH 34.1 L. donovani AA
3
 j 
Fucus spiralis CF:MeOH 34.3 L. donovani AA
3
 j 
Fucus vesiculosus CF:MeOH 33.0 L. donovani AA
3
 j 
Pelvetia canaliculata CF:MeOH 35.7 L. donovani AA
3
 j 
 EtOAc 
EtOH 
9.7/37.0
*
 
9.7/32.0
*
 
L. donovani AA
3
 m 
Fucophyceae Dictyota dichotoma EtOH 52.0 L. donovani AA
3
 c 
Himanthaliaceae Himanthalia elongata CF:MeOH 64.7 L. donovani AA
3
 j 
EtOAc 
EtOH 
9.7/43.0
*
 
9.7/40.0
*
 
L. donovani AA
3
 m 
Laminariaceae  Laminaria digitata CF:MeOH 34.5 L. donovani AA
3
 j 
EtOAc 
EtOH 
9.7/8.0
*
 
9.7/11.0
*
 
L. donovani AA
3
 m 
Phaeophyceae Turbinaria turbinata DCM:H2O 10.9 L. mexicana P
1
 d 
Phyllariaceae  Saccorhiza polyschides CF:MeOH 31.8 L. donovani AA
3
 j 
Sargassaceae Bifurcaria bifurcata CF:MeOH 6.4 L. donovani AA
3
 j 
EtOAc 
EtOH 
3.8 
9.7/40.0
*
 
L. donovani AA
3
 m 
Cystoseira baccata CF:MeOH 15.7 L. donovani AA
3
 j 
Cystoseira barbata MeOH 23.5
a 
69.9
b
 
L. donovani AA
3
 l 
Cystoseira crinita MeOH 28.2 L. donovani AA
3
 l 
Cystoseira tamariscifolia CF:MeOH 19.6 L. donovani AA
3
 j 
HEX 
ETH 
CF 
H2O 
n.d 
>100 
>100 
n.d 
L. infantum P
2
 o 
Halidrys siliquosa CF:MeOH 8.6 L. donovani AA
3
 j 
Sargassum fluitans DCM:H2O >100 L. mexicana P
1
 d 
Sargassum muticum EtOAc 
EtOH 
9.7/48.0* 
9.7/37.0* 
L. donovani AA
3
 m 
 CF:MeOH 34.7 L. donovani AA
3
 j 
Sargassum natans EtOH 90.9 L. donovani AA
3
 c 
Sargassum oligocystum 
 
H2O hot 
H2O cold 
78.0 
105.0 
L. major P
2 
h 
H2O hot 
H2O cold 
78.0 
105.0 
L. major P
2
 h 
       
Scytosiphonaceae Colpomenia peregrina CF:MeOH 29.1 L. donovani AA
3
 j 
Scytosiphon lomentaria CF:MeOH 34.3 L. donovani AA
3
 j 
Stypocaulaceae Halopteris scoparia EtOH >100 L. donovani AA
3
 c 
Stypocaulaceae Stypocaulon scoparium CF:MeOH 30.4 L. donovani AA
3
 j 
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Phylum 
    Family 
Algal  
species 
Crude  
extract  
IC50 
(μg/mL) 
Tested 
organism 
Parasite 
form  
References 
(a-p)
 
Rhodophyta       
 
Acrotylaceae Claviclonium ovatum CF:MeOH 61.2 L. donovani AA
3
 f 
Bangiaceae Porphyra leucosticta CF:MeOH 90/0.0
*
 L. donovani AA
3
 f 
Porphyra linearis CF:MeOH 55.5 L. donovani AA
3
 f 
Bonnemaisoniaceae 
  
Asparagopsis armata HEX 
EtOH 
EtOAc 
MeOH 
480.43 
149.50 
≥500.0 
≥500.0 
L. infantum P
2
 p 
 HEX 
DCM 
EtOH-
Hex:EtOAc 
EtOH-EtOAc 
EtOH-
EtOAc:MeOH 
EtOH-MeOH 
EtOH-H2O 
>40.0 
>40.0 
10.0 
 
19.0 
na 
 
na 
na 
L. donovani P
2
 e 
Asparagopsis taxiformis HEX 
DCM 
EtOH-
Hex:EtOAc 
EtOH-EtOAc 
17.0 
16.0 
14.0 
 
20.0 
L. donovani P
2
 e 
Bornetieae Bornetia secundiflora HEX 
EtOH 
EtOAc 
MeOH 
≥500.0 
188.3  
150.7   
≥500.0 
L. infantum P
2
 p 
Ceramiaceae Centroceras clavulatum EtOH 57.9 L. major P
1
 a 
 EtOH 57.9 L. major P
1
 i 
Ceramium nitens DCM:H2O >100.0 L. mexicana P
1
 d 
Ceramium rubrum MeOH 16.8 L. donovani AA
3
 l 
Ceramium virgatum CF:MeOH 25.6 L. donovani AA
3
 f 
Halurus flosculosus EtOAc 9.7/49.0
*
 L. donovani AA
3
 m 
Champiaceae Champia salicornioides DCM:H2O >100 L. mexicana P
1
 d 
Chylocladia verticillata CF:MeOH 47.3 L. donovani AA
3
 f 
Corallinaceae Corallina granifera MeOH 35.02 L. donovani AA
3
 l 
Corallina officinalis CF:MeOH 22.7 L. donovani AA
3
 f 
Jania capillacea DCM:H2O >100.0 L. mexicana P
1
 d 
 HEX 
EtOH 
EtOAc 
MeOH 
≥500.0 
≥500.0 
≥500.0 
197.1 
L. infantum P
2
 p 
Jania rubens CF:MeOH 60.7 L. donovani AA
3
 f 
 MeOH 28.0 L. donovani AM
3
 l 
Cystocloniaceae Calliblepharis jubata CF:MeOH 49.8 L. donovani AA
3
 f 
 EtOAc 
EtOH 
9.7/40.0
*
 
9.7/34.0
*
 
L. donovani AA
3
 m 
Cystoclonium purpureum CF:MeOH 67.3 L. donovani AA
3
 f 
Dasyaceae Dasya pedicellata MeOH 23.0 L. donovani AA
3
 l 
Heterosiphonia gibbesii DCM:H2O >100.0 L. mexicana P
1
 d 
Delesseriaceae Cryptopleura ramosa CF:MeOH 85.6 L. donovani AA
3
 f 
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    Family 
Algal  
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Crude  
extract  
IC50 
(μg/mL) 
Tested 
organism 
Parasite 
form  
References 
(a-p)
 
Dumontiaceae  Dilsea carnosa EtOAc 
EtOAc 
EtOH 
9.5 
9.7/31.0
*
 
9.7/15.0
*
 
L. donovani AA
3
 m 
Dumontiaceae  Dumontia incrassata CF:MeOH 68.6 L. donovani AA
3
 f 
Furcellariaceae Furcellaria lumbricalis CF:MeOH 43.3 L. donovani AA
3
 f 
Galaxauraceae Scinaia furcellata EtOH 64.4 L. donovani AA
3
 c 
Scinaia hatei EtOH 14.1 L. major P
1
 a, i 
Scinaia indica  na L. donovani - b 
EtOH 59.6 L. major P
1
 a 
Scinaia fascicularis EtOH 59.6 L. major P
1
 i 
Gelidiaceae Gelidium crinale MeOH 19.9 L. donovani AA
3
 l 
Gelidium latifolium EtOAc 9.7/49.0
*
 L. donovani AA
3
 m 
Gelidium pulchellum CF:MeOH 32.5 L. donovani AA
3
 f 
Gigartinaceae  Chondrus crispus EtOAc 
EtOH 
9.7/12.0
*
 
9.7/95.0
*
 
L. donovani AA
3
 m 
Gracilariaceae Gracilaria caudata DCM:MeOH 
ME2CO 
50/9.3
*
 
50/35.2
*
 
L. braziliensis P
1
 n 
 DCM:H2O >100.0 L. mexicana P
1
 d 
Gracilaria corticata H2O hot 
H2O cold 
38.0 
65.0 
L. major P
2
 h 
 EtOH 37.5 L. major P
1
 a, i 
Gracilaria cervicornis DCM:H2O >100.0 L. mexicana P
1
 d 
Gracilaria damaecornis DCM:H2O >100.0 L. mexicana P
1
 d 
Gracilaria gracilis CF:MeOH 53.3 L. donovani AA
3
 f 
 EtOAc 
EtOH 
9.7/36.0
*
 
9.7/29.0
*
 
L. donovani AA
3
 m 
Gracilaria salicornia H2O hot 
H2O cold 
46.0 
74.0 
L. major P h 
Gracilaria verrucosa MeOH 36.0 L. donovani AA
3
 l 
Hydropuntia cornea DCM:H2O >100.0 L. mexicana P
1
 d 
Halymeniaceae Grateloupia cuneifolia DCM:MeOH 50/37.0
*
 L. braziliensis P
1
 n 
Grateloupia turuturu EtOAc 9.7/33.0
*
 L. donovani AA
3
 m 
Halymenia floresii  DCM:H2O >100.0 L. mexicana P
1
 d 
Lomentariaceae Lomentaria articulata CF:MeOH 60.0 L. donovani AA
3
 f 
Palmariaceae Palmaria palmata EtOAc 
EtOH 
9.7/10.0
*
 
9.7/0.0
*
 
L. donovani AA
3
 m 
Peyssonneliales Peyssonnelia decaisne HEX 
EtOH 
EtOAc 
MeOH 
391.1 
41.8 
277.1 
≥500.0 
L. infantum P
2
 p  
Phyllophoraceae Mastocarpus stellatus CF:MeOH 44.1 L. donovani AA
3
 f 
 EtOAc 
EtOH 
9.7/39
*
 
9.7/20
*
 
L. donovani AA
3
 m 
Plocamiaceae Plocamium cartilagineum CF:MeOH 21.2 L. donovani AA
3
 f 
Polyidaceae Polyides rotundus CF:MeOH 57.3 L. donovani AA
3
 f 
Pterocladiaceae Pterocladiella capillacea HEX 
EtOH 
EtOAc  
MeOH 
≥500.0 
168.4 
332.7 
>500 
L. infantum P
2
 p 
Rhizophyllidaceae Ochtodes secundiramea ME2CO 50/99.7
*
 L. braziliensis P
1
 n 
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Crude  
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(μg/mL) 
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Parasite 
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References 
(a-p)
 
Rhodomelaceae Boergeseniella fruticulosa CF:MeOH 26.6 L. donovani AA
3
 f 
Bostrychia tenella DCM:MeOH-
HEX 
DCM:MeOH-
DCM 
1.5 
 
4.3 
L. amazonensis P
2
 g 
Botryocladia leptopoda EtOH 60.8 L. major P
1
 a, i 
Bryothamnion seaforthii DCM:MeOH 50/33.5
*
 L. braziliensis P
1
 n 
Bryothamnion triquetrum DCM:H2O >100.0 L. mexicana P
1
 d 
Digenea simplex DCM:MeOH 50/26
*
 L. braziliensis P
1
 n 
Halopitys incurvus CF:MeOH 16.5 L. donovani AA
3
 f 
Laurencia dendroidea DCM:MeOH 50/14.6
*
 L. braziliensis P
1
 n 
Laurencia microcladia DCM:H2O 16.3 L. mexicana P
1
 d 
Melanothamnus afaqhusainii EtOH 32.5 L. major P
1
 a, i 
Osmundea hybrida CF:MeOH 49.2 L. donovani AA
3
 f 
Osmundea pinnatifida CF:MeOH 32.7 L. donovani AA
3
 f 
 EtOH 6.3 L. major P
1
 n 
Palisada flagellifera DCM:MeOH 50/21.0
*
 L. braziliensis P
1
 n 
Solieriaceae Agardhiella sp. DCM:H2O >100.0 L. mexicana P
1
 d 
Eucheuma isiforme DCM:H2O >100.0 L. mexicana P
1
 d 
Wrangeliaceae Halurus equisetifolius CF:MeOH 69.2 L. donovani AA
3
 f 
IC50 – half maximal inhibitory concentration μg/mL; 
*[Max conc.tested  μg/mL / % cell inhibition]; HEX - hexane; CF - clorophorm; DCM - 
dicloromethane;  EtOAc - ethyl acetate; Me2CO - acetone; EtOH - ethanol; MeOH - methanol; H2O - water; P - promastigotes; AA - axenic 
amastigotes; 1Direct observation by optical microscopy; 2MTT 3-4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide assay; 3Rezasurin, 
aCollected in Turkey - Sile, north Istanbul; bCollected in Turkey – Tekirdag; na -  not active; n.d – not determined. 
a - Sabina et al. 2005; b - Lakshmi et al.2006; c - Orhan et al. 2006; d - Freile-Pelegrin et al. 2008; e - Genovese et al. 2009;  f - Allmendinger et 
al. 2010;  g - Felício et al. 2010;  h - Fouladvand et al. 2011; i - Sabina and Aliya, 2011; j - Spavieri et al. 2010a; k - Spavieri et al. 2010b; l - 
Süzgeç-Selçuk et al. 2010;  m - Vonthron-Sénécheau et al. 2011; n - Bianco et al. 2013;  o - Saher and Rahman 2013; p - Ainane et al. 2014. 
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 1H NMR spectrum (500 MHz, CDCl3) of the C. baccata (B1), C. barbata (B2), ANNEX 2.
C. tamariscifolia (B3) and C. usneoides (B4) hexane extracts. 
B1 
B2 
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B3 
B4 
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 1H NMR spectrum (500 MHz, CDCl3) of the C. baccata (C1), C. barbata (C2), ANNEX 3.
C. tamariscifolia (C3) and C. usneoides (C4) CH2Cl2 extract. 
  
C1 
C2 
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C3 
C4 
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1
H NMR spectrum (500 MHz, CDCl3) of the tetraprenyltoluquinols 1a/1b. ANNEX 4.
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 13C NMR spectrum (125 MHz, CDCl3) of the tetraprenyltoluquinols 1a/1b. ANNEX 5.
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 DEPT spectrum (125 MHz, CDCl3) of the tetraprenyltoluquinols 1a/1b. ANNEX 6.
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 HSQC spectrum (500 and 125 MHz, CDCl3) of the tetraprenyltoluquinols 1a/1b. ANNEX 7.
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 HMBC spectrum (500 and 125 MHz, CDCl3) of the tetraprenyltoluquinols 1a/1b. ANNEX 8.
  
ANNEXES 
201 
 
 Positive HRESIMS spectrum of the tetraprenyltoluquinols 1a/1b. ANNEX 9.
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 IR spectrum of the tetraprenyltoluquinols 1a/1b. ANNEX 10.
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 1H NMR spectrum (500 MHz, CDCl3) of the tetraprenyltoluquinones 2a/2b. ANNEX 11.
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 13C NMR spectrum (125 MHz, CDCl3) of the tetraprenyltoluquinones 2a/2b. ANNEX 12.
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  DEPT spectrum (125 MHz, CDCl3) of the tetraprenyltoluquinones 2a/2b. ANNEX 13.
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 HSQC spectrum (500 and 125 MHz, CDCl3) of the tetraprenyltoluquinones 2a/2b. ANNEX 14.
 
ANNEXES 
207 
 
 HMBC spectrum (500 ans 125 MHz, CDCl3) of the tetraprenyltoluquinones 2a/2b. ANNEX 15.
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  Positive (A) and negative (B) HRESIMS spectra of the tetraprenyltoluquinones 2a/2b. ANNEX 16.
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  UV spectrum of the tetraprenyltoluquinones 2a/2b. ANNEX 17.
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 IR spectrum of the tetraprenyltoluquinones 2a/2b. ANNEX 18.
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 Information of the sequences included in this study - species, geographical origin, voucher, GenBank accession numbers and haplotypes. ANNEX 19.
Sample  Geographic origin  Sample information and sequences GenBank acession n.º 
Species Reference  Country Location  Voucher  COI 23S mt-spacer Author 
Cystoseira abies-marina C. abies marina 1  Spain Tenerife, Mesa del Mar  L:0609335 MP3
#
 FM958377 FM993042 Draisma 
Cystoseira abies-marina C. abies marina 2  Spain Tenerife, Bajamar  L:0609338 MP3
#
 FM958376 FM993042 Draisma 
Cystoseira abies-marina C. abies marina MP19  Spain Tenerife, Punta del Hidalgo  MD0000400 x x - This study 
Cystoseira abies-marina C. abies marina MP26  Spain Tenerife, Punta del Hidalgo  MD0000522 x x - This study 
Cystoseira abies-marina C. abies marina MP27  Spain Tenerife, Punta del Hidalgo  MD0000557 x x x This study 
Cystoseira abies-marina C. abies marina MP29  Portugal S. Miguel ls, Ponta dos 
Mosteiros 
 MD0000746 x x x This study 
Cystoseira abies-marina C. abies marina MP3  Spain Tenerife, Punta del Hidalgo  PG072209 x - x This study 
Cystoseira abies-marina C. abies marina MP30  Portugal S. Miguel ls, Ponta dos 
Mosteiros 
 MD0000778 MP3
#
 x x This study 
Cystoseira amentacea C. amentacea  Italy Sicily, Capo Passero  L:0609436 - FM958359 FM993021 Draisma 
Cystoseira amentacea C. amentacea GV3  Spain Almería, Guardias Viejas  GV3 x x x This study 
Cystoseira amentacea C. amentacea MU1  Spain Murcia, Cabo de Palos  MU1 x x - This study 
Cystoseira amentacea var. 
stricta 
C. amentacea var. stricta 1  Italy Sicily, Capo Gallo  L:0609384 - FM958371 FM993017 Draisma 
Cystoseira amentacea var. 
stricta 
C. amentacea var. stricta 2  Italy Sicily, S. Maria la Scala  L:0609446 - FM958356 FM993016 Draisma 
Cystoseira amentacea var. 
stricta 
C. amentacea var. stricta RB95  Spain Almería, Las Negras  MBR95 x - x This study 
Cystoseira baccata C. baccata 1  Spain A Coruña  SANT:16322 EU681399
”
 FM958368 FM993034 Draisma 
Cystoseira baccata C. baccata MB1  Portugal Viana do Castelo, Areosa  MB1 x x x This study 
Cystoseira baccata C. baccata MB2  Portugal Caminha, Moledo  MB2 x x x This study 
Cystoseira barbata C. barbata  Spain Menorca, Moll d'es Miami  L:0609316 - FM958378 FM993043 Draisma 
Cystoseira barbata f. 
repens 
C. barbata f repens RB87  Spain Cádiz, Santibañez  MBR87 x x x This study 
Cystoseira barbata C. barbata MB17  Spain Cádiz, Santibañez  MB17 x x x This study 
Cystoseira barbata C. barbata/susanensis  Italy Sicily, Marzameni  L:SGAD1638 - FM958379 FM993044 Draisma 
Cystoseira barbatula C. barbatula  Italy Sicily, Marzameni  L:0609441 - FM958365 - Draisma 
Cystoseira brachycarpa C. sp RB105  Spain Almería, El Playazo  MBR105 - - x This study 
Cystoseira brachycarpa C. brachycarpa var. balearica 1  Spain Menorca, Cala Viola de  L:0609251 - FM958361 - Draisma 
ANNEXES 
212 
 
Sample  Geographic origin  Sample information and sequences GenBank acession n.º 
Species Reference  Country Location  Voucher  COI 23S mt-spacer Author 
var. balearica Llevant 
Cystoseira brachycarpa 
var. balearica 
C. brachycarpa var. balearica 2  Spain Menorca, La Llosa d'en Patro 
Pere 
 L:0609308 - FM958362
*
 FM993025 Draisma 
Cystoseira brachycarpa 
var. balearica 
C. brachycarpa var. balearica 3  Italy Sicily, Capo Milazzo  L:0609404 - FM958362
*
 FM993027 Draisma 
Cystoseira brachycarpa 
var. brachycarpa 
C. brachycarpa var. brachycarpa 1  Italy Sicily, S. Maria la Scala  L:0609414 - FM958362 FM993026 Draisma 
Cystoseira brachycarpa 
var. brachycarpa 
C. brachycarpa var. brachycarpa 2  Italy Aeolian Is, Salina  L:SGAD1633 - - FM993028 Draisma 
Cystoseira brachycarpa 
var. brachycarpa 
C. brachycarpa var. brachycarpa 3  France Cote Vermeille, Banyuls-sur-
Mer 
 PC:FR194 - - FM993023 Draisma 
Cystoseira compressa C. compressa  Spain Tenerife, Punta del Hidalgo  L:0609343 MP17
#
 FM958355 FM993015 Draisma 
Cystoseira compressa C. compressa MB4  Portugal Albufeira, Arrifes  MB4 x x - This study 
Cystoseira compressa C. compressa MB6  Portugal Albufeira, Olhos de Água  MB6 x x x This study 
Cystoseira compressa C. compressa MP17  Spain Tenerife, Mesa del Mar  MD0000360 x - - This study 
Cystoseira compressa C. compressa RB25  Spain Girona, Blanes  MBR25 x x x This study 
Cystoseira compressa C. compressa MP4  Spain Tenerife, Mesa del Mar  PG072363 x - - This study 
Cystoseira compressa C. compressa MP25  Spain Tenerife, Mesa del Mar  MD0000506 x x - This study 
Cystoseira compressa var. 
pustulata 
C. compressa var. pustulata  Italy Sicily, Marzameni  L:0609427 - FM958354 FM993014 Draisma 
Cystoseira compressa var. 
pustulata 
C. compressa var. pustulata RB67  Spain Almería, La isleta del Moro  MBR67 x - - This study 
Cystoseira compressa var. 
pustulata 
C. compressa var. pustulata RB103  Spain Almería, La isleta del Moro  MBR103 x x x This study 
Cystoseira crinita C. crinita 1  Spain Menorca, Illots de Tirant  L:0609275 - FM958363 FM993029 Draisma 
Cystoseira crinita C. crinita 2  Italy Sicily, Marzameni  L:0609440 - FM958360 FM993024 Draisma 
Cystoseira crinita C. crinita 3  Spain Menorca, Cala Mica  L:0609314 - - FM993030 Draisma 
Cystoseira crinita C.  crinita RB90  France Antibes, Pointe I´lette  MBR90 - x x This study 
Cystoseira elegans C. elegans  Italy Sicily, Capo Passero  L:0609444 - FM958375 FM993038 Draisma 
Cystoseira elegans C. elegans RB68  Spain Almería, El Playazo  MBR68 - x x This study 
Cystoseira foeniculacea C. foeniculacea  Spain Tenerife, Punta del Hidalgo  L:0609350 - FM958353 FM993013 Draisma 
Cystoseira foeniculacea C. foeniculacea MP20  Spain Tenerife, Mesa del Mar  MD0000403 x - x This study 
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Cystoseira foeniculacea C. foeniculacea MP22  Spain Tenerife, Mesa del Mar  MD0000421 x x x This study 
Cystoseira funkii C. funkii  Italy Aeolian Is, Salina  L:0609449 - FM958357 FM993018 Draisma 
Cystoseira granulata C. granulata  France Brittany  PC:FR295 - - FM993039 Draisma 
Cystoseira humilis C. humilis MB7  Portugal Albufeira, Manuel Lourenço  MB7 x KF525359 - This study 
Cystoseira humilis var. 
myriophyoides 
C. humilis var. myriophylloides 
RB22 
 Spain Cádiz, El Mirlo  MBR22 x x x This study 
Cystoseira mauritanica C. mauritanica RB18  Spain Cádiz, El Mirlo  MBR18 x x x This study 
Cystoseira mediterranea C. mediterranea  France Cote Vermeille, Le Troc  L:0609379 - FM958371
*
 FM993022 Draisma 
Cystoseira mediterranea C. mediterranea BL14  Spain Girona, Blanes  BL14 x KF525356 x This study 
Cystoseira mediterranea C. mediterranea BL5  Spain Girona, Blanes  BL5 x KF525357 KF525365 This study 
Cystoseira nodicaulis C. nodicaulis 2  France Brittany, Santec  PC FR289 EU681400 FM958369
*
 FM993036 Draisma 
Cystoseira nodicaulis C. nodicaulis MB14  Spain A Coruña, Santa Mariña  MB14.2 x x x This study 
Cystoseira nodicaulis C. nodicaulis MB18  Spain A Coruña, Santa Mariña  MB18 x x x This study 
Cystoseira sonderi C. sonderi 1  Cape Verde Branco Is  L:CANCAP-VII 
9718 
- - FM993040 Draisma 
Cystoseira sonderi C. sonderi 2  Cape Verde São Tiago ls, Tarrafal Bay  L:CANCAPVII 
8621 
- - FM993041 Draisma 
Cystoseira sp. Cystoseira sp. 1  Croatia Prvic Island  GENT: 
KRK 005 
- FM958364 FM993031 Draisma 
Cystoseira sp. Cystoseira sp. 2  Spain Menorca, Illa d'es Porros  L:0609306 - FM958369 FM993035 Draisma 
Cystoseira sp. Cystoseira  sp. MP1  Portugal Madeira Is, Caniço  PG071164 - x x This study 
Cystoseira sp. Cystoseira  sp. MP14  Malta Xghajra  PG081405 x - x This study 
Cystoseira sp. Cystoseira  sp. MP2  Portugal Madeira Is, Caniço  PG071220 x - x This study 
Cystoseira sp. Cystoseira  <sp. MP31  Portugal Graciosa Is, Carapacho  MD0003137 x x - This study 
Cystoseira spinosa C. spinosa  Croatia Brac Island  - - HQ438490 HQ438492 Puizina 
Cystoseira spinosa C. spinosa ALI4  Spain Alicante, Santa Pola  ALI4 x x x This study 
Cystoseira spinosa C. spinosa RB24  Spain Almería, La Serena  MBR24 - - x This study 
Cystoseira spinosa var. 
tenuior 
C. spinosa var. tenuior  Spain Menorca, Cala Mica  L:0609312 - FM958374 FM993037 Draisma 
Cystoseira squarrosa C. squarrosa  Croatia Dubrovnik city area  - - HQ438491 HQ438494 Puizina 
Cystoseira tamariscifolia C.  tamariscifolia 1  Spain A Coruña  SANT16323 EU681401
”
 FM958358 FM993019 Draisma 
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Species Reference  Country Location  Voucher  COI 23S mt-spacer Author 
Cystoseira tamariscifolia C. tamariscifolia 3  Spain A Coruña  SANT:16325 EU681401
”
 FM958370 FM993020 Draisma 
Cystoseira tamariscifolia C. tamariscifolia CB5  Spain Málaga, Calaburras  CB5 x x x This study 
Cystoseira tamariscifolia C. tamariscifolia HE7  Spain Granada, Herradura  HE7 x x x This study 
Cystoseira tamariscifolia C. tamariscifolia MB10  Portugal Albufeira, Olhos de Água  MB10 - x x This study 
Cystoseira tamariscifolia C. tamariscifolia MB11  Portugal Albufeira, Olhos de Água  MB11 x x x This study 
Cystoseira tamariscifolia C. tamariscifolia MB12  Portugal Albufeira, Olhos de Água  MB12 x x x This study 
Cystoseira tamariscifolia C. tamariscifolia MB16  Portugal Albufeira, Olhos de Água  MB16 x - x This study 
Cystoseira tamariscifolia C. tamariscifolia MB19  Portugal Albufeira, Olhos de Água  MB19 x x x This study 
Cystoseira tamariscifolia C. tamariscifolia MB20  Portugal Albufeira, Olhos de Água  MB20 x x x This study 
Cystoseira tamariscifolia C. tamariscifolia MB5  Portugal Albufeira, Manuel Lourenço  MB5 x - KF525364 This study 
Cystoseira tamariscifolia C. tamariscifolia MB8  Portugal Viana do Castelo, Areosa  MB8 x x x This study 
Cystoseira tamariscifolia C. tamariscifolia MB9  Portugal Albufeira, Manuel Lourenço  MB9 x x x This study 
Cystoseira tamariscifolia C. tamariscifolia TA2  Spain Cádiz, El Mirlo  TA2 x x x This study 
Cystoseira usneoides C. usneoides  Spain A Coruña  SANT:15803 MB13
#
 FM958367 FM993033 Draisma 
Cystoseira usneoides C. usneoides MB13  Portugal Albufeira, Olhos de Água  MB13 x - - This study 
Cystoseira usneoides C. usneoides MB15  Portugal Albufeira, Manuel Lourenço  MB15 x KF525360 KF525362 This study 
Cystoseira usneoides C. usneoides MB21  Portugal Albufeira, Olhos de Água  MB21 x x x This study 
Cystoseira usneoides C. usneoides MB3  Portugal  Aljezur, Odeceixe  MB3 x x x This study 
Cystoseira zosteroides C. zosteroides  Italy Sicily, S. Maria la Scala  L:0609421 - FM958366 FM993032 Draisma 
Bifurcaria bifurcata Bifurcaria bifurcata 1  France Brittany, Santec  PC:FR287/FRA0520 EU681394 FM958373 FM992996 Draisma 
Bifurcaria bifurcata Bifurcaria bifurcata MB34  Spain A Coruña, Lires  MB34 MB37 x x This study 
Bifurcaria bifurcata Bifurcaria bifurcata MB35  Spain A Coruña  MB35 MB37 - x This study 
Bifurcaria bifurcata Bifurcaria bifurcata MB36  Spain Asturias, Porcia  MB36 MB37 x MB35 This study 
Bifurcaria bifurcata Bifurcaria bifurcata MB37  Spain Murcia, Lastra  MB37 MB37 - x This study 
Polycladia heinii Polycladia heinii  Oman Al Ashkharah  GENT:ASH 030 - FM958335 FM992993 Draisma 
Polycladia indica Polycladia indica  Oman Dhofar, Mirbat  GENT:DHO2 0297 - FN435994 FM992994 Draisma 
Sirophysalis trinodis Sirophysalis trinodis  Indonesia/ 
Australia 
Thousand Is, Semak Daun  L:SGAD0509396/ 
AD-A95058A 
KF285949 FM958348 FM993008 Draisma / 
Soisup 
Stephanocystis geminata Stephanocystis geminata  Canada British Columbia  GWS004223 FJ409138 - - McDevit 
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Stephanocystis 
hakodatensis 
Stephanocystis hakodatensis  Japan Hokkaido, Muroran  SAP:086290 - FM958350 FM993010 Draisma 
Stephanocystis setchelli Stephanocystis setchelli  USA California, Anacapa Island  AC2 - FM958351 FM993011 Draisma 
Stephanocystis dioica Stephanocystis dioica  USA California, Catalina Island  CT2 - FM958352 FM993012 Draisma 
Turbinaria ornata Turbinaria ornata 3  Indonesia Thousand Is, Pulau Sepa  L:SGAD0509269 /  
- 
JF718405 FM958414 FM993083 Draisma/ 
Yu 
Fucus distichus Fucus distichus 1  Spain Tenerife, Punta del Hidalgo  AY659916/ 
CSM007A 
EU646709 AY659916 AY659884 Draisma/ 
Kucera 
Fucus serratus Fucus serratus 3  - / Canada - / Nova Scotia  AY659920/ 
DM05-014 
EU646717 AY659920 AY659875 Draisma/ 
Kucera 
Fucus spiralis Fucus spiralis 1  - / Canada - / Nova Scotia  AY659921/ 
CSM009A 
EU646738 AY659921 AY659907 Draisma/ 
Kucera 
Fucus vesiculosus Fucus vesiculosus 5  - / Canada - / Nova Scotia  AY494079 AY494079 AY494079 AY494079 Draisma/ 
Kucera 
X Sequences obtained in this study and under registration process in the GenBank database.* Sequences identical to, as indicated by Draisma; #  Sequences assumed to be identical to the sequence given 
because available sequences from other individuals did not show any variation; “  Sequences assumed to be identical to other individual from the same specie available at  GenBank database.  
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 Bayesian phylogenetic tree obtained with MrBayes and based on concatenated COI-ANNEX 20.
23S-mt-spacer sequences of the samples from the Sargassaceae family. Values on the 
branches represent Bayesian posterior probabilities ≥ 90%. 
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 Bayesian phylogenetic tree obtained with MrBayes and based on concatenated COI-ANNEX 21.
23S-mt-spacer sequences of the samples from Cystoseira genus. Values on the branches 
represent Bayesian posterior probabilities ≥ 90%. 
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 Maximum likelihood phylogenetic tree obtained with RAXML and based on the COI ANNEX 22.
sequences of the samples from Cystoseira genus. Values on the branches represent 
maximum likelihood bootstrap support values ≥ 75 on the left, and Bayesian posterior 
probabilities ≥ 90% on the right. 
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 Bayesian phylogenetic tree obtained with MrBayes and based on the COI sequences of ANNEX 23.
the samples from Cystoseira genus. Values on the branches represent Bayesian posterior 
probabilities ≥ 90%. 
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 Maximum likelihood phylogenetic tree obtained with RAXML and based on the 23S ANNEX 24.
sequences of the samples from the Cystoseira genus. Values on the branches represent 
maximum likelihood bootstrap support values ≥ 75 on the left, and Bayesian posterior 
probabilities ≥ 90% on the right. 
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 Bayesian phylogenetic tree obtained with MrBayes and based on the 23S sequences of ANNEX 25.
the samples from Cystoseira genus. Values on the branches represent Bayesian posterior 
probabilities ≥ 90%. 
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 Maximum likelihood phylogenetic tree obtained with RAXML and based on the mt-ANNEX 26.
spacer sequences of the samples from Cystoseira genus. Values on the branches represent 
maximum likelihood bootstrap support values ≥ 75 on the left, and Bayesian posterior 
probabilities ≥ 90% on the right. 
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 Bayesian phylogenetic tree obtained with MrBayes and based on the mt-spacer ANNEX 27.
sequences of the samples from Cystoseira genus. Values on the branches represent Bayesian 
posterior probabilities ≥ 90%. 
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 Evolutionary divergence between COI Cystoseira sequences. ANNEX 28.
A. 
Group I species C. amentacea 
var. stricta
*
 
C. amentacea C.  
tamariscifolia 
C. mediterranea       
 C. amentacea var. stricta
*
 *          
 C. amentacea 0.3 0.3         
 C. tamariscifolia 0.3 - 0.5 0.0 - 0.2 0.0 - 0.2        
 C. mediterranea 0.9 0.9 0.9 – 1.1 0.0       
            
B. 
Group II species C. abies- 
marina 
Cystoseira sp. 
MP14
*
 
C. spinosa
*
 C. mauritanica
*
 C. barbata f. 
repens
*
 
C. barbata
*
 C. nodicaulis C. baccata C. usneoides 
 C. abies-marina 0.0         
 Cystoseira sp. MP14
*
 0.0 *        
 C. spinosa
*
 5.6 5.6 *       
 C. mauritanica
*
 5.4 5.4 0.3 *      
 C. barbata f. repens
*
 5.4 5.4 0.3 0.0 *     
 C. barbata
*
 5.8 5.8 0.6 0.3 0.3 *    
 C. nodicaulis 5.8 5.8 0.6 0.3 0.3 0.0 5.6   
 C. baccata 6.3 – 6.8 6.3 – 6.8 3.0 – 3.4 3.0 – 3.4 3.0 – 3.4 3.3 – 3.8 3.3 – 3.8 0.0 – 0.5  
 C. usneoides 5.9 5.9 2.3 2.0 2.0 2.3 2.3 1.7 – 2.2 0.0 
            
C. 
Group III species C. compressa C. compressa 
var. pustulata 
Cystoseira sp. 
MP31* 
Cystoseira sp. 
MP2* 
C. humilis* C. humilis var. 
myriophylloides* 
C. foeniculacea    
 C. compressa 0.0 - 0.6          
 
C. compressa var. 
pustulata 
0.9 – 1.0 0.0 
       
 
 Cystoseira sp. MP31
*
 1.0 0.0 *        
 Cystoseira sp. MP2
*
 0.6 0.6 0.6 *       
 C. humilis
*
 0.6 0.6 0.6 0.0 *      
 
C. humilis var. 
myriophylloides
*
 
0.6 0.6 0.6 0.0 0.0 * 
   
 
 C. foeniculacea 4.2 – 4.4 4.2 – 4.3 4.2 – 4.4 4.2 – 4.4 4.2 – 4.4 4.2 – 4.4 0.0    
*Species represented by only one specimen  
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 Evolutionary divergence between 23S Cystoseira equences. ANNEX 29.
A. 
Group I species C.  
zosteroides
*
 
C. amentacea C. amentacea 
var. stricta 
C. funkii
*
 C.  
mediterranea 
Cystoseira sp. 1
*
 C. b. var. 
brachycarpa
*
 
C. b. var. 
balearica 
C. crinita C. barbatula
*
 C.  
tamariscifolia 
 C. zosteroides
*
 *           
 C. amentacea 1.9 – 2.4  0.5 - 2.2           
 
C. amentacea var. 
stricta 
1.6 – 2.4 0.5 - 1.3 0.8         
 C. funkii
*
 2.6 1.0 - 2.0 0.8 - 1.0 *        
 C. mediterranea 1.6 0.5 - 1.9  0.0 - 0.8 1.0 0.0       
 Cystoseira sp. 1
*
 2.6 3.7 - 4.3  3.2 - 3.5 4.3 3.2 *      
 
C. brachycarpa var. 
brachycarpa
*
 
3.2 3.5 - 4.3 3.7 3.5 3.7 1.0 *     
 
C. brachycarpa var. 
balearica 
2.9 – 3.2 3.4 - 4.3 3.2 - 3.7 3.5 - 3.7 3.5 - 3.5 0.8 - 1.0 0.0 - 0.3 0.0 - 0.3    
 C. crinita 2.4 – 2.9  3.5 - 4.3 2.9 - 3.7 3.5 - 4.0 2.9 - 3.5 0.3 - 0.8 0.3 - 0.8 0.0 - 0.8 0.3 - 0.8   
 C. barbatula* 3.2 4.3 - 4.9  3.7 - 4.3 4.9 3.7 0.8 1.6 1.3 - 1.6 0.8 - 1.6 *  
 C. tamariscifolia 1.7 – 2.4 0.0 - 2.3 0.3 -  1.3 1.0 - 1.6 0.3 - 1.0 3.4 - 4.3 3.7 - 4.3  3.5 - 4.3 3.4 - 4.3 4.3 - 4.9 0.0 - 0.6 
              
B. 
Group II species C. barbata C. barbata f. 
repens
*
 
C. elegans C. nodicaulis C.  
mauritanica
*
 
C. spinosa var. 
tenuior
*
 
C. spinosa Cystoseira sp. 2
*
 C. squarrosa
*
 C. baccata C. usneoides 
 C. barbata 0.0 - 1.6           
 C. barbata f. repens
*
 0.0 - 1.6 *          
 C. elegans 0.5 - 1.9 0.5 - 1.1 1.3         
 C. nodicaulis 0.0 - 1.6 0.0 0.5 - 1.1 0.0        
 C. mauritanica
*
 0.0 - 1.6 0.0 0.5 - 1.1 0.0 *       
 C. spinosa var. tenuior
*
 0.0 - 1.6 0.0 0.5 - 1.1 0.0 0.0 *      
 C. spinosa 0.0 - 1.9 0.0 - 1.1 0.0 - 1.3  0.0 - 1.1 0.0 - 1.1 0.0 - 1.1 1.1     
 Cystoseira sp. 2
*
 0.0 - 1.6 0.0 0.5 - 1.1 0.0 0.0 0.0 0.0 - 1.1 *    
 C. squarrosa
*
 1.1 - 1.9 1.1 0.0 - 1.3  1.1 1.1 1.1 0.0 - 1.1 1.1 *   
 C. baccata 2.1 - 3.1 2.1 - 2.3 2.1 - 2.6 2.1 - 2.3 2.1 - 2.3 2.1 - 2.3 2.1 - 2.3 2.1 - 2.3 2.1 - 2.3 0.0  
 C. usneoides 1.9 - 2.9 1.9 1.9 - 2.1 1.9 1.9 1.9 1.9 1.9 1.9 1.0 - 1.1 0.0 
              
C. 
Group III species C. compressa 
var. pustulata 
Cystoseira sp. 
MP31
*
 
C. compressa C. humilis var. 
myriophylloides 
*
 
C. humilis
*
 Cystoseira sp. 
MP1
*
 
C.  
foeniculacea 
C. abies- 
marina 
   
 
 
C. compressa var.  
pustulata 
0.0           
 
 Cystoseira sp. MP31
*
 0.0 *           
 C. compressa 0.8 - 1.0 0.8 - 1.0 0.0 - 0.3          
 
C. humilis var.  
myriophylloides
*
 
0.5 0.5 0.3 -  0.5 *        
 
 C. humilis
*
 0.5 0.5 0.3 -  0.5 0.0 *        
 Cystoseira sp. MP1
*
 0.6 0.6 0.3 -  0.3 0.0 0.0 *       
 C. foeniculacea 2.1 2.1 1.8 - 2.1 1.6 1.6 1.7 0.0      
 C. abies-marina 10.4 10.4 10.4 - 10.7 10.1 10.1 10.1 9.7 0.0     
* Species represented by only one specimen  
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 Evolutionary divergence between mt-spacer Cystoseira sequences.  ANNEX 30.
A. 
Group I species C. amentacea 
var. stricta 
C. amentacea C. mediterranea C. 
 tamariscifolia 
C. funkii
*
 C. brachycarpa
*
 
C. b. var. 
balearica 
C. b. var. 
brachycarpa 
C. crinita Cystoseira sp. 
1
*
 
C. zosteroides
*
 
     
 
C. amentacea var. 
stricta 
1.1 - 2.6                
 C. amentacea 0.7 - 4.4 0.4               
 C. mediterranea 0.4 - 3.0 1.1 - 1.7 0.0              
 C. tamariscifolia 0.4 - 3.9 0.0 - 3.0 0.7 - 1.4 0.0 - 2.6             
 C. funkii
*
 1.1 - 3.4 1.8 - 2.6 0.7 1.5 - 2.2 *            
 C. brachycarpa
*
 0.4 - 3.0 1.1 - 1.7 0.0 0.7 - 1.5 0.7 *           
 
C. brachycarpa var. 
balearica 
5.6 - 7.0 6.0 - 7.6 5.2 - 5.7 6.0 - 6.8 4.9 - 5.4 5.3 - 5.7 2.9          
 
C. brachycarpa var. 
brachycarpa 
5.7 - 7.7 7.6 - 8.5 5.2 - 6.0 6.0 - 7.4 4.9 - 6.1 5.3 - 6.0 0.0 - 2.9 0.4 - 2.5         
 C. crinita 1.1 - 9.0 1.8 - 9.5 0.7 - 6.8 1.4 - 8.3 0.0 - 6.5 0.7 - 6.8 2.1 - 3.3 2.1 - 6.8 0.3 - 7.6        
 Cystoseira sp. 1
*
 6.4 - 7.3 6.8 - 8.5 6.0 6.8 - 7.4 6.1 6.0 1.8 - 3.2 1.4 - 3.2  3.5 - 6.8 *       
 C. zosteroides
*
 7.3 - 8.7 7.7 - 9.6 7.3 7.3 - 8.1 6.6 7.3 5.1 - 6.8 5.1 - 7.5 6.2 - 7.7 7.7 *      
                  
B. 
Group II species C. abies-
marina 
Cystoseira sp. 
MP14
* 
C. sonderi C. squarrosa
*
 C. 
elegans
*
 
C. baccata C. barbata C. 
mauritanica
*
 
C. barbata 
f. repens
*
 
C. elegans
*
 C. granulata
*
 C. nodicaulis Cystoseira sp. 
2
*
 
C. spinosa C. spinosa 
var. tenuior
*
 
C. usneoides 
 C. abies-marina 0.0 - 0.4                
 Cystoseira sp. P14
*
 0.0 - 0.7 *               
 C. sonderi 2.4 - 3.5 2.7 - 2.4 0.0              
 C. squarrosa
*
 11.1 - 12.0 11.1 9.3 *             
 C. elegans
*
 11.5 - 12.4 11.5 9.7 0.3 *            
 C. baccata 11.7 – 13.1 11.2 - 12.1 9.8 - 10.4 7.3 - 8.1 6.9 - 7.6 0.0           
 C. barbata 12.0 – 13.8 11.5 - 12.9 9.7 - 11.5 3.9 - 4.7 1.7 - 4.3 5.4 - 7.2 0.7 - 3.9          
 C. mauritanica
*
 11.1 - 12.0 11.1 9.7 2.1 1.7 6.5 - 7.2 0.0 - 3.9 *         
 C. barbata f. repens
*
 11.5 - 12.4 11.5 9.7 2.1 1.7 6.5 - 7.2 0.0 - 3.9 0.0 *        
 C. elegans
*
 10.9 - 11.8 10.9 9.5 1.8 1.4 6.7 - 7.4 1.1 - 3.3 1.1 1.1 *       
 C. granulata
*
 11.6 - 12.5 11.6 10.2 2.1 1.7 6.9 - 7.7 0.7 - 3.9 0.7 0.7 1.1 *      
 C. nodicaulis 11.5 - 14.0 11.5 – 13.5 10.1 - 11.8 2.1 - 2.4 1.7 - 2.0 7.6 - 8.9 0.7 - 4.5 0.7 - 0.8 0.7 - 0.8 1.1 - 1.2 0.0 0.0     
 Cystoseira sp. 2
*
 10.6 - 11.5 10.6 9.3 1.4 1.0 6.2 - 6.8 0.7 - 3.2 0.7 0.7 0.4 0.7 0.7 - 0.8 *    
 C. spinosa 10.6 - 12.9 10.6 - 12.0 9.3 - 10.1 0.7-1.4 0.3 - 1.0 6.2 - 8.1 0.7 - 4.7 0.7 - 2.1 0.7 - 2.1 0.4 - 1.8 0.7 - 2.1 0.7 - 2.4 0.0 - 1.4 0.0 - 1.4   
 
C. spinosa 
var.tenuior
*
 
10.6 - 11.5 10.6 9.3 1.4 1.0 6.2 - 6.8 0.7 - 3.2 0.7 0.7 0.4 0.7 0.7 - 0.8 0.0 0.0-1.4 *  
 C. usneoides 12.0 - 12.9 11.5 - 12.0 9.9 - 11.0 4.5 - 4.9 4.1 - 4.5 4.0 - 4.5 2.2 - 4.1 3.7 - 4.1 3.7 - 4.1 3.4 - 3.8 3.3 - 3.7 3.3 - 4.2 2.9 - 3.3 2.9 – 4.4 2.9 - 3.3 0.0 - 0.4 
                  
C. 
Group III species C. compressa C. c. var. 
pustulata
*
 
C. humilis var. 
myriophyoides
*
 
Cystoseira sp. 
MP2
*
 
Cystoseira 
sp. MP1
*
 
C. foeniculacea  
         
 C. compressa 0.4 - 0.8                
 
C. compressa var. 
pustulata
*
 
0.7 - 1.5 *               
 
C. humilis var. 
myriophyoides
* 0.4 - 0.8 0.4 - 0.8 *              
 Cystoseira sp. MP2
*
 1.5 - 1.9 1.5 - 1.9 1.1 *             
 Cystoseira sp. MP1
*
 1.5 - 1.9 1.5 - 1.9 1.1 0.0 *            
 C. foeniculacea 9.7 - 10.9 8.8 - 9.3 9.3 - 9.9 10.6 - 11.4 10.6 - 11.4 0.0           
* Species represented by only one specimen 
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 Median-Joining networks of Cystoseira-I mt-spacer, 23S and COI haplotypes. Pie ANNEX 31.
charts are proportional to haplotype frequencies. Theoretical median vectors are represented 
by black dots. Colors represent the different Cystoseira species as described in the legend. 
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 Median-Joining networks of Cystoseira-II mt-spacer, 23S and COI haplotypes. Pie ANNEX 32.
charts are proportional to haplotype frequencies. Theoretical median vectors are represented 
by black dots. Colors represent the different Cystoseira species as described in the legend. 
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 Median-Joining networks of Cystoseira-III mt-spacer, 23S and COI haplotypes. Pie ANNEX 33.
charts are proportional to haplotype frequencies. Theoretical median vectors are represented 
by black dots. Colors represent the different Cystoseira species as described in the legend. 
  
 
